Clinical Study Protocol -7.[ADDRESS_297829]/EU CT 
Number2019-001363 -67
A Randomized, Double -blind, Placebo -controlled, Parallel Group, 
Multicenter, Phase 2a Study to Explore the Efficacy and Safety of 
Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructive 
Pulmonary Disease (COPD) (COURSE)
Sponsor Name: [CONTACT_245011]: 151 85 Södertälje, Sweden
Regulatory Agency Identifying Number(s):
IND number: [ADDRESS_297830] number: 2019-001363-[ADDRESS_297831] procedures. The 
protocol is publicly registered, and the results are disclosed and/or published according to the 
[COMPANY_008] Global Standard -Bioethics and in compliance with prevailing laws and regulations.
Redacted for Public Disclosure
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 2of 217Version Scope: Global version 7.0, 18October 2022
Amend ment Number: 6.0
Study  Intervent ion: Tezepel umab
Study  Phase: 2a
Short Title: Tezepel umab COPD Exacerbation study
Acronym : COURSE
Study  Clinical  Lead is responsible for the clinical integrity  of the study  (for exam ple, the 
study  physician or sci entist).
Study Physician Name [CONTACT_9352] [CONTACT_244918] -ordinating Investigator:
[COMPANY_003]
Clinical Study Protocol -7.[ADDRESS_297832] - 2022
Amendment 5.0 21-Mar -2022
Amendment 4.0 15-Mar -2021
Amendment 3.0 11-Aug -2020
Amendment 2.0 26-May -2020
Amendment 1.0 16-Dec -2019
Original Protocol 03-May -2019
Amendment 6.0 (18- Oct-2022)
This m odificat ion is considered to be substant ial based on the criteria set forth in article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n 
and in the EU Clinical Trial Regulat ion Art icle 2, 3 (13) because it might impacts the safet y of 
participants and the scientific value of the study .
Overall Rationale for the Amendment:
The m ain reason for this amendment is to update the important potential risks and adverse 
event sof special interests ( AESI )to align with Investi gator’s Brochure (IB) Edi tion 5.1 (dated 
22 July  2022) , as well as, to update the scope of the Independent Adjudication Co mmittee 
assessment.
Other changes are minor and non-substantial , including alignment withregul atory  trial 
requi rements, correcting ty pos, am ong others.
Section # and 
NameDescription of Change Brief Rationale Substantial/Non -
substantial
Protocol title and 
Section 1.[ADDRESS_297833]/EU CT Number 
to Title and Synopsis page .Toalign with regulato ry 
requirements related to 
Clinical Trial Transparency 
(CTT) language .Non-substantial
Section 1.1
Schedule of 
activities, Table 
1and Section 6.5
Concomitant 
Therapy , Table 6Restriction for inactive/killed 
vaccinations (e.g. inactive 
influenza vaccine) revised from 
within 7 days to 5 days before or 
after any IP dosing.To align with IB Edition 5.1. Non-substantial
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 4of 217Section # and 
NameDescription of Change Brief Rationale Substantial/Non -
substantial
Section 1.2
Synopsis, 
Independent 
Adjudication 
Committee and 
Section 8.4.7
Independent 
Adjudication 
CommitteeThe scope of the IAC changed.
Added serious cardiac events as 
an event requiring adjudication.
Added that the IAC will assess 
whether there is a causal 
relatio nship between IP use and 
MACE events, serious cardiac 
events ,and deaths.To update the scope of the 
IAC assessment to align with
IB Edition 5.1.Substantial
Section 2.3
Benefit/Risk 
Assessment , 
Table 3 –Risk 
AssessmentNew Table 3 –Risk Assessment :
“Important potential risks” 
added including serious 
infections, malignancies ,and 
serious cardiac events; “Potential 
risks" added including serious 
hypersensitivity reactions, and 
helminth i nfections; “Study 
procedures” added including 
COVID 19. The r ationale for 
risk and mitigation strategy is 
provided for all risks in Table 3.To align with IB Edition 5.1. Substantial
Section 4.[ADDRESS_297834] Randomized.Non-substantial
Section 4.4End-
of-studyAdded the End of Study 
Definitio n under FDA and EU 
requirements .To align with regulatory 
requirements related to 
Clinical Trial Transparency 
(CTT) language.Non-substantial
Section 5.1
Inclusion criteriaUpdated Criterion#11: ‘ Subjects 
on theophylline or roflumilast 
prior to Visit 1…’ by [CONTACT_1583] 
“Note ”.To clarify the check of the 
blood concentration levels of 
theophylline is a 
recommendation, not an 
inclusion criterion.Non-substantial
Section 5.2
Exclusion 
criteria, Section 
[IP_ADDRESS] General 
requirements, 
and section 
[IP_ADDRESS] SARS -
Cov-2 testingUpdated Criterion #39: ‘SARS -
COV -[ADDRESS_297835]’ by [CONTACT_244919] (approved by [CONTACT_244920]).
Related sections were updated 
for consistency.To allow alternative tests 
approved by [CONTACT_244921] -
COV -2 infection.Non-substantial
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 5of 217Section # and 
NameDescription of Change Brief Rationale Substantial/Non -
substantial
Section 6.5
Concomitant 
Therapy ,
Table 6Added COVID -19 vaccination 
based on the existing section 
8.2.10. The COVID -19 
vaccination restriction has not 
been changed.To align with section 8.2.10 
where all this information was 
in the previous CSP version.Non-substantial
Section [IP_ADDRESS]
Severity  of 
COPD 
ExacerbationSevere COPD exacerbation 
definition was clarified. 
Following two bullet points in 
this section… (severe)
“Hospi[INVESTIGATOR_244765]
The subject been admitted 
for ≥ 24 hours to an 
observation area, the 
emergency department, or 
other equivalent healthcare 
facility  (depending on the 
country and healthcare 
system) for the COPD 
exacerbation ”
…were merged in a single bullet 
point with the following
wording:
“Hospi[INVESTIGATOR_244766] ≥ 24 
hours to an observation area, 
the emergency department, 
or other equivalent 
healthcare facility 
(depending on the country 
and healthcare system) for 
the COPD exacerbation .”To clarify thedefinition of 
severe COPD exacerbation.Non-substantial
Section [IP_ADDRESS]
Adverse Events 
of Pneumonia 
Requiring a 
Confirmed 
DiagnosisAmended wording to clarify the 
severe infection pages in eCRFs 
must be completed for infections 
which are defined as SAE, or 
requiring treatment with 
systemic antiviral medications, 
intravenous antibiotics, or 
medications for helminth 
parasitic infection or requiring a 
permanent discontinuation of 
study drug.To clarify reporting rules for 
pneumonia in eCRFs and align 
with secti on 8.3.8.Non-substantia l
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 6of 217Section # and 
NameDescription of Change Brief Rationale Substantial/Non -
substantial
Section 8.3.8
Adverse Events 
of Special 
InterestAdded new AESI: ‘Serious 
cardiac events’.
Rem oved “Injection Site 
reactions ”.
Replaced “Anaphy lactic 
reactions ”and “Immune 
complex disease (Type III 
hypersensitivity reactions) ”with 
“Serious hy persensitivity 
reactions ”.
Replaced “Severe infections ”
and “Opportunistic infections ”
with “Serious infections ”, and 
added a footnote clarifying when 
to complete the eCRF Severe 
infection pages.To align wi th IB Edition 5.1, 
and to ensure consistent 
reporting in the eCRF.Substantial
Section 8.3.10
Medical Devices 
DeficienciesRem oved “and with third party 
medical devices ”.
Replaced bullet points 
- “Device constituent parts of the 
tezepelumab combination 
product
-the [COMPANY_008] medical 
device complaint report will be 
used to collect the deficiency.’
with ‘The [COMPANY_008] Clinical 
Study Medical Device/Device 
Constituent Report Form and/or 
Product Complaint Intake Form 
will be used to collect the 
deficiency. ”To clarify that as only device 
constituents of combination 
products are provided for use 
in the study and to align with 
Appendix J.
To clarify the device 
constituent deficiency 
reporting instructions (a ligned 
with the Pharmacy Manual).Non-substantial
Section [IP_ADDRESS] 
Prompt 
Reporting of 
Medical Device 
Deficiencies to 
Sponsor Added two bullet points: 
- “The [COMPANY_008] Clinical 
Study Medical Device/Device 
Constituent Report Form and/or 
Product Complaint Intake Form 
will be sent to [COMPANY_008] by 
[CONTACT_6968]. ”
- “Where an SAE has occurred 
in additio n to the malfunction, 
the SAE will be recorded in the 
eCRF as detailed in Section 
8.4.1.”To clarify the device 
constituent deficiency 
reporting instructions (Aligned 
with the Pharmacy Manual) .
To amend instructions on 
reporting to specify use of the 
[COMPANY_008] Clinical Study 
Medical Device/Device 
Constituent Report Form 
and/o r Product Complaint 
Intake Fo rm and to remove 
email addresses.Non-substantial
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 7of 217Section # and 
NameDescription of Change Brief Rationale Substantial/Non -
substantial
Deleted bullet points:
- “The [COMPANY_008] Report Form 
will be sent to the sponsor via 
email.
-Medical Device 
Deficiency with an 
associated SAE
-AEMailboxClinicalTria
[EMAIL_4758]
-gsqincomingcomplaints
@astrazeneca.com
NOTE: For SAE ’s, the eCRF 
must also be populated -see 
Section 8.4.1.
-Medical Device 
Deficiency with an 
associated AE
-gsqincomingcomplaints
@astrazeneca.com
-Medical Device 
Deficiency without an 
associated adverse or 
serious adverse event
-GCSCProductComplain
tOriginators@astrazene
ca.com ”
Section 8.4.4
Medication 
Error, Drug 
Abuse and Dru g
Misuse, and 
Appendix B 8Added definition and timelines 
for reporting drug abuse and 
drug misuse .Also, added the 
definition of  medication error to 
align with Appendix B.8Toalign with EU regulatory 
trials regulations .Non-substantial
Appendix A 1 Added wording related to 
regulato ry requirements for 
Serious Breaches .Toalign with EU regulatory 
trials regulations.Non-substantial
Appendix A 6 Added requirement sand 
timelines to submit clinical 
results to EU Clinical Trial 
Information System (CTIS ).To align with regulatory 
requirements related to 
Clinical Trial Transparency 
(CTT) language.Non-substantial
Clinical Study Protocol -7.[ADDRESS_297836] ivities (SoA) ............................................................................. 14
1.2 Synopsis ........................................................................................................... 20
1.3 Schema ............................................................................................................. 28
2. INTRODUCTION ............................................................................................ 29
2.1 Study  Rati onale ................................................................................................ 29
2.2 Background ...................................................................................................... 29
2.3 Benefit/Risk Assessment ................................................................................... [ADDRESS_297837] igational Products .................................................................................... 58
6.1.2 Medical Devices ............................................................................................... 59
6.2 Preparati on/Handling/Storage/Accountabilit y................................................... 59
6.3 Measures to Minimise Bias: Rando mization and Blinding ................................ 63
6.4 Com pliance to IP .............................................................................................. 66
6.5 Concomitant Therapy ........................................................................................ 66
6.5.1 Background (Maintenance) Medication ............................................................. [ADDRESS_297838] to Follow -Up............................................................................................. 81
7.3 Withdrawal fro m the Study ............................................................................... 82
7.3.1 Withdrawal Due to Recruit ment Com pletion..................................................... 82
7.3.2 Discontinuati on or Suspensio n of entire study  and Si te Cl osure ........................ 83
8. STUDY ASSESSMENTS AN D PROCEDURES ............................................. 83
8.1 Efficacy Assessments ........................................................................................ 84
8.1.1 COPD Exacerbat ion Definit ion......................................................................... 84
[IP_ADDRESS] Severit y of COPD Exacerbat ions...................................................................... 85
[IP_ADDRESS] Durati on of  COPD Exacerbat ions..................................................................... 85
[IP_ADDRESS] Approach for Capturing COPD Exacerbations .................................................. 86
[IP_ADDRESS] Invest igator Justified COPD Exacerbat ions....................................................... 86
[IP_ADDRESS] COPD Exacerbat ion visit .................................................................................. 87
8.1.2 Spi[INVESTIGATOR_038]........................................................................................................ 88
[IP_ADDRESS] General Requirements ....................................................................................... 88
[IP_ADDRESS] Post-BD Spi[INVESTIGATOR_038].......................................................................................... 90
[IP_ADDRESS] Sputum  post -BD spi[INVESTIGATOR_96656].............................................................................. 91
8.1.3 FeNO ................................................................................................................ 91
8.1.4 COPDCo mpEx ................................................................................................. 92
8.1.5 Clinically Important Deterioration (CID) .......................................................... 92
8.1.6 Patient Reported Outcomes ............................................................................... 92
[IP_ADDRESS] Major/Minor Symptom  Worsening Assessment and Alert Sy stem ..................... 93
[IP_ADDRESS] Rescue Medicat ion............................................................................................ 93
8.
1.6.3 Nocturnal  Awakenings ...................................................................................... 94
[IP_ADDRESS] Maintenance Medication ................................................................................... 94
[IP_ADDRESS] St. George’s Respi[INVESTIGATOR_96692] (SGRQ) ............................................... 94
[IP_ADDRESS] COPD Assessment Test (CAT) ......................................................................... 94
[IP_ADDRESS] Exacerbat ions of Chronic Pulmo nary Disease Tool –Patient -reported Outcome 
(EXACT -PRO) and Evaluat ing Respi[INVESTIGATOR_238439] (E -RS™: 
COPD) .............................................................................................................. 95
8.2 Safety Assessments ........................................................................................... 95
8.2.1 Clinical Safety  Laboratory  Assessments ............................................................ 95
[IP_ADDRESS] Pregnancy Test ................................................................................................. [ADDRESS_297839] emental  Oxy gen (O 2)............................................................................... 99
8.2.8 Oxygen Saturation (SpO 2)............................................................................... [ADDRESS_297840] X -ray.................................................................................................... 100
8.2.10 Vaccinat ion Restrictions ................................................................................. 100
8.2.11 Other Safet y Assessments ............................................................................... 103
[IP_ADDRESS] Serol ogy......................................................................................................... 103
[IP_ADDRESS] SARS -CoV -[ADDRESS_297841] ing AE and SAE Informat ion.............. 104
8.3.3 Follow-up of  AEs and SAEs ........................................................................... 105
8.3.4 Adverse Event Data Collection ....................................................................... 105
8.3.5 Causalit y Collection........................................................................................ 106
8.3.6 Adverse Events Based on Signs and Symptoms .............................................. 106
8.3.7 Adverse Events Based on Examinat ions and Tests .......................................... 106
[IP_ADDRESS] Adverse Events of Pneumo nia Requiring a Co nfirmed Diagnosis ................... [ADDRESS_297842] ................................
.................................. 107
8.3.9 Hy’s Law ........................................................................................................ 108
8.3.10 Medic al Device Deficiencies ........................................................................... 108
[IP_ADDRESS] Time Period for Detecting Medical Device Deficiencies ................................. 108
[IP_ADDRESS] Follow-up of  Medical Device Deficiencies ..................................................... 109
[IP_ADDRESS] Prom pt Reporting of Medical Device Deficiencies to Sponsor ........................ 109
[IP_ADDRESS] Regulatory  Reporting Requirements for Device Deficiencies .......................... 109
8.4 Safety Reporti ng and Medical Management .................................................... 110
8.4.1 Reporting of Serious Adverse Events .............................................................. 110
8.4.2 Pregnancy ....................................................................................................... 110
[IP_ADDRESS] Mate rnal Exposure .......................................................................................... 111
[IP_ADDRESS] Paternal  Exposure ........................................................................................... 111
8.4.3 Overdose ........................................................................................................ 111
8.4.4 Medicat ion Error, Drug Abuse and Drug Misuse ............................................. 112
[IP_ADDRESS] Timelines ........................................................................................................ 112
[IP_ADDRESS] Medicat ion error ............................................................................................. 112
[IP_ADDRESS] Drug Abuse .................................................................................................... 112
[IP_ADDRESS] Drug Mi suse ................................................................................................... [ADDRESS_297843] ion of Samples to Measure for the Presence of ADAs .......................... 115
8.5.3 Storage and Destruction of Pharmacokinet ic/Immunogenicit y Sam ples........... [ADDRESS_297844] Baseline Analyses ..................................... 123
9.4.2 Calculation or Derivat ion of Efficacy Variables .............................................. 124
[IP_ADDRESS] Exacerbat ion Rate ........................................................................................... 124
[IP_ADDRESS] Proporti on of  Subjects wi th ≥ 1 COPD Exacerbat ion...................................... 125
[IP_ADDRESS] Time to First Exacerbat ion.............................................................................. 125
[IP_ADDRESS] Annual Rate of Severe COPD Exacerbat ions.................................................. 126
[IP_ADDRESS] Forced Expi[INVESTIGATOR_21581] 1 Second ........................................................... 126
9.4.3 Calculation or Derivat ion of Safet y Variables ................................................. 126
[IP_ADDRESS] Safety Variables .............................................................................................. 126
[IP_ADDRESS] Adverse Events ............................................................................................... 126
[IP_ADDRESS] Other Si gnificant Adverse Events ................................................................... 127
[IP_ADDRESS] Laboratory  Variables ...................................................................................... 127
[IP_ADDRESS] ECGs .............................................................................................................. 128
[IP_ADDRESS] Physical Examinat ion...................................................................................... 128
[IP_ADDRESS] Vital signs ................................
....................................................................... 129
9.4.4 Calculation or Derivat ion of PRO variables .................................................... 129
[IP_ADDRESS] SGRQ ............................................................................................................. [ADDRESS_297845] ing Procedure ............................................................................. 130
9.5.2 Efficacy Analyses ........................................................................................... 130
[IP_ADDRESS] Primary Analysis Methods .............................................................................. 130
[IP_ADDRESS] Secondary  Analysis Methods .......................................................................... 131
9.5.3 Subgroup Analyses ......................................................................................... 132
9.5.4 Safety Analyses .............................................................................................. 133
9.5.5 Pharmacokinet ic and Immunogenicit y Analyses ............................................. 133
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 12of 2179.5.6 Biomarker Analyses ........................................................................................ 133
9.6 Interim Analyses ............................................................................................. 133
9.6.1 Independent Data Monitoring Co mmittee (IDMC) .......................................... 134
10. REFERENCES ............................................................................................... 135
11. SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS ...................................................................................... 139
APPENDIX A REGULATORY, ETHICAL AND STUDY OVERSIGHT 
CONSIDERATIONS ...................................................................................... 139
APPENDIX B ADVERSE EVENT DEFINI TIONS AND ADDITIONAL SAFETY 
INFORMATION ............................................................................................ 146
APPENDIX C HANDLING OF HUMAN BI OLOGICAL SAMPLES ............................ 151
APPENDIX D GENETICS .............................................................................................. 154
APPENDIX E ACTIONS REQUIRED IN CASES OF INCREASES I N LIVER 
BIOCHEMISTRY AND EVALUATION OF HY’S LAW .............................. 158
APPENDIX F MAINTENANCE THERAPY EQUIVALENCE TABLE ........................ 163
APPENDIX G ANAPHYLAXIS: SIGNS A ND SYMPTOMS, MANAGEM ENT ........... 164
APPENDIX H ABBREVIATIONS .................................................................................. 168
APPENDIX I CORONAVIRUS (COVID
-19) PANDEMIC GUIDANCE ...................... 175
APPENDIX J MEDICAL DEVICE AES, ADES, SAES, SADES, [LOCATION_003]DES AND 
MEDICAL DEVICE DEFIC IENCIES: DEFINITIONS AND PROCEDURES 
FOR RECORDING, EVALU ATING A ND FOLLOW -UP............................. [ADDRESS_297846] OF TABLES
Table 1 –Screening Period –Enrolment, Run -in................................................................. 14
Table 2 –Treatment Period -Rando mizat ion, Treatment and Fo llow-Up............................ 16
Table 3 –Risk Assessment .................................................................................................. [ADDRESS_297847] ion Sites ................................................. 62
Figure 3 -COVID -19 Vaccinat ion between IP Dosing ...................................................... 102
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 14of 2171. PROTOCOL SUMMARY
1.1 Schedule of Activities (SoA)
Table 1 –Screening Period –Enrolment, Run -in 
Assessment/ActivityScreening Details in CSP Section or 
AppendixEnrolment Run-in
Visit 1a2a
Day -42 to -35 -35
Visit Window (days) 0 +/- 4b
Pre-visit Assessments 
Telephone assessment of possible COVID -19  
symptoms kX XSection 4.1and Appendix I
Study Procedures
Informed Consent Form (ICF) and addendum to ICF 
(sputum/nasal sub -studies) (if applicable)X Section 5.1
COVID-19 addendum to ICF (if applicable) mX Appendix A 3and Appendix I
Inclusion/exclusion criteria X X Section 5.1and 5.2
Demography X Section 5.1
Medical, Surgical and COPD history X Section 5.1
Concomitant medication X X Section 6.5
Adverse events X X Section 8.3and Appendix B
Assessment of COPD exacerbation X X Section 8.1.1
Smoking status X X Section 8.2.2
Fractional Exhaled Nitric Oxide (FeNO) cX Section 8.1.[ADDRESS_297848] (CAT) X Section [IP_ADDRESS]
Site assigns electronic Patient Reported Outcome 
(ePRO) device and trains subject per the training 
guidelinesX Section 8.1.6
Patient Reported Outcome Assessments at Home
Home ePRO daily completion dX Section [IP_ADDRESS]
EXACT -PRO/E -RS™: COPD dX Section [IP_ADDRESS]
Clinical Lung Function Assessments
Pre-BD spi[INVESTIGATOR_244767] X Section 8.1.[ADDRESS_297849]-BD spi[INVESTIGATOR_038] X Section [IP_ADDRESS]
Routine Safety Procedures f
Complete physical examination eX Section 8.2.4
Weight, HeighteX Section 8.2.3
Vital SignseX Section 8.2.5
Supplemental oxygen (O 2) status eX Section 8.2.7
Oxygen saturation (SpO 2)eX Section 8.2.[ADDRESS_297850] x -ray egX Section 8.2.9
12-Lead digital Electrocardiogram (dECG) X Section 8.2.6
Laboratory Assessments
Clinical chemistry X Section 8.2.1
Hematology hX Section 8.2.1
Urinalysis X Section 8.2.1
Serology (Hepatitis B, C; HIV -1; HIV -2) X Section [IP_ADDRESS]
Serum pregnancy test X Section [IP_ADDRESS]
FSH iX Section [IP_ADDRESS]
TB Test (if applicable) eX Section 5.2
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 15of 217Pneumococcal and annual influenza vaccination, if 
applicableXjSection 8.2.10
SARS -CoV- 2 naso/oropharyngeal swab test (or rapid 
test) lX Section [IP_ADDRESS]
aScreening lung function assessments and ECG can only be done when there are no restrictions to medications (refer to Section 6.5.5 
and 8.1.3) and Visit 1 SARS -CoV -2 naso/oropharyngeal swab test (or rapid test) result is negative. If the SARS -CoV -2 
naso/oro pharyngeal swab test (or rapid test) result will not be available on the day of Visit 1, the screening lung function assessme nts 
and ECG must be postponed until next visit, the postponed Visit 1, after the SARS -CoV -2 naso/oropharyngeal swab test (or rapid test) 
result is confirmed negative. At a minimum, the following assessments/activities must be performed at Visit 1: obtain informe d 
consent, temperature measurement, enrolment of subject in IWRS and SARS -CoV -2 naso/oropharyngeal swab test. The remaining 
Visit [ADDRESS_297851] -BD spi[INVESTIGATOR_038], FeNO and ECG (combined Visit 1 and Visit 2) to be performed. Visit [ADDRESS_297852] -BD spi[INVESTIGATOR_244768] 1. Preferably, Visit 2 should be 
scheduled no later than 1 week after Visit 1 but the enrolment can be extended to accommodate additional waiting time r equired to 
obtain Visit 1 SARS -CoV -2 naso/oropharyngeal swab test result. 
bThe run -in phase (35 days) can be shortened by 4 days (to 31 days) or extended by 4 days (to 39 days). In case of a COPD 
exacerbation or respi[INVESTIGATOR_4416] (excluding pneumonia ) during the screening phase, the screening period may be extended up to 
14 days (including the 4 days i.e., to 49 days) to allow for the completion of the course of systemic corticosteroids and/or antibiotics or 
antiviral medication or to meet FeNO restrictions (Refer to section 5.4 ).
cThe sponsor will be blinded to the FeNO values except at screening visit, at any repeat testing that is performed during the screeni ng 
period and prior to Investigational Product (IP) administration. The sites will be blinded to the FeNO values for the whole s tudy 
duration.
dDaily Morning Diary: Nocturnal awakening and items related to: rescue medication use, major/minor symptoms; Dai ly Evening Diary: 
EXACT -PRO/E -RS™: COPD and items related to: rescue medication and maintenance medication.
eThese Visit 1 procedures can be performed at any time between Visit 1 and Visit 2 inclusive.
fThe suggested order of assessments: ePRO, vital signs, ECG, FeNO, spi[INVESTIGATOR_244769].
IMPORTANT: Applicable during COVID -19 pandemic: the suggested order of assessments: Vital signs, ePRO, blood draws and 
SARS -CoV -2 naso/oropharyngeal swab testing. The lung function assessments and ECG can only be done after Visit 1 SARS -CoV -2 
naso/oropharyngeal swab test (or rapid test) result is negative. 
gA chest X -ray must be done at Visit 1, or at any time that allows the chest X -ray assessment prior to randomization. Under special 
circumstances, a recently done historical chest X -ray (anterior -posterior and lateral)/CT/MRI for other reasons (not study related) 
might be acceptable. The outcome of the X -ray/CT/MRI must be documented in the patients’ medical records. Study Physician 
approval of historical chest X-ray must be obtained prior to randomization.
hThe sponsor and site will be blinded to the immunoglobulin, eosinophil, basophil and monocyte counts from the central laborat ory 
reports except screening visits (Visit 1 and Visit 2), any repeat testing tha t is performed during the screening period and prior to first 
Investigational Product (IP) administration.
iFSH test done only for female subjects to confirm postmenopausal status in women <[ADDRESS_297853] been amenorrheic for >[ADDRESS_297854] IP administration. Annual influenza vaccination can be 
done at any other time throughout the study (except for within ±5 days of IP administration) at the discretion of Investigato r. 
Inactive /killed vaccinations e.g. influenzae should be withheld 3 weeks prior to EOT for patients in the sub study (if no safety 
concerns) as it might influence exploratory sputum analysis. Refer to Section 8.2.[ADDRESS_297855] be contact[CONTACT_244922] -19 screening assessments within 72 hours prior 
to every study visit (except remote visits). Refer to Appendix I for details.
l Central laboratory SARS -CoV -2 nasopharyngeal or locally performed SARS -CoV -2 naso/oropharyngeal swab test result (or rapid test 
result) must be available and nega tive prior to performing screening lung function assessments and ECG (refer to footnote a under 
Table 1, section 1.1).
mDuring re -consenting of subjects during the COVID -[ADDRESS_297856] be followed. Refer to Appendix I
for further details.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 16of 217Table 2 –Treatment Period -Randomization, Treatment and Follow -Up
Assessment/
ActivityTreatment Period Follow -up IPD UNS aEXA bDetails in CSP Section or 
Appendix
Visit 3 4 5 6 7 8 9 10 11 12 13 14 15EOT/
1617 18
Week 0 4 8 12 16 20 24 28 32 36 40 44 48 52 58 64
Visit Window (days) 0 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±7 ±7 ±5  N/A N/A
Pre-visit Assessments 
Telephone assessment of possible 
COVID -19 symptoms pX X X X X X X X X X X X X X X X X X XAppendix I
Study Procedures
COVID-19 addendum to ICF 
(if applicable) mXAppendix A 3and 
Appendix I
Inclusion/exclusion criteria X Section 5.1and 5.2
Concomitant medication n, oX X X X X X X X X X X X X X X X X X X Section 6.5
Adverse events n, oX X X X X X X X X X X X X X X X X X XSection 8.3and 
Appendix B
Assessment of COPD exacerbation n, oX X X X X X X X X X X X X X X X X X X Section 8.1.1
Smoking status n, o X X X X X X X X X X X X X X X X X X X Section 8.2.2
Healthcare resource utilizationn, oX X X X X X X X X X X X X X X X X Section 8.9
FeNO cX X X X X X X Section 8.1.3
Patient Reported Outcome Assessments at Visit d
CAT n, oX X X X X X Section [IP_ADDRESS]
SGRQ n, oX X X X X X X Section [IP_ADDRESS]
ePRO compliance check n, oX X X X X X X X X X X X X X X Section 8.1.6
Patient Reported Outcome Assessments at Home d
Home ePRO daily completion X X X X X X X X X X X X X X X Section [IP_ADDRESS]
EXACT -PRO/E -RS™: COPD X X X X X X X X X X X X X X X Section [IP_ADDRESS]
Routine Safety Procedures
Brief physical examination nX X X X X X X X X X X X X X X X Section 8.2.4
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 17of 217Assessment/
ActivityTreatment Period Follow -up IPD UNS aEXA bDetails in CSP Section or 
Appendix
Visit 3 4 5 6 7 8 9 10 11 12 13 14 15EOT/
1617 18
Week 0 4 8 12 16 20 24 28 32 36 40 44 48 52 58 64
Visit Window (days) 0 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±7 ±7 ±5  N/A N/A
Complete physical examination nX X X Section 8.2.4
Weight X X Section 8.2.3
Vital Signs nX X X X X X X X X X X X X X X X X X X Section 8.2.5
Supplemental O 2status nX X X X X X X X X X X Section 8.2.7
Oxygen saturation (SpO 2) nX X X X X X X X X X X Section 8.2.8
12-lead digital Electrocardiogram (ECG) X X X X X X X Section 8.2.[ADDRESS_297857]-BD spi[INVESTIGATOR_038] X X X X Section [IP_ADDRESS]
Laboratory Assessments 
Clinical chemistry nX X X X X X X X Section 8.2.[ADDRESS_297858] (dipstick)h nX X X X X X X X X X X X X X X X X Section [IP_ADDRESS]
Serum for Pharmacokinetics (PK) X X X X X X X X Section 8.5
Serum for Immunogenicity iX X X X X X X X Section 8.5.2
Serum/Plasma Biomarkers X X X X X X X X Section 8.8
Urine Biomarkers X X X X X X X X Section 8.8
Blood RNA transcript profiling 
(PAXgene®tube)X X X X X X X X Section 8.8.3
[COMPANY_008] (AZ) genetics blood sample 
(optional)j XSection 8.7.[ADDRESS_297859] qX Section [IP_ADDRESS]
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 18of 217Assessment/
ActivityTreatment Period Follow -up IPD UNS aEXA bDetails in CSP Section or 
Appendix
Visit 3 4 5 6 7 8 9 10 11 12 13 14 15EOT/
1617 18
Week 0 4 8 12 16 20 24 28 32 36 40 44 48 52 58 64
Visit Window (days) 0 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±7 ±7 ±5  N/A N/A
Subset of Subjects Participating in Sputum and Nasal Lining Fluid/Epi[INVESTIGATOR_244770] k
Sputum post -BD spi[INVESTIGATOR_038] X X X X Section [IP_ADDRESS]
Sputum microbiome X X X X Section 8.8.5
Sputum biomarkers and Exploratory PK X X X X Section 8.8.5
Sputum cell pellet – cell counts and/or 
RNA transcriptomic profiling X X X X Section 8.8.5
Nasal lining fluid (nasal biomarkers and 
Exploratory PK)X X X X X X X XSection 8.8.6
Nasal epi[INVESTIGATOR_1663] (RNA 
transcriptome)X X X Section 8.8.4
Study treatment administration
Randomization rX Section 6.1
Administration of IP l nX X X X X X X X X X X X X Section 6.1.2
NOTE: The suggested order of assessments to be completed prior IP administration: ePRO, Vital signs, ECG, FeNO, spi[INVESTIGATOR_244771] d draws. Applicable during COVID -19 pandemic: Vital signs, 
ePRO, ECG, FeNO, spi[INVESTIGATOR_244769].
aUnscheduled visits may be initiated as needed and additional assessments can be performed at the discretion of the PI.
bEXA visit is an optional visit and may be initiated when patient experiences COPD exacerbation. Additional assessments can be performed at the discretion of the PI. If the EXA visit falls within 
+/-5 days of the scheduled treatment visit window, the laboratory assessments do not need to be repeated at the next scheduled visit if the same laboratory assessments were already comp leted at 
EXA visit, unless at the PI’s discretion. Refer to Section [IP_ADDRESS] .
cThe sponsor will be blinded to the FeNO values except at screening visit, at any repeat testing that is performed during the screening period and prior to Investigational Product (IP) 
administration.. The sites will b e blinded to FeNO values for the whole study duration.
dDaily Morning Diary: Nocturnal awakening and items related to: Rescue medication use, major/minor symptoms; Daily Evening Dia ry: EXACT -PRO/E -RS™: COPD and items related to: rescue 
medication and main tenance medication. EXACT -PRO/E -RS™: COPD is completed daily via e -diary and checked at visits.
eVisit [ADDRESS_297860] opportunity within the allowed visit window. 
Applicable for the COVID -19 pandemic: Spi[INVESTIGATOR_244772] r egulations and guidance. 
fPre-BD spi[INVESTIGATOR_038] (according to separate instruction manual) will be performed at EXA visit as part of induced sputum procedures during treatment phase if subject is participating in the sputum 
sub study.
gThe sponsor and site will be blinded to the immunoglobulin, eosinophil, basophil and monocyte counts from the central laboratory reports except sc reening visits (Visit 1 and 2), any repeat testing 
that is performed during the screen visits, and prior to IP administration.
hFor WOCBP only, urine HCG test to be done at study site at each treatment visit before the IP administration.
Clinical Study Protocol -7.[ADDRESS_297861] prior to the collection of optional pharmacogenetic sample. 
kInduced sputum and nasal sampling will be performed in a subset of subjects only and selected sites that are participating in the sub -study will consent s ubjects to participate in both induced 
sputum and nasal sample collection. Induced sputum is preferred however spontaneous sputum is acceptable if subjects that can not induce sputum. If sputum and nasal collections occur at the 
same visit, nasal sampling s hould occur before spontaneous/induced sputum collection. If patient is not able to produce sputum (spontaneous or induced) a t Visit 3, the patient should then be 
withdrawn from the sub -study, but can continue in the main study, and the nasal samples shoul d be discarded. Sputum sampling at IPD visit and at EOT visit can be performed up to [ADDRESS_297862]’s home or 
alternative location. Also, laboratory assessments can be completed post IP administration. Please refer to Appendix I .
mDuring re -consenting of subjects during the COVID -[ADDRESS_297863] be contact[CONTACT_244922] -19 screening assessment within 72 hours prior to every study visit (except remote visits). Refer to Appendix I
for details.
qSARS -CoV -[ADDRESS_297864] at Visit 3 is applicable for newly enrolled subjects. For remaining ongoing active subjects (in treatment or in follow -up), the test should be done as soon as possible but 
preferably at the next site visit.
rRandomization transaction in IWRS should be completed after confirmation of subject eligibility.
(EOT) -End of treatment; (EXA) -COPD exacerbation visit; (FU) -Follow -up; (IPD) -IP discontinuation visit; (UNS) -Unscheduled visit
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 20of 2171.2 Synopsis
Protocol Title: A Rando mized, Double -blind, Pl acebo -controlled, Parallel Group, 
Multicenter, Phase 2a Study  to Expl ore the Efficacy  and Saf ety of Tezepelumab in Patients 
with Moderate to Very  Severe Chronic Obstructive Pulmo nary Disease (COPD) (C OURSE)
Brief Title: Tezepel umab COPD Exacerbat ion study
Regulatory Agency Identifying Number(s):
IND number: [ADDRESS_297865] number: 2019-001363-67
Rationale: The purpose of this global study  is to evaluate the efficacy and safet y of 
tezepel umab 420 mg administered by  [CONTACT_6567] (SC) inject ion every  4 weeks (Q4W) in 
adults wi th moderate to very  severe COPD receiving triple inhaled maintenance therapy  
(inhaled corticosteroid/lo ng-acting β2 agonist and lo ng act ing muscarinic antagonist 
[ICS/LABA/LAMA]) 
who have had ≥[ADDRESS_297866] of tezepelumab as 
compared wi th placebo on COPD 
exacerbations in subjects with moderate to 
very severe COPDPrimary endpoint: Rate of moderate or severe 
COPD exacerbat ions
Primary outcome measure: Moderate or 
severe COPD exacerbation rate ratio 
(tezepelumab vs placebo) 
Supportive endpoint: Rate of moderate 
(excluding exacerbat ions treated only with 
antibiotics) or severe COPD exacerbat ions 
Supportive Measure: Moderate (excluding 
exacerbations treated only  with antibiotics) or 
severe COPD exacerbation rate ratio 
(tezepelumab vs placebo) 
Clinical Study Protocol -7.[ADDRESS_297867] 
moderate/severe exacerbationOutcome variables:
Time to first moderate or severe COPD 
exacerbation 
Proporti on of  subjects wi th ≥1 
moderate o r severe COPD exacerbat ion 
Outcome Measures:
Hazard Ratio (tezepelumab vs placebo)
Odds Ratio (tezepelumab vs placebo)
To evaluate the effect of tezepelumab as 
compared wi th placebo on severe COPD 
exacerbationsSecondary outcome variable: Rate of severe 
COPD exacerbat ions
Outcome measure: Rate rati o (tezepel umab 
vs placebo) 
Supportive outcome variables: 
Time to first severe COPD 
exacerbation
Proporti ons of pat ients experiencing a 
severe COPD exacerbation
Supportive outcome measures:
Hazard rati o (tezepel umab vs placebo)
Odds rati o (tezepel umab vs placebo)
To evaluate the effect of tezepelumab as 
compared wi th placebo on pre -
bronchodilator (BD) lung funct ionOutcome variable: Change from baseline in 
pre-BD forced expi[INVESTIGATOR_4034] 1 second 
(FEV 1) at Week 52
Outcome measure: Mean difference in 
change from baseline (tezepelumab vs 
placebo) at Week [ADDRESS_297868] of tezepelumab as 
compared wi th placebo on respi [INVESTIGATOR_244773] h status/healt h-related quali ty of life Outcome variables:
Proporti on of  subjects achieving an 
MCID of 4 units or more in SGRQ total 
score at Week 52
Change from baseline in SGRQ at 
Week 52 
Change from baseline in COPD 
assessment tool (CAT) at We ek 52
Outcome Measures:
Odds Ratio (tezepelumab vs placebo)
Mean difference in change fro m 
baseline (tezepelumab vs placebo) at 
Week 52
To evaluate the pharmacokinet ics (PK) 
and immunogenicit y of tezepel umabPK: Serum  trough concentrati on 
Immunogenicit y:Incidence of ant i-drug 
antibodies (ADA)
Safety Objectives: Safety Variables:
To assess the safet y and tol erabilit y of 
tezepel umab as compared wit h placebo in 
subjects wi th moderate to very  severe 
COPDAdverse events/serious adverse events 
(AEs/SAEs)
Vital signs
Laboratory  assessments
Electrocardiograms (ECG)
Exploratory Objectives: Exploratory Variables:
Clinical Study Protocol -7.[ADDRESS_297869] of tezepelumab on 
COPD Composite Exacerbat ions 
(COPDCompEx) eventOutcome variable: 
Time to COPDCompEx event
Rate of COPDCo mpEx events 
Outcome Measure: 
Hazard Ratio (tezepelumab vs placebo)
Rate rati o (tezepel umab vs placebo) 
over first [ADDRESS_297870] of tezepelumab on 
time to a Clinically  Important 
Deteri oration (CID) eventOutcome variable: Time to CID event
Outcome Measure: Hazard Ratio 
(tezepelumab vs placebo)
To expl ore the impact of tezepelumab on 
blood eosinophil and neutrophil levelsOutcome variable: Change from baseline in 
blood eosinophil and neutrophil levels 
Outcome measure: Change fro m baseline at 
Week [ADDRESS_297871] ion (FEV 1)Outcome variable: Change from baseline in 
post-BD forced expi[INVESTIGATOR_4034] 1 second 
(FEV 1) 
Outcome measure: Mean difference in 
change from baseline (tezepelumab vs 
placebo) at Week [ADDRESS_297872] -PRO defined eventsOutcome variable:
Change from baseline in Exacerbat ions 
of Chronic Pulmo nary Disease Tool -
Respi[INVESTIGATOR_244774] (EXACT -
PRO/E -RS™: COPD)
Rate of EXACT -PRO defined 
exacerbations
Outcome measure:
Mean difference in change fro m 
baseline (tezepelumab vs placebo) at 
Week 52
EXACT -PRO defined exacerbat ion rate 
ratio (tezepel umab vs placebo)
To evaluate tezepelumab’s effect on 
COPD- related healt hcare resource 
utilizat ionOutcome variable:
Rate of COPD -specific resource utilizat ion 
(e.g., unscheduled physician visits, 
unscheduled phone calls to phy sicians, use of 
other COPD medi cations)
Outcome measure:
Difference in rate of COPD -specific resource 
utilizat ions (tezepelumab vs placebo) over [ADDRESS_297873] inflammat ionOutcome variable: Fract ional exhaled nitric 
oxide (FeNO)
Outcome measure: Mean difference in 
change from baseline (tezepelumab vs 
placebo) at Week [ADDRESS_297874] of tezepelumab on 
total serum  immunogl obulinsOutcome variable: Total Immunoglobulins 
(IgE, IgA, IgM, IgG)
Outcome measure: Mean difference in 
change from ba seline (tezepelumab vs 
placebo) at Week [ADDRESS_297875] of tezepelumab on 
sputum  biomarkers, sputum  cell coun ts 
and sputum microbio me, in subjects 
participat ing in sub -study , at baseline, end 
of treatm ent, and at the start of all 
exacerbations during treatment phaseSputum  biomarkers of inflammat ion 
and remodeling   
Sputum  cell counts and cell 
different ials fromcytospi[INVESTIGATOR_2115] 
Sputum  microbio me
To expl ore the effect of tezepelumab on 
the blood and/or nasal epi[INVESTIGATOR_244775]/or sputum  cell transcriptome for 
pharmacodynamic (PD) markers of 
exposure or response to tezepelumab and 
pre-and post -dose predict ive markers of 
clinical responseTranscriptomic bio markers (may include but 
not limited to): RNA- Seq and RNA microarray  
profiling and microbiome profiling. 
Transcriptomics analysis may be carried out on 
blood cells, and/or nasal epi[INVESTIGATOR_39560]/or 
sputum  cells 
To evaluate the effect of tezepelumab on 
nasal lining fluid bio markersNasal bio markers including but not limited to 
inflammat ion and rem odeling
To evaluate the effect of tezepelumab on 
urine bio markersUrine bio markers including but not limited to 
inflam mation and rem odeling
To expl ore the rel ationships between 
pharmacogeno mic DNA markers and 
response/exposure to tezepelumabOptional AZ genomics bl ood sam ple. 
Pharmacogeno mic biomarkers may include 
(but not limited to): SNP and epi[INVESTIGATOR_244776]/or sputum
Note: Some exploratory analyses may be reported separately from the CSR.
Overall design:
This is a Phase 2a, mult icenter, randomized, double- blind, placebo -controlled, parallel group 
study  to eval uate the efficacy  and safet y of tezepelum ab [ADDRESS_297876] ion 
Q4W in subjects with moderate to very  severe COPD receiving triple inhaled maintenance 
therapy  (ICS, LABA and LAMA), and havi ng had ≥2 docum ented COPD exacerbat ions in the 
12 m onths pri or to visi t 1. Approximately  40% of  subjects will have had ≥3 exacerbat ions in 
the 12 m onths pri or to Vi sit 1 and approximately 30% of subjects will have had at least 1 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 26of 217severe exacerbat ion (an exa cerbat ion result ing in hospi [INVESTIGATOR_28689]) in the 12 m onths pri or to 
Visit 1. 
The study  will randomize approximately  338 subjects 1:1 to either tezepelumab or placebo, 
stratified by [CONTACT_11338], and number of prior exacerbatio ns. Approximately 20% of the subject s 
will be targeted to have ≥300 eosinophils/ μL, 40% of the subjects between ≥150 to <300 
eosinophils/μL and a maximum o f approximately  40% of  the subjects with <150 
eosinophils/μL at enrolment.
Induced sputum analyses will be performed in a subset of subjects and in a limited number of 
sites gl obally. The aim of the induced sputum subset analysis is to explore the mechanisms by  
[CONTACT_244923]. In these same selected subjects, 
analysis of nasal lining fluid and epit helial transcriptomics will also be performed. 
The screening period which consist of enrolment and run -in, will be approximately [ADDRESS_297877] a CAT score ≥15 and 70% compliance with the 
maintenance therapy  and acceptable com pliance wi th the eDi ary to be randomized. Subjects 
who meet the eligibilit y criteria will  be randomized to treatm ent.
After rando mizat ion subjects will be t reated at monthly  intervals wi th the l ast treatm ent 
administered at Week 48. The end -of-treatment (EOT) visit (Week 52) will occur at [ADDRESS_297878] treatm ent administered at Week 48 and follow -up visit s will occur at Week 58 and 
Week 64. Subjects will be maintained on their current ly prescribed maintenance therapi[INVESTIGATOR_244777] -in and treatment period. 
Study Period:
Estimated date of first patient enro lledQ3 2019.
Estimated date of last patient completed Q1 2024.
Number of Subj ects:
Approximately  338 subjects will be randomized to either tezepelumab or placebo (1:1) 
globally  from at least 90 si tes. The subjects will be stratified by  [CONTACT_244924] (2 vs ≥3). Since the primary  analysis of the primary  endpoint will include all 
available data, including after treatment discont inuation, no need is envisaged to adjust the 
number of subjects planned to be randomized to obtain a number of evaluable subjects.
Treatments and Treatment Duration:
The study  will consist of a screening period for approximately [ADDRESS_297879] -treatm ent follow-up peri od of 12 weeks. Subjects will be randomized in a 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 27of 2171:[ADDRESS_297880] acebo both administered Q4W SC . 
During the treatment period, IP will be administered fro m Day 0 unt il Week 48. No IP will be 
administered at Week 52. Subjects that complete the 52 -week study  visit will co mplete a 12 
week off -treatm ent follow-up peri od for assessments. Subjects who disc ontinue IP during the 
study  will be encouraged to undergo appropriate study  visits/procedures for the full 52 -week 
period (see Secti on 7.1.1 ). 
Independent Adjudication Committee:
An Independent Adjudicat ion Co mmittee (IAC) will assess blinded data to confirm the 
diagnosis and causalit y of major adverse cardiac events (MACE; defined in the IAC charter), 
serious cardi ac events, and deaths, as well as the diagnosis of malignancies, that occur fro m 
rando misat ion until the end o f the follow-up peri od.
The IAC will also assess whether cases of ER or urgent care visit s and hospi[INVESTIGATOR_24509], that 
occur from  rando misat ion until the end of the fo llow-up perio d, are due to a worsening o f 
COPD. 
Details on the adjudicat ion process, including scope of adjudicat ion and the committee 
membership, will be included in the Adjudicat ion Committee Charter/Manual of Operat ions.
Independent Data Monitoring:
An Independent Data Monitoring Co mmit tee (IDMC) will be tasked with two major 
responsibilit ies.  Fi rst, it will  be responsible for assessing all safet y related data collected 
during the study , including serious adverse events (including deaths and all hospi[INVESTIGATOR_124052]), 
non
-serious adverse events and laboratory  values. The IDMC will periodically review 
unblinded safet y summary  tables and list ings and evaluate for subject safet y and m ake 
appropriate recommendat ions. The committee will operate in accordance wit han IDMC 
Charter.
Second, the IDMC will be responsible for overseeing the two unblinded interim analyses 
based on the primary  endpoint that will be conducted in this study  (see Sect ion 4.1).  
Statistical Methods:
Efficacy analyses will be performed using the full analysis set (FAS), which consists of all 
subjects randomized and receiving any dose of IP. All subjects in the FAS will be included in 
the main efficacy analyses, including subjects who discontinue IP pri or to Week 52 (for which 
every attem pt will  be made to collect data after discontinuat ion of IP up until Week 52). 
The primary  efficacy  variable is the annual COPD exacerbation rate.  The exacerbat ion rate in 
the tezepelumab dose group will be co mpared t o the exacerbat ion rate in the placebo group 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 28of 217using a negat ive bino mial m odel including covariates of treatment group, region and the 
number of exacerbat ions in the year before the study  (2 vs ≥3). The l ogari thm of the follow -up 
time will be used as an offs et vari able in the m odel. 
Secondary  efficacy variables include the time to first COPD exacerbat ion, proportion of 
subjects wi th at least one COPD exacerbat ion, annual rate of severe COPD exacerbat ions, 
change from baseline in Pre -BD FEV1 and SGRQ, and pr oportion of subjects with at least 4 
units decrease in SGRQ.  These endpoints will be compared to the placebo group using 
appropriate models (Cox proportional hazards for time to event endpo int, logist ic regressio n 
for proporti on endpoints, Negative Bino mial regressi on for annual rate endpoints, Mixed 
effect Model Repeated Measures (MMRM) for change fro m baseline endpo ints.)
All safet y param eters will  be analyzed descript ively. Safet y analyses will be based on the 
safet y analysis set, defined as all subjec ts who received at least 1 dose of IP.
1.3 Schema
The general study  design is summarised in Figure 1.
Figure 1
-Study Flow Chart
V1 V2 R/V3 V4-V15 EOT/V16 V17, V18
Week
-6Week
-5Week 
0Week 
4-48Week 
52Week 
58, 64
EnrolmentRun-in
Treatment PhaseFollow -up
Screening
Screening Period
(Enrolment, Run -in)Tezepelumab 420 mg, SC every 4 weeks (n=169)
Placebo, SC every 4 weeks (n=169)
V: Visit, R: Rando mizat ion1:1
Randomization
1:1
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 29of 2172. INTRODUCTION
2.1 Study Rationale
2.2 Background
Chronic obstructive pulmo nary disease (COPD) is a progressive disease and a significant 
cause of morbidit y and m ortali ty worl dwide.  In contrast to other chronic diseases, COPD is 
increasing in prevalence and is projected to be the third leading cause of death and disabilit y 
worldwide by 2020 (Global Init iative for Chroni c Obstructive Lung Disease [ GOLD 2019 ]). 
Acute exacerbat ions of COPD (AECOPD) are responsible for a large portion of the econo mic 
burden of COPD. In addit ion to a substant ial economic burden, AECOPDs are also 
responsible for much of the morbidi ty and m ortali ty from COPD.  Pati ents wi th frequent 
AECOPD show associated increased airway inflammat ion and accelerated decline in lung 
funct ion compared wit h patients with infrequent exacerbat ions (Donal dson et al  2002 ). 
Thymic stromal lymphopoiet in (TSLP) is an upstream pleiotropic cytokine which is released 
by [CONTACT_244925][INVESTIGATOR_244778] -specific st imuli such as 
viruses , bacteri a, and cigarette smoke, all o f which are known to be associated with COPD 
exacerbations ( Ziegler et al 2013 ). In response to an allergen or non -specific st imuli, TSLP 
activates dendrit ic cells, which st imulate Type 2 helper T (Th2) cells to different iate and 
produce the Ty pe 2 cy tokines interleukin (IL) -4, IL -5, and IL -13 
(Watson and Gauvreau 
2014). TSLP can also drive Th17 cell expansio n through activat ion of dendrit ic cells, which 
will increase neutrophil recruit ment 
(Ziegler et al 2013 ).
TSLP, al ong wi th the other epi [INVESTIGATOR_018] “alarmins”, IL -25 and IL -33, activates Ty pe 2 innate 
lympho id cells (ILC2) and other inflammatory cell (including mast cells, basophils, and 
macrophages), thus promoting T2 inflammat ion by [CONTACT_25764] -regulat ing Ty pe 2 c ytokines in 
response to an epi[INVESTIGATOR_244779] (e.g., pollutants, microbes, cigarette smoke, bacterial and viral 
infect ions, m echanical  injury , traum a and pro -inflammatory  cytokines etc.) ( Camelo et al 
2017). 
TSLP protein is released fro m COPD epi [INVESTIGATOR_244780] -like receptor (TLR) viral 
(Calvern et al 2012 )
 and pro -inflamma tory cytokine stimulat ion (Kato et al 2007, Lee and 
Ziegler 2007 ). TSLP prot ein has been detected in nasal secret ions from healthy subjects 
undergo ing natural rhino virus infect ion (Perez et al 2014
) as well  as in the bronchoalveolar 
lavage (BA L) fluid and sputum of non -exacerbat ing COPD subjects (Ying et al 2008), and 
sputum  (Anzal one et al  2018 )
. TSLP mRNA expressio n is seen in airway epi[INVESTIGATOR_244781] ( Ying et al 2008).
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 30of 217Tezepel umab is a fully  human immunoglobulin G (IgG) monoclonal ant ibody  (mAb) di rected 
against TSLP.  Tezepelumab binds to human TSLP and prevents its interaction wit h the TSLP 
receptor (TSLPR). The hypothesis for the mechanism of act ion of tezepelumab in COPD is 
two-fold. First, beca use TSLP i s one of the earliest responses to airway  damage caused by  a 
range of st imuli, inhibit ion of TSLP i s expected to prevent the acute response to epi[INVESTIGATOR_244782].  Secondly, given that TSLP is an upstream and 
pleiotropic cy tokine, the blockade of TSLP is ant icipated to have broad impact on the 
spectrum of acute and chronic airway inflammatory  responses seen in COPD. Both effects are 
expected to reduce COPD exacerbations and improve COPD symptoms ( Camelo et al 2017 ).  
Thus, i t is hypothesized that inhibit ion of upstream TSLP by  [CONTACT_244926].  The purpose of the present study  is to invest igate the abilit y of 
tezepel umab versus placebo to enable reduction o f the annualized COPD exacerbat ion rate in 
subjects wi th moderate to very  severe COPD receiving standard mainten ance therapy .  
2.3 Benefit/Risk Assessment
COPD i s a progressive disease which is characterized by  [CONTACT_244927] y of life loss ( GOLD 2019 ). Des pi[INVESTIGATOR_244783] e and tri ple inhaled 
therapy , many COPD pati ents continue to have exacerbat ions (Wedzicha et al 2013 ).  
It has been shown that tezepelumab, as add -on therapy to standard -of-care (SoC), significantly 
reduces asthma exacerbat ions, including exacerbatio ns associated with hospi[INVESTIGATOR_244784], and improves lung function, asthma control, and qualit y of life in pat ients with severe 
uncontrolled asthma. Moreover, clinical improvements were seen irrespect ive of pat ient 
phenoty pe or bi omarker status ( Corren et al 2017). In the same study , tezepelumab was shown 
to decrease blood eosinophil counts, FeNO, and IgE levels, suggest ing that mult iple pathways 
are being impacted by  [CONTACT_244928]. 
No clinical data are available to show the effect of tezepelumab in COPD.  However, efficacy 
and safet ydata obtained in asthma supports clinical development of tezepelumab in COPD.
Use of tezepelumab has been demo nstrated to show an important benefit in asthma in a phase 
2b and phase [ADDRESS_297881] ions considered related to 
tezepel umab were reported in the Phase 3 program. To date th ere has been a low incidence of 
ADA and neutralising ant ibodies (nAb) reported wit h tezepelumab treatment in the Phase [ADDRESS_297882] of 
this study  (refer to Table 3), in conjunct ion with the perform ance of the As traZeneca’s routine 
pharmacovigilance act ivities.
A detailed assessment of the overall risk/benefit of tezepelumab in pat ients with COPD is 
given in the Invest igator’s Brochure.
Table 3
–Risk Assessment
Important 
potential RiskSummary of data/rationale 
for riskMitigation strategy
Study intervention
Serious infections
are defined as 
infect ions fulfilling 
criteria for 
regul atory  reportingThe m echanism  of action of 
tezepel umab suggests potential 
inhibitory  effects on immune 
responses mediated by  [CONTACT_78443]2 
cells, leading to the possibilit y 
of diminut ion of the host’s 
protective response to 
infect ion. Alt hough there is a 
theoreti cal risk of  serious 
infect ions wit h tezepelumab 
treatm ent, there is no data to 
support this potential risk . 
There i s also no evidence for 
causal relat ionship with 
tezepel umab.Vulnerable participants will be 
excluded based on eligibilit y 
criteria, and rando mised 
participants will be monitored by 
[CONTACT_45308] y blood work throughout the 
study ; and through standard 
AE/S AE reporting. 
Parti cipants will be excluded if they  
received systemic 
immunosuppressive or 
immuno modulating drugs within 3 
months prior to Visit 1; or if they 
have a history  of a known 
immunodeficiency  disorder; or 
have a history  of clinically 
significan t infect ion requiring 
treatm ent wi th systemic ant ibiotics 
or antiviral medications finalised < 
2 weeks before Visit 1 or during the 
run-in period or at randomisat ion; 
or who have evidence of act ive 
coronavirus disease 2019 (COVID -
19) infect ion during the r un-in 
period; or have had tuberculosis
requi ring treatm ent.
Serious infect ions are an AESI and 
participants who develop serious 
Clinical Study Protocol -7.[ADDRESS_297883] 
an increase in malignancies in 
the tezepeluma b data to -date in 
either pre -clinical or clinical 
studi es. No causal  relati onship 
with tezepel umab coul d be 
established for cases reported. Parti cipants wi th current 
malignancy or whose curative 
therapy  was com pleted recently will 
be excluded fro m participation 
based on eligibilit y criteria. All 
participants will be closely 
followed during the study  for any  
adverse events /serious adverse 
event , including malignancies that 
are considered AESI.
Serious cardiac 
eventsA numerical imbalance in 
cardi ac disorder SAEs was 
observed in the 
DESTINATION Long Term 
Extensio n study  (see 
Invest igator’s Brochure) with 
more events in participants 
treated with tezepelumab 
versus participants treated with 
placebo. None of the cardiac 
disorder SAEs was considered 
causa lly related to tezepel umab 
by [CONTACT_244929]. There is no known 
mechanism by [CONTACT_244930].Parti cipants wi th cardi ac disorders 
that are not stable in the opi[INVESTIGATOR_3078] n of 
the inves tigator or who present 
meaningful abnormal findings in 
examinat ion, lab assessments or 
ECG will be excluded based on 
eligibilit y criteria. 
All participants will be closely  
followed during the study  for any  
adverse events, including serious 
cardi ac events that are considered 
AESI.
Potential risksSummary of data/rationale 
for riskMitigation strategy
Study intervention
Serious 
hypersensitivity 
reactionsSystemic react ions to large 
therapeuti c molecules can be 
IgE or non -IgE-mediated and 
are generally  characteri sed by [CONTACT_244931], specific requirements 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 33of 217signs and symptoms such as 
skin rash, urticaria, pruritus, 
local or diffuse ery thema, 
angioedema, fever, chills, 
cough, dyspnoea, wheezing, 
bronchospasm, 
nausea/vo miting, diaphoresis, 
chest pain, tachycardia or 
bradycardia, and/or 
hypotens ion, which can all be 
severe or life -threatening. 
Effects ty pi[INVESTIGATOR_244785] m ay be 
delayed.
The administration of a 
monoclonal antibody  can resul t 
in the format ion of ADA. The 
occurrence of ADA coul d 
resul t in immune com plex 
disease (Ty pe [ADDRESS_297884] ions) 
with manifestati ons such as 
serum  sickness, nephrit is, and 
vasculit is, or altered 
tezepel umab l evels or acti vity. for observing participants for 
AEs/SAEs and for monitoring vital 
signs are included in this CSP. In 
addition, m edical equipment to treat 
acute anaphylactic reactions will be 
immediately  available and site staff 
will be trained to recognise and 
treat anaphylaxis.
To mit igate the potential risk of 
immune complex disease 
participants will be mo nitored for 
confirmed immune complex disease 
through routi ne m onitoring of 
AEs/SAEs.
Parti cipants with sensit ivity to any  
component of the study  intervent ion 
or a hi story  of drug or other allergy  
that, in the opi[INVESTIGATOR_3078] n of the 
investigator or medical mo nitor, 
contraindicates their participat ion 
will be excluded. Participants who 
have a history  of anaphyla xis or 
docum ented immune complex 
disease fo llowing any  biologic 
therapy  will also be excluded.
Serious hy persensi tivity reacti ons 
are an AESI and these events will 
be monitored cl osely throughout the 
study .
Helminth 
infectionsPotenti al inhibi tory effect s on 
immune responses mediated by 
[CONTACT_78443]2 cells, leading to the 
possibilit y of diminution o f the 
host’s protective response to 
parasit ic infestation/infection.Parti cipants wi th a helmint h 
infect ion diagnosed wi thin [ADDRESS_297885] ions will be monitored closely 
throughout the study .
Study procedures
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 34of 217COVID -19 
Pandemic, risk of 
COVID -19 
infectionThere i s the ri sk of  exposure to 
COVID -19 to parti cipants 
during site visit sLocal  guidelines will be followed to 
mitigate risk of part icipant’s 
exposure to COVID -19.
To identify potential COVID -[ADDRESS_297886] ion during the study  a 
COVID -19-related questionnaire is 
recommended prior to every  visit. 
Visits will be def erred if 
abnorm alities noted.
Sites are recommended to fo llow 
local severe acute respi[INVESTIGATOR_244786] 2 (SARS -CoV -2) 
testing guidelines, if applicable.
COVID -19 vaccinat ionis allowed 
during the study  (see
 Table 6).
Refer to Appendix I Coronavirus 
(COVID 19) Pandemic Guidance.
Clinical Study Protocol -7.[ADDRESS_297887] of tezepelumab as 
compared wi th placebo on COPD 
exacerbations in subjects with moderate to 
very severe COPDPrimary endpoint: Rate of moderate or severe 
COPD exacerbat ions
Primary outcome measure: Moderate or 
severe COPD exacerbation rate ratio 
(tezepelumab vs placebo) 
Supportive endpoint: Rate of moderate 
(excluding exacerbat ions treated only with 
antibiotics) or severe COPD e xacerbat ions 
Supportive Measure: Moderate (excluding 
exacerbations treated only  with antibiotics) or 
severe COPD exacerbation rate ratio 
(tezepelumab vs placebo) 
Secondary Objectives Outcome measure
To evaluate the effect of tezepelumab 
compared wi th placebo on time to first 
moderate/severe exacerbationOutcome variables:
Time to first moderate or severe COPD 
exacerbation 
Proporti on of  subjects wi th ≥1 
moderate or severe COPD exacerbat ion 
Outcome Measures:
Hazard Ratio (tezepelumab vs placebo)
Odds Ratio (tezepel umab vs placebo)
To evaluate the effect of tezepelumab as 
compared wi th placebo on severe COPD 
exacerbationsSecondary outcome variable: Rate of severe 
COPD exacerbat ions
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 36of 217Outcome measure: Rate rati o (tezepel umab 
vs placebo) 
Supportive outco me variables: 
Time to first severe COPD 
exacerbation
Proporti ons of pat ients experiencing a 
severe COPD exacerbation
Supportive outcome measures:
Hazard rati o (tezepel umab vs placebo)
Odds rati o (tezepel umab vs placebo)
To evaluate the effect of tezepel umab as 
compared wi th placebo on pre -
bronchodilator (BD) lung funct ionOutcome variable: Change from baseline in 
pre-BD forced expi[INVESTIGATOR_4034] 1 second 
(FEV 1) at Week 52
Outcome measure: Mean difference in 
change from baseline (tezepelumab vs 
placebo) at Week [ADDRESS_297888] of tezepelumab as 
compared wi th placebo on respi [INVESTIGATOR_244787] h status/healt h-related quali ty of life Outcome variables:
Proporti on of  subjects achieving an 
MCID of 4 units or more in SGRQ total 
score at Week 52
Change from baseline in SGRQ at 
Week 52 
Change from baseline in COPD 
assessment tool (CAT) at Week 52
Outcome Measures:
Odds Ratio (tezepelumab vs placebo)
Mean difference in change fro m 
baseline (tezepelumab vs placebo) at 
Week 52
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 37of 217To evaluate the pharmaco kinet ics (PK) 
and immunogenicit y of tezepel umabPK: Serum  trough concentrati on 
Immunogenicit y: Incidence of ant i-drug 
antibodies (ADA)
Safety Objectives: Safety Variables:
To assess the safet y and tol erabilit y of 
tezepel umab as compared wit h placebo in 
subjects wi th moderate to very  severe 
COPDAdverse events/serious adverse events 
(AEs/SAEs)
Vital signs
Laboratory  assessments
Electrocardiograms (ECG)
Exploratory Objectives: Exploratory Variables:
To expl ore the effect of tezepelumab on 
COPD Composite Exacerbat ions 
(COPDCompEx) eventOutcome variable: 
Time to COPDCompEx event
Rate of COPDCo mpEx events 
Outcome Measure: 
Hazard Ratio (tezepelumab vs placebo)
Rate rati o (tezepel umab vs placebo) 
over first [ADDRESS_297889] of tezepel umab on 
time to a Clinically  Important 
Deteri oration (CID) eventOutcome variable: Time to CID event
Outcome Measure: Hazard Ratio 
(tezepelumab vs placebo)
To expl ore the impact of tezepelumab on 
blood eosinophil and neutrophil levelsOutcome variable: Change from baseline in 
blood eosinophil and neutrophil levels 
Outcome measure: Change fro m baseline at 
Week [ADDRESS_297890] ion (FEV 1)Outcome variable: Change from baseline in 
post-BD forced expi[INVESTIGATOR_218548] 1 second 
(FEV 1) 
Outcome measure: Mean difference in 
change from baseline (tezepelumab vs 
placebo) at Week [ADDRESS_297891] -PRO defined ev entsOutcome variable:
Change from baseline in Exacerbat ions 
of Chronic Pulmo nary Disease Tool -
Respi[INVESTIGATOR_244774] (EXACT -
PRO/E -RS™: COPD)
Rate of EXACT -PRO defined 
exacerbations
Outcome measure:
Mean difference in change fro m 
baseline (tezepelumab vs placebo) at 
Week 52
EXACT -PRO defined exacerbat ion rate 
ratio (tezepel umab vs placebo)
To evaluate tezepelumab’ s effect on 
COPD- related healt hcare resource 
utilizat ionOutcome variable: Rate of COPD -specific 
resource utilizat ion (e.g., unscheduled 
physician visit s, unscheduled phone calls to 
physicians, use of other COPD medicat ions)
Outcome measure: Difference in rate of 
COPD
-specific resource utilizations 
(tezepelumab vs placebo) over [ADDRESS_297892] inflammat ionOutcome variable: Fract ional exhaled nitric 
oxide (FeNO)
Outcome measure: Mean difference in 
change from baseline (tezepelumab vs 
placebo) at Week [ADDRESS_297893] of tezepelumab on 
total serum  immunogl obulinsOutcome variable: Total Immunoglobulins 
(IgE, IgA, IgM, IgG)
Outcome measure: Mean difference in 
change from baseline (tezepelumab vs 
placebo) at Week [ADDRESS_297894] of tezepelumab on 
sputum  biomarkers, sputum  cell counts 
and sputum microbio me, in subjects 
participat ing in sub -study , at baseline, end 
of treatm ent, and at the start of all 
exacerbations during treatment phaseSputum bio markers of inflammat ion 
and remodeling   
Sputum  cell counts and cell 
different ials from cytospi[INVESTIGATOR_2115] 
Sputum  microbio me
To expl ore the effect of tezepelumab on 
the blood and/or nasal epi[INVESTIGATOR_244775]/or sputum  cell transcriptome for 
pharmacodynamic (PD) markers of 
exposure or response to tezepelumab and 
pre-and post -dose predict ive markers of 
clinical responseTranscriptomic bio markers (may include but 
not limited to): RNA- Seq and RNA microarray  
profiling and microbiome profiling. 
Transcriptomics an alysis may  be carri ed out on 
blood cells, and/or nasal epi[INVESTIGATOR_39560]/or 
sputum  cells 
To evaluate the effect of tezepelumab on 
nasal lining fluid bio markersNasal bio markers including but not limited to 
inflammat ion and rem odeling
To evaluate the effect of tezepelumab on 
urine bio markersUrine bio markers including but not limited to 
inflammat ion and rem odeling
To expl ore the rel ationships between 
pharmacogeno mic DNA markers and 
response/exposure to tezepelumabOptional AZ genomics bl ood sam ple. 
Pharmacogeno mic biomarkers may include 
(but not limited to): SNP and epi[INVESTIGATOR_244788]/or sputum
Note: Some exploratory  analyses may  be reported sepa rately  from the CSR
Clinical Study Protocol -7.[ADDRESS_297895] ion 
Q4W in subjects with moderate to very  severe COPD receiving triple inhaled maintenance 
therapy  (ICS, LABA and LAMA), and having had ≥2 docum ented COPD exacerbat ions in the 
12 m onths pri or to visi t 1. Approximately  30% of  subjects will have had at least 1 severe 
exacerbation (an exacerbat ion result ing in hospi [INVESTIGATOR_28689]) wi thin the 12 m onths pri or to Visit 
1. Approximately  40% of  subjects will have had ≥3 exacerbat ionswithin the 12 months prior 
to Visit 1. 
The study  will randomize approximately  338 subjects 1:1 to the treatment arms, stratified by  
[CONTACT_11338], and number of prior exacerbat ions. Approximately 20% of the subjects will be 
targeted to have ≥300 eosinophils/ μL, 40% of the subjects between ≥150 to <300
eosinophils/μL and a maximum o f approximately  40% of  the subjects with <150 
eosinophils/μL at enrolment. When the target percentage of subjects for the prior 
exacerbations or eosinophil subgroup in a region or overall is reached, considerat ion will be 
given to cl osing the Interactive Web Response System ( IWRS) rando mizat ion for that 
subgroup [by  [CONTACT_244932]]. Once a subgroup is closed, subjects in the screening period in 
the closed subgroup will not be allowed to be randomized and will be screen fail ed.
Induced sputum analysis will be performed in a subset of subjects and in a limited number of 
sites gl obally. The aim of the induced sputum subset analysis is to explore the mechanisms by  
[CONTACT_244923]. In these same selected subjects, 
analysis of nasal lining fluid and epit helial transcriptomics will also be performed. 
Pre-visit assessment during COVID -[ADDRESS_297896] be contact[CONTACT_244933] -19 symptom s 
within 72 hours pr ior to every  study  visit (except rem ote vi sits). Pl ease refer to Appendix I for 
details.
Screening Period (Enrolment and Run -in)
Clinical Study Protocol -7.[ADDRESS_297897] ions 
to medicat ions (re fer to Section
 6.5.5 and 8.1.3 ) andVisit 1 SARS -CoV -2 naso/oropharyngeal 
swab test (or rapi d test) resul t is negative. If the SARS -CoV -2 naso/oropharyngeal swab test 
(or rapi d test) resul t will  not be available on the day  of Visi t 1, the screening lung funct ion 
assessments and ECG must be postponed until next visit, the postponed Visit 1, af ter the 
SARS -CoV -2 naso/oropharyngeal swab test (or rapid test) result is confirmed negative.
At a minimum, the fo llowing assessments/act ivities m ust be performed at Visit 1: obtain 
inform ed consent, temperature measurement, enrolment of subjec t in IWRS and SARS -CoV -2 
naso/oropharyngeal swab test. The remaining Visit  [ADDRESS_297898] -BD spi[INVESTIGATOR_96656], FeNO and ECG (combined 
Visit 1 and Visi t 2) to be perform ed. 
Visit [ADDRESS_297899] -BD spi[INVESTIGATOR_244789] 1. Preferably, Visit 2 should be scheduled no later than 1 week after Visit 1 
but the enro lment can be extended to accommodate addit ional wait ing time required to obtain 
Visit 1 SARS -CoV -2 naso/oropharyngeal swab test result.
Subjects who have a blood eosinophil count <[ADDRESS_297900] for bl ood eosinophils is performed not earlier than 4 weeks fro m the previous 
testing. In case o f recent treatm ent wi th systemic corti costeroi ds, an interval o f ≥[ADDRESS_297901] dose is recommended.
The 35 day  run-in can be extended by:
4 day s for all pat ients (maximum run -in durat ion is then 39 day s) or
14 day s (including 4 days for all patients) for patients with exacerbat ion or respi[INVESTIGATOR_41376] (excluding pneu monia) during screening (maximum run- in duration is then 
49 day s) (Refer to secti on 5.4).
waiting time required to obtain Visit 1 SARS -CoV -2 naso/oropharyngeal swab t est 
resul t
28 day s for patients receiving COVID- 19 vaccine during screening
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 42of 21728 day s for wai ting t ime required to receive central lab kits  
Extensio n of the screening/run -in for any other reason will be allowed only  upon 
approval  of the [COMPANY_008] Study  Physician (Refer to section 5.4).
The 35 day  run-in can be shortened by :
4 day s for all pat ients (run -in duration is then 31 days)
At the end of the run -in period, subjects must continue to have a CAT score ≥15, 70% 
compliance wi th maintenance therapy  and acceptable com pliance wi th the eDiary  in order to 
be randomized. Subjects who meet the eligibilit y criteria will  be randomized to t reatment. 
Acceptable Documentation for COPD disease state and Historical COPD Exacerbations 
and Background Therapy 
A pat ient's verbal history  suggest ive o f COPD symptoms and/or COPD exacerbat ion(s) in the 
previous year, but without supporting documentat ion, is not sufficient to satisfy these 
inclusio n criteria. The bel ow defines what i s acceptabl e docum entati on for COPD di sease and 
histori cal COPD exacerbat ions (inclusio n criterion 6) in thi s program :
COPD di sease state and COPD exacerbat ion(s) in the pr evious year:
Clinic visit (primary or specialist healt hcare provider [HCP]) notes or emergency 
room /hospi [INVESTIGATOR_244790] a current diagnosis and providing evidence 
of ≥2 m oderate or severe exacerbat ions in the previous year (52 weeks prior to 
enrolment)
Documented prescri ption of systemic corticosteroids of at least 3 days duration (or 
1 injection o f depot form ulation) and/or antibiot ics for treatment of exacerbat ion
Discharge summaries from a hospi[INVESTIGATOR_307], emergency room, or an urgent care facilit y
indicat ing that a subject was hospi[INVESTIGATOR_244791] a COPD exacerbat ion
NOTE: In case of re -screening, moderate to severe COPD exacerbat ions from screening 
period are consi dered as histori cal COPD exacerbati ons wi thin 2to 52 weeks prior to re 
screening Visit 1 (Inclusio n 6) and should be entered in eCRF module COPDEXH and 
included in total number of historical COPD exacerbat ion during IWRS stratificat ion 
transi tion at re -screening visit. Refer to section 5.4
The below defines what is acceptable documentation for background COPD therapy  
(inclusio n criterion 7) in this program:
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 43of 217Use of tri ple (ICS/LABA/LAMA) background therapy  for CO PD throughout the previous 
year (52 weeks prior to enrolment), including assessment of patient’s compliance and any 
ident ified gaps in treatment or periods of double/monotherapy during the previous year:
Recent, active medicat ion list as per HCP note
Filled prescri ptions based on a pharmacy record
Another acceptable medical record as per local clinical practice
During the screening period the subject must undergo all assessments per Table 1. 
Randomization, Treatment and Follow -up
After rando mizat ion subjects will be treated at monthly  intervals wi th the l ast treatm ent 
administered at Week 48. The end -of-treatment (EOT) visit (Week 52) will occur at [ADDRESS_297902] an on- site visi t and on -site IP 
administration can be replaced wit h home/alternat ive location IP administration. Patient must 
sign the COVID -[ADDRESS_297903] will enter the optional COPD exacerbation visit (EXA) and complete the 
assessments according to Table 2if he/she experiences a COPD exacerbat ion during the 
treatm ent peri od, if deemed necessary  by [CONTACT_244934] (refer to Section [IP_ADDRESS] ). 
The subject can also return t o the site to complete an unscheduled visit (UNS) for the 
following reasons but not limited to, missed assessment(s) at last scheduled visit, safet y follow 
up, issues wi th equi pment, or other reasons that th e site deem s necessary. The UNS visit 
shoul d not be used for a COPD exacerbat ion as there is an EXA visit for this reason. In 
addition to the assessments listed in
 Table 2, other assessments may be p erformed at the PI’s 
discreti on. 
Secti on
 6.5(Table 6) provi des a list of medicat ion restrict ions and prohibit ions to be fo llowed 
throughout the conduct of the clinical trial.
Interim Analyses
Clinical Study Protocol -7.[ADDRESS_297904] 3 m onths of fo llow-up represen t approximately  30% of  all potenti al follow-up 
data and will be a fut ility analysis to potentially stop the study  early  if lack of  efficacy 
observed.  
The second interim analysis will be conducted approximately [ADDRESS_297905] 
been rando mized. This interim analysis will be used to guide an ‘Early Go’ decisio n by [CONTACT_244935].  Both interim analyses 
will be carried out using pre -defined rules by [CONTACT_244936] y and blinded nature of the study . After the second interim analysis, the 
study  will cont inue, regardless of whether the criteria for 'Early Go' was met.
4.2 Scientific Rationale for Study Design
The purpose of this glo bal study  is to provi de evidence of the efficacy  and safet y of a 420 m g 
dose of tezepelumab administered Q4W SC in adults wit h a history  of COPD exacerbat ions 
and moderate to very  severe COPD receiving triple inhaled maintenance ther apy with 
ICS/LABA/LAMA. 
The primary  endpoint (COPD exacerbat ion) is a well -accepted m easure for a study  in COPD. 
In order to avoid bias the study  will be rando mized and double blinded. Subject entry will be 
stratified by [CONTACT_244937] (2 vs ≥3) to ensure equitable 
distribut ion for analysis.
Given that TSLP is an upstream and pleiotropic cytokine, the blockade of TSLP is ant icipated 
to have impact on the broad spectrum of inflammatory  responses seen in COPD. Subject entry  
into the study  will be m onitored to ensure that there are adequate numbers of patients within 
different phenoty pes (level o f blood eosinophils and number of exacerbat ions in the previous 
year) for analysis.
Induced sputum analysis will be performed in a selected group of sites. The aim of this subset 
analysis is to further help to answer mechanist ic and conceptual quest ions regarding the effect 
of tezepel umab in COPD exacerbat ions. Sputum biomarkers may be measured to evaluate the 
pharmaco logy of tezepel umab, explo ratory  PK, ai rway  microbi ome and bi omarkers related to 
COPD, inflammat ion and the TSLP pathway . Key understandings are believed to come from 
sputum  samples obtained at the time of COPD exacerbat ion. In these same subjects, analyses 
of nasal  lining fluid an d nasal epi[INVESTIGATOR_244792].
Clinical Study Protocol -7.[ADDRESS_297906] been evaluated and well tolerated in healt hy subjects in the Phase 1 mult iple 
ascending dose study 20080390 as well as the allergen challenge study  20101183 in patients 
with mild asthma. Further, in study  CD-RI-MEDI9929- 1146, repeated dosing at 70 mg Q4W, 
210 m g Q4W, and 280 m g Q2W SC for 52 weeks were well tolerated in subjects with severe 
asthma, and the safet y profile was well balanced between the tezepelumab and placebo groups 
with no evidence o f a dose rel ationship in treatment -emergent adverse events. Based on 
popul ation PK model simulat ion, the predi cted area under the concentration -time curve 
(AUC) of serum tezepeluma b concentration at steady  state was  l ower and the predicted 
maximum concentration (C max) at steady  state was  lower at 420 m g Q4W co mpared to 
280 m g Q2W SC. Therefore, the dose of 420 mg Q4W SC  
4.4 End of Study Definition
For the purpose of Clinical Trial Transparency ( CTT) t he definit ion of the end of the study  
differs under FDA and EU regulatory  requi rements:
European Unio nrequi rements define study  com pletion as the l ast vi sit of the l ast subject for 
any protocol related activit y.
Food and Drug Administration requirements defines two complet ion dates:
Primary Co mpletion Date –the date that the final participant is examined or receives an 
intervent ion for the purposes of final co llection of data for the primary  outcom e measure, 
whether the clinical study  concluded according to the pre -specified protocol or was 
terminated. In the case of clinical studies with more than one primary outcome measure with 
CCI
CCI
CCI
Clinical Study Protocol -7.[ADDRESS_297907] ion is completed 
for all of the primary  outcom es.
Study  Com pletion Date –the date the final part icipant is examined or receives an intervent ion 
for purposes of final co llection o f data for the primary  and secondary  outcom e measures and 
AEs (for example, last participant’s last visit), whether the clinical study  concl udes according 
to the pre -specified protocol or is terminated.
A subject i s considered to have co mpleted the study whe n he/she has co mpleted his/her last 
scheduled contact.
See Appendix A 6for guidelines for the dissemination of study  resul ts.
5. STUDY POPULATION
Prospective approva l of protocol  deviati ons to recrui tment and enro lment criteria, also known 
as protocol waivers or exemptions, is not permitted.
Each subject should meet all the inclusio n criteria and none of the exclusio n criteria for thi s 
study  in order to be assigned/ra ndomized to the study intervent ion. Under no circumstances 
can there be exceptions to this rule. Subjects who do not meet the eligibilit y requi rements are 
screen failures (refer to Section 5.4).
In thi s protocol , “enrolled” subjects are defined as those who sign the informed consent.  
“Rando mized” subjects are defined as those who undergo randomizat ion and receive a 
rando mizat ion number. 
5.1 Inclusion Criteria
Subjects are eligible to be included in the study  only  if all the foll owing incl usion criteria and 
none of the exclusio n criteria apply :
Informed consent:
1. Provisio n of signed and dated, written informed consent form prior to any 
mandatory  study  specific procedures, sampling, and analyses. 
2. Provisio n of signed and dated written addendum to informed consent form for 
sputum /nasal sub studies pri or to collect ionof sputum /nasal samples (if applicable). 
3. Provisio n of signed and dated written genet ic informed consent prior to collect ion 
of optional samples for geneti c analysis (if applicable). 
The ICF process is described in Appendix A 3.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 47of 217Age:
4. Female or m ale subjects aged ≥40 to 80 y ears inclusive at the time of enrolment 
(Visit 1). 
Type of subject and disease characteristics:
5. History  of moderate to very  severe docum ented physician -diagnosed COPD for at 
least [ADDRESS_297908] -bronchodilator FEV1/FVC<0.[ADDRESS_297909] -bronchodilator FEV 1≥20% and ≤80% of predicted normal value at Visit 2 
(or Vi sit 1 if  Visi t 1 and 2 are combined). 
6. History  of at least 2 documented moderate to severe COPD exacerbat ions, within 2 
to 52 weeks prior to enrolment (Visit 1) or re -screening Visit 1.  See Section 4.1for 
requi red source d ocum entati on for this inclusi on.
A moderate COPD exacerbation is defined as an exacerbat ion that required 
treatm ent wi th systemic corti costeroi ds for at l east 3 day s durati on (or [ADDRESS_297910] ion of depot formulat ion) and/or antibiot ics.
Asevere COPD exacerbat ion is defined as an exacerbat ion that required 
hospi [INVESTIGATOR_28689] (defined as an inpat ient admissio n ≥24 hours in the hospi[INVESTIGATOR_307], 
in an observation area, the emergency  departm ent or other equivalent 
healt hcare facilit y depending on the country  and heal thcare s ystem ).  
Prior use of ant ibiotics alo ne does not qualify as a moderate exacerbat ion 
unless the ant ibiotic was specifically prescribed for the treatment of 
worsening COPD symptoms.
Previous exacerbat ions should be confirmed to have occurred while pat ient 
was on stable triple (ICS/LABA/LAMA) background therapy for COPD and 
not as a result of a step down in therapy , i.e. change fro m triple to dual  
therapy .
NOTE: In case of re -screening, moderate to severe COPD exacerbat ions 
from screening period are considere d as histori cal COPD exacerbat ions 
within 2 to 52 weeks prior to re -screening visit and should be included in 
total number of histori cal COPD exacerbati ons. Refer to section 5.4
7. Docum ented treatm ent wi th medium  or hi gh dose ICS at a total daily dose 
corresponding to >250μg flut icasone propi[INVESTIGATOR_244793] (Visit 1). 
The dose of I CS shoul d be stable for 3 m onths pri or to Vi sit 1. See Secti on 4.1for 
requi red source documentation for this inclusion criterion. See Appendix F for ICS 
dose conversion table. 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 48of 217 Patient coul d have switched therapi[INVESTIGATOR_244794] y ear and/or 
stepped down for short periods of time, although the total cumulat ive 
durati on that the patient was not using triple (ICS/LABA/LAMA) 
background therapy  must not exceed 2 m onths.
 If an Invest igator decides to switch a subject who is on an ICS in a separate 
single device to a fixed -dose com binat ion device therapy, this should be done 
at Vi sit [ADDRESS_297911] remain at the same dose and schedule 
as used in the 3 months prior to Visit 1 (provided dose and regimen are 
locally approved for COPD).
8. CAT score ≥15 at Vi sit 1(only  based on ePRO questionnaire).
9. Current sm oker or ex -smoker wi th a tobacco history o f ≥10 pack- years (1 pack y ear 
= 20 cigarettes smoked per day  for 1 y ear). Never smokers are not eligible for study  
entry .
10. If on allergen -specific immunotherapy , subjects must be on a m aintenance dose and 
schedule f or at l east [ADDRESS_297912] 12 m onths pri or to Visit 1 and on stable dose 3 months prior to Visit 1. 
Note: Subjects on maintenance treatment with theophy lline shoul d have blood 
concentration levels wit hin the therapeutic range documented within 8 weeks prior 
to Visit 1. If this is not documented before signing the informed consent, it can be 
obtained after informed consent has been given or as part of the Visit 1 procedures 
(see Section 6.3and Table 6.
12. Inclusio n criterion 12 rem oved with versio n 4.0 of Clinical Study Protocol and 
replaced wi th Exclusio n criterion 40.
Weight:
13. Weight ≥40 kg at Visit 1.
Reproduction:
14. Negative serum pregnancy  test f or female subjects of childbearing potential.
15. Women of childbearing potential (WOCBP) who are sexually act ive must use a 
highly  effect ive form of birth control  from enro lment and must agree to continue 
using such precaut ions for [ADDRESS_297913] inence, the rhythm method, and the wit hdrawal method are not 
acceptable methods of contraception. 
An effect ive method of contraception is defined as one that results in a low 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00 001
CONFIDENTIAL AND PROPRIETARY Page 49of 217failure r ate (i .e., less than 1% per y ear) when used consistent ly and correctly . 
Highly effect ive birth control methods include: sexual abst inence [periodic 
abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation methods), 
declaration of abst inence for the duration of exposure to IMP, and withdrawal 
are not acceptable methods of contraception], a vasectomized partner, 
Implanon®, bilateral tubal occlusio n, intrauterine device/levonorgestrel 
intrauterine system, Depo -Provera™ inject ions, oral contraceptiv e, and Evra 
Patch™, Xulane™, or NuvaRing®.
Women not of childbearing potential are defined as women who are either 
perm anent ly sterilized (hysterectomy, bilateral oophorectomy, or bilateral 
salpi[INVESTIGATOR_1656] ), or who are postm enopausal . Women will be considere d 
postm enopausal if they  have been amenorrhoei c for 12 m onths pri or to the 
planned date of randomization wit hout an alternat ive medical cause. The 
following age -specific requirements apply:
(a)Women <[ADDRESS_297914] 
been amenorrhoeic for 12 months or more fo llowing cessat ion of exogenous 
horm onal treatm ent and follicle stimulat ing horm one (FSH) l evels in the 
postm enopausal range. Unt il FSH i s docum ented to be wi thin menopausal 
range, treat the subject as WoCBP.                                                                                                                                  
(b)Women ≥[ADDRESS_297915] 
been amenorrhoeic for 12 months or more fo llowing cessat ion of all 
exogenous hormonal treatment. 
Additional criteria to be checked prior to randomization (Visit 3): 
16. Com pliance wi th the eDi ary com pletion during the run -in period defined as 
completing at least [ADDRESS_297916] -PRO/E -RS assessments in the 12- day period pri orto 
Visit 3.
17. At least 70% compliance wit h the subject’s maintenance therapy  (defined as taking 
all maint enance medicat ion as scheduled for the day) during the run- in period fro m 
Visit 2 (or Vi sit 1 if  Visi t 1 and 2 are combined) to Visit 3 based on the eDi ary.
18. A CAT score of ≥15 (only  based on ePRO questionnaire).
19. Stabl e FEV 1during the screening period, defined as a change in pre -BD FEV 1≤400 
mL and/or ≤25% compared to baseline pre -BD (Visi t 1) assessment. If a patient 
demonstrates si gnificant change (>400 mL and/or >25% in eit her di rection) in pre -
BD FEV 1during the screening period, the AZ study physician must be consulted to 
determine the patient's disposit ion; randomizat ion may not occur without 
consultation and agreement with AZ study  physician/delegat e.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 50of [ZIP_CODE]. Acceptable inhaler and spi[INVESTIGATOR_244795]/European Respi[INVESTIGATOR_96661] (ATS/ERS) guidelines (Miller et al 2005) 
during the run -in period. 
5.2 Exclusion Criteria 
Subjects should not enter the study  if any of th e following exclusio n criteria are fulfilled:
Medical conditions:
1. Clinically important pulmonary disease other than COPD, as judged by 
[CONTACT_244938], (e.g., active lung infect ion, main clinical feature is bronchiectasis or 
emphysema, pulm onary fibrosis, cy stic fibrosis, hypovent ilation syndrome 
associ ated wi th obesi ty, lung cancer, al pha 1 ant i-trypsin deficiency  and primary 
ciliary  dyskinesia) or another diagnosed pulmo nary or systemic di sease that is 
associ ated wi th elevated peri pheral  eosinophil  counts (e .g., allergic 
bronchopulmo nary aspergill osis (ABPA)/mycosis, eosinophilic granulo matosis with 
polyangiit is (EGPA), hy pereosinophilic syndrome) and/ or radiological and/or 
laboratory  findings suggest ive of a respi[INVESTIGATOR_244796]’s respi[INVESTIGATOR_1856].  
2. Current asthma diagnosis according to the Global Init iative for Asthma (GINA) 
guidelines ( GINA 2018) or other accepted guidelines. Patients with a history  of 
asthma, including paediatric asthma or asthma -COPD Overl ap Syndrom e (ACOS), 
are not eligible for the study .  
3. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepat ic, 
renal, neuro logical, muscul oskeletal , infect ious (including risk factors for 
pneumo nia), endocrine, metabolic, haematological, immune, psychiatric, or major 
physical impairment that is not stable in the opi[INVESTIGATOR_3078] n of the Invest igator and/or 
could:
(a)Affect the s afety of the subject throughout the study
(b)Influence the findings of the study  or thei r interpretation
(c)Impede the subject’s abilit y to complete the ent ire durati on of  study
Note: Subjects who have epi[INVESTIGATOR_244797] a stable dose of medicat ion for [ADDRESS_297917] igator’s judgement 
may put the patient at risk or negatively affect the outcome of the study .
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 51of 2175. Treatment with systemic corticosteroids and/or antibiot ics, and/or hospi[INVESTIGATOR_244798] a COPD exacerbat ion within 14 days prior to enrolment (Visit 1), based on last 
dose of corticosteroids or last date of hospi[INVESTIGATOR_059], whichever occurred later.
Note: Refer to Exclusion criteria [ADDRESS_297918] ion with maintenance systemic 
steroi d treatm ent.
6. History of clinically  significant infecti on (excluding pneumonia), acute upper or 
lower respi [INVESTIGATOR_103415], requi ring ant ibiotics or antiviral medicat ion within 14 
days pri or to enrolment (Visit 1) based on the last day  of antibiotic/antiviral 
treatm ent or hospi [INVESTIGATOR_244799], whatever occurred later.  
7. History  of pneum onia requi ring ant ibiotics or antiviral medicat ion within 28 days 
prior to enrolment (Visit 1) or during the screening period, based on the last day  of 
antibiotics or hospi[INVESTIGATOR_244799], whatever occurred later or during the enrolment 
andscreening period. 
8. Known history  of allergy  or reacti on to any  com ponent of the invest igational 
product formulat ion.
9. History  of anaphylaxis to any  other bi ologic therapy .
10. Donati on of  blood, pl asma, or platelets within the past [ADDRESS_297919] igator or Study Physician.
13. History  of cancer: 
Subjects who have had basal cell carcino ma, l ocalized squamous cell 
carcino ma of the skin or in si tu carcinoma of the cervix are eligible to 
participate in the study  provi ded that c urative therapy was co mpleted at least 12 
months prior to Visit 1. 
Subjects who have had other malignancies are eligible provided that curative 
therapy  was com pleted at l east [ADDRESS_297920] ive tuberculosis 
(TB), either treated or untreated, or latent TB without completion of an appropriate 
course of treatment. Evaluation will be according to the local standard of care as 
determined by [CONTACT_244939], chest x -ray, sputum  stain and/or cul ture, and/or TB test (e.g., purified 
protein derivat ive or QuantiFeron test). 
15. Major surgery  within 8 weeks pri or to Visit 1 or planned surgical procedures 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 52of 217requi ring general anaesthesi a or i n-patient status for >[ADDRESS_297921] of 
the study .
Prior/concomitant therapy:
16. Subjects currently receiving background therapy  that i s not l ocally  approved for 
COPD are not eligible for the study  (refer to Secti on 6.5.1 )
17. Long term  oxygen therapy  (LTOT) wi th signs and/or symptoms of cor pulmonale 
and/or ri ght ventri cular failure, orsubjects receiving LTOT >4.0 litres/minute 
(L/min), orsaturation <89% despi [INVESTIGATOR_244800]. 
18. Use of any  non-invasive posit ive pressure vent ilation device (NIPPV).  Note: 
Subjects using cont inuous posit ive airway pressure (CPAP) or bilevel posit ive 
airway pressure (BiPAP) for Sleep Apnea Syndrome are allowed in the study .
19. Use of syste mic immunosuppressive medication (including but not limited to 
methotrexate, cy closporine, m aintenance systemic steroid treatment, any  
experimental anti -inflammatory  therapy ) within 3 mo nths prior to enrolment (Visit 
1) or throughout the screening period. Use of systemic steroids for treatment of 
exacerbations is allowed (see exclusion criterion 5). 
20. Receipt of immunoglobulin or blood products within 30 days prior to enrolment 
(Visit 1).
21. Receipt of any  investi gational non -biologic product wi thin 30 days or 5 half -lives 
whichever i s longer, pri or to Visit 1.
22. Receipt of any  marketed (e.g., omalizumab) or any invest igational monoclonal or 
polyclo nal antibody  therapy  (e.g., gamma gl obulin) taken for any  reason wi thin [ADDRESS_297922] ic use of COPD 
exacerbation if duration o f treatm ent is < 9 m onths pri or to enrolment (Visit 1) or 
re-screening visit. If the patient was previously on prophylact ic treatment but is no 
longer taking it, the patient cannot be rando mized unt il [ADDRESS_297923] dose.
Chronic macrolide or other antibiot ic therapy is allowed provided the pat ient has 
been on a stable dose/regimen for ≥ 9 m onths pri or to enrolment (Vi sit 1) or re -
screening visit andhave had at least [ADDRESS_297924] ic treatment.
Note : Pati ents who received ≥[ADDRESS_297925] be interviewed for potential 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 53of 217hearing issues/t innitus at enrolment; any reported issues will be recorded as part of 
medical history .  
25. Influenza vaccinat ion within [ADDRESS_297926] ion (Vi sit 3) f or subset 
of subjects only . Vaccinat ion prior to that or after that time is acceptable.
26. Subjects with lung vo lume reduction surgery  within the 6 months prior to Visi t 1.  
Subjects with history  of partial  or total  lung resection (single lo be or 
segmentectomy  is acceptable).
27. Subjects that have been treated with bronchial thermoplast y or received 
endobronchial valves in the last 12 months prior to Visit 1. 
Prior/concur rent clinical study experience: 
28. Subjects participat ing in, or scheduled for, an intensive (active) COPD 
rehabilitat ion program (however subjects who are in the maintenance phase of a 
rehabilitat ion program are eligible to take part).
29. Employees of the clinical study  centre or family members (first -degree relat ives) of 
such individuals or any one invo lved in the planning and/or conduct of the study .
30. Previous treatment with tezepelumab (MEDI9929/AMG157).
Diagnostic assessments:
31. Any clinically  significant a bnormal findings in physical examinat ion, vital signs, 
hematol ogy, clinical chemistry , or uri nalysis during screening period, which in the 
opi[INVESTIGATOR_3078] n of the Invest igator, may put the subject at risk because of his/her 
participat ion in the study, or may influe nce the results of the study , or the subject’s 
abilit y to complete enti re durati on of  the study .
32. Evidence of act ive liver disease (with or without ongo ing treatment), including 
jaundice or aspartate transaminase (AST), alanine transaminase (ALT), or alkali ne 
phosphatase (ALP) > 2 times the upper limit of normal (ULN) at Visit 1.
33. Subjects are excluded if they have any of the fo llowing:
A history  of known immunodeficiency  disorder incl uding a posi tive test for 
human immunodeficiency virus, HIV -1 or HIV -2 at V isit 1.
Positive hepat itis B surface ant igen, or posit ive hepatit is C virus ant ibody  
serol ogy, or a posi tive medical history  for hepat itis B or C at Visit 1.  Patients 
with a history  of hepatitis B vaccinat ion without history  of hepatitis B are 
allowed to enrol.
Other exclusions:
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 54of [ZIP_CODE]. Pregnant, breastfeeding, or lactating wo men.
A serum β -HCG pregnancy  test m ust be drawn for women of childbearing 
potenti alatthe screening visit. If test result is positive, the subject should be 
excluded. Since urine and serum tests may miss a pregnancy in the first day s 
after concepti on, rel evant m enstrual history  and sexual history , incl uding 
methods of contraception, should be considered. Any subject whose 
menstrual and/or sexual history  suggests the possibilit y of early pregnancy  
shoul d be excluded. 
35. Judgment by  [CONTACT_96751] i s unlikely to comply wit h study procedures, restri ctions and 
requi rements or for safet y reasons.
Genetic Research exclusion criteria:
36. Previous allogeneic bone marrow transplant.
37. Non-leukocyte depleted whole blood transfusio n wit hin [ADDRESS_297927] ion.
COVID -19 pan demic exclusion criteria:
38. Judgment by  [CONTACT_244940] -[ADDRESS_297928] ion or i s 
febrile ( ≥ 38°C; ≥ 100.4°F) suspected due to COVID -[ADDRESS_297929] ion. 
39. Positive SARS -CoV -2 naso/oropharyngeal swab test, positive rapid antigen test or  
positive alternat ive test (approved by [CONTACT_54021] h authorities) for active infection at 
Visit 1. 
40. Chest X -ray performed during the screening perio d which shows abnormalit ies or 
evidence of  COVID -19 pneumonia that precludes the patient’s abilit y to complete 
the study . 
Note: Under special circumstances, a recent ly done historical chest X -ray (anteri or-
posteri or and l ateral )/CT/MRI for other reasons (not study  related) might be 
acceptable. The outcome of the X- ray/CT/MRI m ust be docum ented in the patients’ 
medical records. Study  Physician approval o f histori cal chest X -ray must be 
obtained prior to randomization.
41. Receipt of any  COVID -[ADDRESS_297930] abstain fro m donating blood and plasma from the time of informed consent, and 
for 16 weeks (5 half -lives) after last dose of IP.
5.3.[ADDRESS_297931] of the study .
Current tobacco smokers or subjects with smoking history  ≥ 10 pack -years (1 pack y ear = 20 
cigarettes sm oked per day  for 1 year) at Visit 1 are allowed. Never smokers are not allowed to 
enter the study . Smoking status w ill be captured on the eCRF throughout the study . See 
Secti on 8.2.2 .
The use of e -cigarettes (e.g., JUUL) is allowed during the course of the study . 
Subjects shou ld not smoke on the assessment day  prior to all lung funct ion assessments at the 
site.
5.3.[ADDRESS_297932] ion assessments at the site.
5.4 Screen Failures and Re -screening
Screen failures are defined as subjects who signed the informed consent form to participate in 
the clinical study  but are not subsequently rando mized. A minimal set of screen failure 
inform ation is required to ensure transparent reporting of screen failure subjects to meet the 
Conso lidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authori ties. Minimal information includes demography , 
screen failure details, eligibilit y criteria, and any  serious adverse event (SAE).
These subjects should have the reason for study  withdrawal  recorded as ‘Screen Failure’ (i.e., 
subject does not meet the required inclusio n/exclusio n criteria) in the el ectroni c case report 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 56of 217form (eCRF). This reason f or study withdrawal  is only  valid for screen failures, and not 
rando mized subjects. 
In following situations, the screening may be extended without prior approval from 
[COMPANY_008] Study Physician:
Subjects that experience a COPD exacerbation during the scr eening period: May  
remain in screening and the screening period may be extended up to 14 days to allow 
for the com pletion of  the course of systemic corticosteroids and/or antibiot ics if 
deem ed sui table by  [CONTACT_24342].
Note: Enrolment: Subjects treate d with systemic corticosteroids and/or antibiotics 
and/or hospi [INVESTIGATOR_95658] a COPD exacerbat ion within 14 day s prior to enrolment 
(Visit 1 or re -screening Visit 1), should be delayed allowing pat ient to be eligible for 
the study  (exclusi on criterion 5).
Subjects with respi[INVESTIGATOR_4416] (excluding pneumonia) requiring ant ibiotics or 
antiviral medicat ion within 14 days prior to Visit 1 or during the screening period:
May remain in screening and the screening period may be extended up to [ADDRESS_297933] igator.
Note: Subjects treated with antibiot ics or antiviral medicat ions for respi[INVESTIGATOR_244801] 14 days prior to enrolment (Visit 1 or re -screening Visit 1) should be delayed 
allowin g patient to be eligible for the study  (exclusi on criterion 6).
Subjects with respi[INVESTIGATOR_4416] (excluding pneumonia) NOT requiring ant ibiotics 
or antiviral medication during the screening period:
May remain in screening and the screening period may be extended up to [ADDRESS_297934] ions.
Note: Subjects without antibiotics or antiviral medicat ions for respi [INVESTIGATOR_244801] 14 days prior to enrolment (Visit 1 or re -screening Visit 1) should be delayed 
allowing pati ent to m eet FeNO restri ctions.
Extensio n of the screening period for any  other reason will be allowed only  upon approval  of 
the [COMPANY_008] Study  Physician. 
In following situation, subject must be screen failed:
Subjects who experience pneumonia during the screening period should be screen 
failed. They  may be re -screened but no sooner than [ADDRESS_297935] date of hospi[INVESTIGATOR_059], whatever occurred later 
(exclusio n criterion 7).
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 57of 217Judgment by  [CONTACT_24342] t hat the subject should not participate in the study  based 
on assessment of COVID -[ADDRESS_297936] can 
be re -screened within 2 to 4 weeks, upon approval of the AZ Study  Physician 
(exclusio n criterion 38).
Subject who had positive SARS -CoV -2 naso/oropharyngeal test (or rapid test) at 
Visit [ADDRESS_297937] ion, upon approval of the AZ Study  Physician 
(exclusio n criterion 39) .
Re-screening:
If the reason for screen failure was transient (including but not limited to study -supplied 
equipment failure, unforeseen personal events that mandate missed screening visit s, etc), 
subjects may  potenti ally be re -screened. These cases shoul d be discussed wit h the 
[COMPANY_008] study  physician and docum ented in the Invest igator Study  File (ISF).
Re-screening for subjects who have screen -failed due to ePRO criteria (e.g., did not meet 
minimum EXACT -PRO/E -RS™: COPD requirement or did not report a dequate compliance 
with maintenance medicat ions) is not allowed. 
Re-screening of a subject for any  reason will be allowed only  upon approval  of the
[COMPANY_008] Study  Physician. A documented approval for re -screening should be filed in the 
Invest igator Study File (ISF).
Any re -screened subject will be re -enrolled and reassigned their originally assigned subject 
number after signing a new ICF and addendum to ICF (if applicable) and after all Visit [ADDRESS_297938] been performed as listed in Table 1(with the except ion of testing for HIV -1 
and HIV -2, hepatit is B and C, and FSH). If the timeframe between Screening and Re -
screening is more than 30 days, th en all Visit 1 assessments should be repeated.
In case of re -screening, m oderate to severe COPD exacerbations from screening period are 
considered as historical COPD exacerbat ions wit hin 2 to 52 weeks prior to re -screening Visit 
1 (Incl usion 6) and shoul d be entered in eCRF module COPDEXH and included in total 
number of historical COPD exacerbat ion during IWRS stratification transit ion at re -screening 
Visit 1.
Rescreened subjects should be assigned the same subject number as for the init ial screening. 
How ever, rescreening should be documented so that its effect on study results, if any, can be 
assessed. 
Subjects who were screen failed when the recruitment was temporarily paused due to the 
COVID -[ADDRESS_297939] igator Study  File (ISF).
6. STUDY TREATMENTS
Study  treatm ent is defined as an IP (including placebo) intended to be administered to a study 
participant according to the study  protocol . Study  treatm ent in this study  refers to tezepel umab 
or placebo.
6.[ADDRESS_297940] igational products will be manufactured in accordance wit h Good Manufacturing 
Practi ce (GMP).
Each subject will receive two SC inject ions at each dosing interval to receive a total dose of 
[ADDRESS_297941] acebo.
Table 5 -Study Treatments
Treat ment 1 Treat ment 2
Study treatment name: [CONTACT_245012]: 0.7% (w/v) sodium carboxy 
methyl cellulose in 10 mM 
acetate, 250 mM L-proline, 
0.01% (w/v) polysorbate 80, 
pH 5.0
Route of administration Subcutaneous Subcutaneous
Dosing instructions: Refer to Section 6.1.2 Refer to Section 6.1.2
Packaging and labelling Study treatment will be
provided in an APFS with
1.91 mL fill volume. Each
APFS will be labelled in
accordance with GMP
Annex 13 per country
regulatory requirement. The 
labels will be translated into
local language where
applicable.Study treatment will be
provided in an APFS with
1.91 mL fill volume. Each
APFS will be labelled in
accordance with GMP
Annex 13 per country
regulatory requirement. The 
labels will be translated into
local language where
applicable.
APFS –Accessorised Pre -Filled Sy ringe
CCI
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 59of 217The accessorized pre- filled syringe (APFS) i s a singl e use, disposable system that is designed
to deliver the labelled dose to the subcutaneous space during one inject ion and automat ically 
provi de a safet y mechanism to reduce the occurrence of accidental needle sticks during 
disposal  of the system .
The APFS consists of a pre -filled syringe sub -assembly  (PFS -SA; 1 m L long prefilled syringe
barrel wit h a 1/2- inch 27 -gauge thin wall staked in needle, rigid needle shield, plunger 
stopper) and a safet y device.
6.1.[ADDRESS_297942] ituent part, provided for use in this study  is:
Accessorised pre- filled syringe (APFS)
Instructions for m edical  device use are provided in IP Handling Instructions and Pharmacy 
Manual.
All medical device deficiencies (including malfunction, use error and inadequate labelling) 
shall be documented and reported by  [CONTACT_244941] (see Section 
8.3.10 ) and appropriately managed by [CONTACT_3455].
6.2 Preparation/Handling/Storage/Accountability
IP will be supplied to the site in a kit containing APFS tezepelumab or matching placebo. 
Each kit has a unique number that is printed on all labels wit hin the kit (i.e., the outer carton 
label and the label of each APFS wit hin the carton).
The Investigator or designee must confirm appropriate temperature condit ions have been
maintained during transit for all study  treatm ent received and any  discrepancies are reported 
and reso lved before use of the IP. 
The IP is to be stored at the study  centre in a secured facilit y with limited access and 
controlled temperature. The temperature should be monitored on a daily  basis and documented 
in the temperature monitoring log while IP is stored at the study  centre. The IP m ust be kept in 
the original outer container and under condit ions specified on the label (between 2°C to 8°C 
[36°F to 46°F], protected from light ). Only subjects rando mized in the study may receive 
study  treatm ent. Only  authori zed si te staff may  supply  or administer study  treatm ent. 
Clinical Study Protocol -7.[ADDRESS_297943] itution (where applicable) is 
responsible for study  treatm ent accountabilit y, reconciliat ion, and record maintenance (i.e., 
recei pt, reconciliat ion, and final disposit ion records). 
The centre staff should not administer the affected IP and should immediately contact [CONTACT_244942] m et:
Temperature excursion upon receipt or during storage at the study  centre
Storage condit ions were not met (e.g., frozen) or cannot be confirmed
Dam aged ki t upon recei pt
Dam aged APFS device
Securi ty seal on the cart on has been broken
The expi[INVESTIGATOR_244802]
Other reason(s) that may  have affected the IP
Dam aged IP shoul d be docum ented vi a IWRS (pl ease refer to IWRS manual for further 
details).
Please Note: If allowed by [CONTACT_244943], IP preparation and administration 
may be performed at the subject’s ho me/alternat ive location by a qualified HCP. Before 
initiating consent for home IP administration visit, the subject must have received at le ast the 
first 2 IP administrations at the site. Please refer to Appendix I for further details.
Dose preparation 
Each APFS should be visually inspected prior to do se preparation. The IP will be provided to 
the study  sites as a clear to slight ly opalescent, colorless to slight ly yellow clear so lution 
contained in a pre -filled syringe to be stored between 2°C to 8°C [36°F to 46°F] until used.
If defects are noted with the IP, the Invest igator and site monitor should be notified 
immediately . Preparati on of  IP m ust be performed by  a qualified person (e.g., pharmacist, 
Invest igator, or nurse) at the site.
The IP does not contain preservatives and any unused portion must b e discarded. Preparation 
of the IP i s to be perform ed asept ically. Total in -use storage time fro m removal of  the IP from  
the refrigerator to start of administration should not exceed [ADDRESS_297944]’s dose, two IP kits will be selected for administration according to the 
kit identificat ion numbers assigned by  [CONTACT_10966].  
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 61of 217Dose preparation steps:
1. Allow the IP to equilibrate to room temperature 68°F to 77°F (20°C to 25°C) for at 
least [ADDRESS_297945] b e discarded 
immediately  after dose preparation as per site’s Standard Operating Procedures (SOP), the 
syringe labels alo ng with the kit boxes must be retained for IP accountabilit y.
Dose administration
The IP will be administered by [CONTACT_24342]/author ized delegate. Two inject ions are 
requi red and will be administered at the same anatomical site with a distance of at least 1 inch 
(3 cm ) between the two injections. The inject ion site m ust be recorded in the source 
docum ents at each treatm ent vi sit and re corded in the eCRF.
The person administering the dose will wipe the skin surface of the upper arm, anterior thigh
or abdomen wit h alcohol and allow to air dry . The skin will  be pi[INVESTIGATOR_244803] i solate the SC
tissue from  the m uscle. The needle will be fully  inserted at a [ADDRESS_297946] ion site is not feasible, an d/or the subject prefers not to rotate inject ion sites, the reason 
for not rotating the inject ion site should be documented in the source documents. The 
suggested inject ion site rotation sequence is presented below in Figure 2.
Clinical Study Protocol -7.[ADDRESS_297947] ion.
If any of the f ollowing should occur, the IP shoul d not be administered: 
The subject received allergen immunotherapy  injection on the sam e day  as scheduled 
IP admini strati on. 
The subject has an intercurrent illness that in the opi[INVESTIGATOR_3078] n of the Invest igator and/or 
medical mo nitor may com promise the safet y of the subject in the study  (e.g., vi ral 
illnesses). 
The subject is febrile ( ≥ 38°C; ≥ 100.4°F) wi thin 72 hours pri or to IP administration. 
The subject is confirmed to have an active COVID -[ADDRESS_297948] results.
The subject is suspected to have an act ive COVID -[ADDRESS_297949] ion based on assessment of 
COVID- 19 symptom s.
The subject received COVID -[ADDRESS_297950] ion or fever ( ≥ 38°C; ≥ 100.4°F) 
suspected due to COVID -[ADDRESS_297951] ion, the visit should be rescheduled (and IP administration 

Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 63of 217deferred) and subject should be re -assessed for symptoms of COVID -[ADDRESS_297952] participat ion in the 
following situat ions:
The subject has been diagnosed with an act ive COVID-[ADDRESS_297953] ion.
The subject skips [ADDRESS_297954] to do so.
6.3 Measures to Minimise Bias: Randomization and Blinding
The Investigator(s) wi ll:
1.Obtain signed informed consent fro m the potenti al subject before any  study  specific 
procedures are performed.
2.Assign the potential subject a unique enrolment number (which begins with an ‘E’) via 
IWRS.
3.Determine subject eligibilit y. 
4.Assign the eligible subject unique rando mizat ion code via IWRS.
5.Subjects will be allocated to receive tezepelumab or placebo in a 1:[ADDRESS_297955] withdraws from the study , then his/her 
enrolment/randomization code cannot be reused. Wit hdrawn subjects will not be 
replaced.
Specific information concerning the use of the IWRS will be provided in a separate manual.
Procedures for handling incorrectly enrolled or randomized subjects
Subjects who fail to meet the eligibilit y criteria shoul d not, under any  circumstances, be 
rando mized or receive study medication . There can be no except ions to this rule. Subjects who 
are enrolled, but subsequent ly found not to m eet all  the eligibilit y criteria must not be 
rando mized or init iated on treatment and must be withdrawn from the study .
Clinical Study Protocol -7.[ADDRESS_297956] prepared by a 
computeri zed system  provi ded by  [CONTACT_244944] (AZRand). All subjects wi ll be 
stratified at randomizat ion by [CONTACT_244945] n and number of exacerbat ions in the 12 months prior to 
Visit 1 (or re -screening Visit 1) (2 vs ≥ 3).
In order to achieve the assumed exacerbat ion rates used to determine sample size, it is 
expected that approximat ely 30% of subjects will have had at least 1 severe exacerbat ion (an 
exacerbation result ing in hospi[INVESTIGATOR_3094]) wi thin 12 m onths pri or to Visit 1 (or re -screening 
Visit 1) and approximately 40% of subjects will have had ≥3 exacerbat ions within 12 months 
prior to Visit 1 (or re -screening Visit 1). (Refer to Section 4.1)  
Consideration will be given to closing the Interactive Web Response System (IWRS) 
rando mizat ion for a subgroup [by  [CONTACT_244932]] to ensure that approximately  20% of  the 
subjects will be targeted to have ≥300 eosinophils/ μL, 40% of the subjects between ≥150 to 
<300 eosinophils/μL and a maximum of approximately 40% of the subjects with <150 
eosino phils/μL at enrolment.
Ensuring blinding 
This is a double -blind study  in which tezepelumab and placebo are not visually  distinct from 
each other. All packaging and labelling of IP will be done in such way as to ensure blinding 
for all sponsor and investi gational site staff. Neit her the subject nor any  of the Investi gators or 
sponsor staff who are invo lved in the treatment or clinical evaluat ion and m onitoring of the 
subjects will be aware of the treatment received. Since tezepelumab and placebo are not 
[COMPANY_003]
Clinical Study Protocol -7.[ADDRESS_297957], IP will be handled by a qualified person (e.g., pharmacist or study nurse) at 
the site. 
An [COMPANY_008] site monitor will perform IP accountabilit y. In the event that the treatment 
allocat ion for a subject becomes known to the Investigator or other study  staff invo lved in the 
management of study  subjects or needs to be known to treat an individual subject for an AE, 
the sponsor m ust be notified immediately  by [CONTACT_207429], if possible, before 
unblinding.
The fo llowing personnel will have access to the rando mizat ion list:
 Those carrying out the packaging and labelling of IP
 Those generat ing the randomization list
 Personnel at the IWRS company
 Supply  Chain Management department
 Patient Safet y department at [COMPANY_008]
 Bioanaly tical labperforming the PK sample analysis
 Those involved in the reporting and reviewing the unblinded IDMC presentations
The informat ion in the randomization list will be kept from other personnel invo lved in the 
conduct of the study  and in a secure location unt il the end of the study.
No other m ember of the extended study  team  at [COMPANY_008], or any  Contract Research 
Organizat ion (CRO) handling data, will have access to the rando mizat ion scheme during the 
conduct of the study  until after the primary  database l ock.
Methods for unblinding
Individual treatment codes, indicat ing the treatment randomizat ion for each rando mized 
subject, will be available to the Investigator(s) and delegate(s) at the study  sites from the 
IWRS. Routines for this will be described in th e IWRS user m anual  that will be provi ded to 
each site.
The treatment code should not be broken except in medical emergencies when the appropriate 
management of the subject requires knowledge of the treatment randomizat ion. The 
Invest igator should document and report the action to [COMPANY_008], without revealing the 
treatm ent given to subject to the [COMPANY_008] staff.
[COMPANY_008] retains the right to break the code for SAEs that are unexpected and are 
suspected to be causally  related to an IP and that potenti ally require expedi ted reporti ng to 
regul atory  authori ties. Treatment codes will not be broken for the planned analyses of data 
until all decisio ns on the evaluabilit y of the data from each individual subject have been made 
and docum ented and unt il primary database l ock after l ast subject com pletes week [ADDRESS_297958] igator/authorized delegate at each visit (as shown in 
Table 1and Table 2) and recorded in the eCRF.
The subject’s usual pre -study  triple inhaled therapy  (medium  to hi gh dose ICS/LABA/LAMA) 
formulation, dose and regimen, and any other additio nal allowed COPD m edicat ions that may 
have been taken prior to enrolment, should be continued without any  change throughout the 
enrolment, run -in, treatment and fo llow
-up peri odas outlined below. 
As theophylline has a narrow therapeutic window, please note that subjects on maintenan ce 
treatm ent wi th theophylline should have blood concentration levels within therapeut ic range 
docum ented wi thin 8 weeks pri or to Visit 1 (see Table 6). If this is not d ocum ented before 
signing the informed consent, it can be obtained after informed consent has been given or as 
part of the Visit 1 procedures. The sample can be analyzed at the central or local lab as 
applicable. Theophylline blood levels greater than 12mg/ dl should be managed according to 
local standards o f care and the Invest igator’s judgment and discussed with AZ study physician 
prior to randomizat ion. It i s recommended that addit ional increments in dose are evaluated 
with blood l evels. Investigator can u se thei r clinical judgement about the therapeutic range of 
theophylline levels on the basis o f sampling t ime and other factors that may impact the results.
Any medicat ion or vaccine including over -the-counter or prescript ion medicines, vitamins, 
and/or herbal supplements that the subject is receiving at the time o f enrolment or receives 
during the study  must be recorded along wit h:
 Reason for use
 Dates of administration including start and end dates
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepe lumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 67of 217Table 6 -Allowed, Restricted and Prohibited Medications
MedicationAllowed/ 
Restricted/ 
ProhibitedDetails
Background 
(maintenance) COPD 
medicat ion 
(ICS/LABA/LAMA) Allowed Docum ented treatm ent wi th medium  or hi gh 
dose ICS at a total daily dose corresponding to 
>250 μg fluticasone propi[INVESTIGATOR_244804] a LABA and 
LAMA for COPD throughout the y ear pri or to 
enrolment (Visit 1) and throughout the study. 
The dose of ICS should be stable 3 months 
prior to V1 and throughout the study . See 
inclusio n criterion 7. 
ICS in a separate, single device is permitted if 
all the fo llowing criteria are met:
-it is administered at the same dose and 
schedule as in the fixed dose combinat ion 
product; 
-it is not given in co mbinat ion with a LAMA 
alone. 
If an Inve stigator decides to switch a subject 
who is on an ICS in a separate single device to 
a fixed -dose combinat ion device therapy , this 
shoul d be done at Vi sit [ADDRESS_297959] rem ain at the same dose and 
schedule as used in the 3 months prior to Vi sit 
1 (provi ded dose and regimen are locally 
approved for COPD).
Nebulized budesonide is accepted as part of 
maintenance therapy  if the dosing regimen is 
equivalent to that of budesonide approved as 
part of a combinat ion product for COPD (e.g., 
for budesonide/formoterol co mbinat ion 
320m cg/9mcg BID equivalent dose of 
nebulized budesonide is 0.5mg BID [ GOLD 
2019]
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 68of 217MedicationAllowed/ 
Restricted/ 
ProhibitedDetails
Nebulized LABA is accepted as part of 
maintenance therapy .
Twice daily triple inhaled 
(ICS/LABA/LAMA) medicat ions should be 
withheld at l east 12 hours pri or to scheduled 
spi[INVESTIGATOR_96666].
Once daily  triple inhaled (ICS/LABA/LAMA) 
medicat ions should be withheld at least [ADDRESS_297960] 24 
hours prior to scheduled spi[INVESTIGATOR_96666].
Addit ional ICS on top of 
COPD ICS maintenance 
medicat ionRestricted Can only  be given concomi tantly  with 
systemic steroids during acute COPD 
exacerbation treatment while at site or other 
healt h care provider. Addit ional use of  ICS 
outsi de of  this is not allowed.
Systemic corti costeroi ds 
(tablets or inject ions)Restricted Prohibited as maintenance treatment within [ADDRESS_297961] 
be contact[INVESTIGATOR_530].
Maintenance SABA 
(short -acting β2 -Prohibited if Please see below. Use on their own, or for 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 69of 217MedicationAllowed/ 
Restricted/ 
ProhibitedDetails
agonists) administered by  
[CONTACT_244946] e/triple 
therapy .step-up or step- down are not allowed.
SABA (short -acting β2 -
agonists administered by 
[CONTACT_244947])Allowed as 
rescue 
medicat ion and
for treatm ent 
of acute COPD 
exacerbation.
Prohibited if 
administered 
as maintenance 
medicat ion or 
in a scheduled 
dose.Prophylactic use of SABA in the absence o f 
symptoms is discouraged. However, if 
deem ed necessary  by [CONTACT_244948] (e.g., prior to pl anned exercise), it 
can be used, but such use of prophylact ic 
inhalat ions should be documented in the 
medical notes and recorded in the eCRF.
Use of SABA is to be avo ided 6 hours before 
a scheduled ECG, FeNO and spi[INVESTIGATOR_244805].
Occasio ns (# of  times used) where SABA was 
administered via an MDI will be recorded 
separately  from the nebulized inhalat ions in 
the eDi ary.
Maintenance SAMA
(short acting muscarinic 
antagonists = short acting 
anticholinergics 
administered by  [CONTACT_244949])Prohibited if 
administered 
as part of 
maintenance 
doubl e/triple 
therapy .Please see below. Use on their own, or for 
step-up or step- down is not allowed.
SAMA (short acting 
muscarinic antagonists = 
short acting 
anticholinergics 
administered by  [CONTACT_244949])Allowed as 
rescue 
medicat ion and 
for treatm ent 
of acute COPD 
exacerbation.
Prohibited if Prophylactic use of SAMA in the absence of 
symptoms is discouraged. However, if 
deem ed necessary  by [CONTACT_244948] (e.g., prior to planned exercise), it 
can be used, but such use of prophylact ic 
inhalat ions should be documented in the 
medical notes and recorded in the eCRF.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 70of 217MedicationAllowed/ 
Restricted/ 
ProhibitedDetails
administered 
as maintenance 
medicat ion or 
in a scheduled 
dose.Use of SAMA is to be avoided 6 hours before 
a scheduled ECG, FeNO and spi[INVESTIGATOR_244805].
Occasio ns (# of times used) where SAMA 
was administered via MDI will be recorded 
separately  from the nebulized inhalat ions in 
the eDiary.
SABA and SAMA 
combinat ion productsAllowed as 
rescue 
medicat ion and 
for treatm ent 
of acute COPD 
exacerbation.
Prohibited if 
administered 
as maintenance 
medicat ion or 
in a scheduled 
dose.Prophylactic use of SABA and SAMA 
combinat ion product in the absence of 
symptoms is discouraged. However, if 
deem ed necessary  by [CONTACT_244948] (e.g., prior to planned exercise), it 
can be used, but such use of prophylact ic 
inhalat ions should be documented in the 
medical notes and recorded in the eCRF .
Use of SABA and SAMA co mbinat ion 
product is to be avo ided 6 hours before a 
scheduled ECG, FeNO and spi[INVESTIGATOR_244805].
Occasio ns (# of times used) where SABA and 
SAMA co mbinat ion product was administered 
via MDI will be recorded separately fro m the 
nebulized inhalat ions in the eDiary.
Antitussives prn Allowed
Muco lytics Allowed
Antihistamines prn Allowed
Derm al topi[INVESTIGATOR_20306], 
intra-articular, nasal 
steroi ds, topi [INVESTIGATOR_244806] -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 71of 217MedicationAllowed/ 
Restricted/ 
ProhibitedDetails
corticosteroi ds
Xanthines Restricted Allowed only if on maintenance treatment for 
12 m onths and on a stable dose for 3 months 
prior to enrolment (Visit 1).
Allowed in a dose equivalent to theophylline 
≤400m g q day . For doses greater than [ADDRESS_297962] be stable and theophylline 
blood levels shoul d be confirmed to be equal 
to or bel ow 12 m g/dl, within 8 weeks pri or to 
Visit 1 or during the screening period.
Theophylline blood levels greater than 
12mg/dl should be managed according to 
local standards o f care and the Invest igator’s 
judgment and discussed wi th AZ study  
physician. It is recommended that additional 
increments in dose are evaluated with blood 
levels.
Twice daily xanthines should be withheld for 
at least 12 hours prior to scheduled spi[INVESTIGATOR_96668].
Once daily  xanthines for at l east24 hours 
prior to scheduled spi[INVESTIGATOR_244807]. 
Antibiotics Restricted Allowed to treat COPD exacerbat ions and/or 
AEs. 
Antibiotics to treat a COPD exacerbat ion 
should not be used for m ore than [ADDRESS_297963] 
be contact[INVESTIGATOR_530].
Chronic use (>3wks) and use for the 
prevent ion of COPD exacerbat ions is 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 72of 217MedicationAllowed/ 
Restricted/ 
ProhibitedDetails
disallowed, unless the pati ent is on stable dose 
and regimen for ≥9months prior to 
rando mizat ion and has had ≥2COPD 
exacerbat ions while on stable therapy  (see 
exclusio n criterion 24, Secti on5.2). In all 
other cases of chronic use, ≥[ADDRESS_297964] ive/killed 
vaccinations (e.g., 
inact ive influenza)Restricted Allowed, except
-within 5 days before or after any  IP dosing 
visit
-within 3 weeks before sputum collection 
(Visit 3) for subset of subjects only.
-[ADDRESS_297965] 28 days after the vaccine 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 73of 217MedicationAllowed/ 
Restricted/ 
ProhibitedDetails
administration.
COVID -[ADDRESS_297966] COVID -19 
shoul d be planne d in advance to ensure the 
study  interventi on dosing/COVID -[ADDRESS_297967] ask if the 
participant has received or is planning to 
receive a COVID -19 vaccinat ion. This is to 
ensure that the required time interval for study  
intervent ion dosing (mentioned above) is 
maintained.
As these intervals might change, please 
discuss wi th [COMPANY_008] Study  Physician for 
the most current recommended time interval 
prior to any vaccine dose
Refer to section 8.2.[ADDRESS_297968] (Daxas®, 
Daliresp®)Restricted Allowed only  if on maintenance treatment for 
12 m onths, on a stabl e dose for 3 m onths prior 
to enrolment (Visit 1), and only if locally  
approved for COPD.
If roflumilast is discont inued at Visit 1, 
approximately  [ADDRESS_297969] el apse before 
performing spi[INVESTIGATOR_244808] 2.
Leukotrienes (LTRA) Restricted Restricted for at least 24 hours prior to 
scheduled spi[INVESTIGATOR_96620].
Immunoglobulin and 
Blood productsProhibited Prohibited wit hin 30 days prior to enrolment 
(Visit 1) and throughout the treatment period.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 74of 217MedicationAllowed/ 
Restricted/ 
ProhibitedDetails
Medicat ions containing 
ephedrineProhibited From  Visi t 3 and throughout the treatment 
period.
Live attenuated vaccines Prohibited Prohibited wit hin 30 days prior to Visit 3, 
during the treatment period and for 16 weeks 
(5 half -lives) after the last dose of IP.
Omalizumab, denosumab 
or any  other m onocl onal 
or polyclo nal antibody  
therapy  (e.g., gamma 
globulin)Prohibited Prohibited if taken for any  reason wi thin 4 
months or 5 half -lives (whichever is longer) 
prior to Visit 1 and during the study  (even if 
the subject has discontinued IP).
Systemic 
immuno modulators and 
immu nosuppressive 
medicat ion (including 
but not limited to 
methotrexate, 
cyclosporine, any  
experimental anti -
inflammatory  therapyProhibited Prohibited wit hin [ADDRESS_297970] dose of IP.
Refer to Systemic corti costeroi ds (tabl ets or 
inject ions) for further restrict ions.
Long term  oxygen 
therapy  (LTOT)Restricted Prohibited wit h signs and/or symptoms of cor 
pulmo nale and/or right ventricular failure or 
receiving LTOT >4.0 litres/minute (L/min), or 
saturation <89% despi[INVESTIGATOR_244800].
During the treatment phase, any increase in 
maintenance oxy gen therapy  up to 4 L/min is 
allowed, based on investigator’s judgement.
Invest igational non -
biologic productsProhibited Prohibited wit hin 30 days or 5 half -lives 
whichever i s longer pri or to Vi sit 1 and during 
the study .
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 75of 2176.5.1 Background (Maintenance) Medication
All subjects are required to be treated with maintenance locally approved triple inhaled 
therapy  (ICS/LABA/LAMA) for COPD for at least 12 months prior to enrolme nt (Visit 1) 
with a stable dose of ICS for the [ADDRESS_297971] eted his/her l ast 
scheduled contact. 
Subjects currently receiving background therapy  that i s not approved for COPD are not 
eligible for the study . However, for individual cases when subjects are treated with 
background therapy  that is not approved for COP D, the subject may be considered for 
enrolment and maintain their maintenance medicatio n during the study  if the fo llowing cri teria 
are met:
Current treatment regimen is considered the best option for the subject by [CONTACT_30780]/Invest igator with out acceptabl e alternat ive;
Medicat ion/dose/device is approved for COPD in other countries or contains 
components and doses equivalent to those in approved medicat ion/combinat ion 
therapy .
These cases should always be consulted wit h the AZ Study  Physician pri or to the deci sion to 
enrol the pati ent into the study .
Changes to the subject’s maintenance therapy are discouraged during the treatment period, 
unless judged medically necessary by [CONTACT_24342]. Any changes should be discussed with 
the [COMPANY_008] Study  Physician and the j ustificat ion for treatment changes should be 
docum ented in the source notes along with the rationale for the change. Changes should be 
recorded in the eCRF.
During the study , inhaled background medications that are given once dail y shoul d be 
administered in the morning to conform wit h spi[INVESTIGATOR_244809]. 
Reco mmended background medicat ion compliance during the treatment period is ≥70%. It i s 
recommended that compliance levels below 70% prompt the site/invest igator to eval uate the 
reasons for low compliance and to provide re -educati on to the patient in regard to the 
importance of co mpliance. It is strongly reco mmended that when co mpliance level falls below 
50%, the si te contacts the AZ study  physician in order to di scuss the potential safet y 
implicat ions for the pati ent and future decisio ns. 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 76of 217Background medicat ion adherence will be assessed daily via the eDiary. The patient will be 
asked if they took their regularly scheduled COPD medicine (y es/no) and instructed not to 
consider instances of rescue inhaler usage when answering this quest ion.
6.5.[ADDRESS_297972]’s safet y and wellbeing, may be given at the discret ion of the Invest igator and recorded 
in the appropriate sections of the eCRF.
6.5.3 Rescue Medication
SABA (short -acting β2 -agonists) and/or SAMA (short acting muscarinic antagonists = short 
acting ant icholinergics) or SABA/SAMA combinations may be used as rescue me dicati on 
during the study  in the event of a worsening of COPD symptoms (see Table 6). 
6.5.[ADDRESS_297973] needs treatment with any  
disallowed m edicat ion, e.g., “step up” or treatment for an exacerbation for more than [ADDRESS_297974] ificat ion for 
disallowed m edicat ion use and /or prol onged oral  corti costeroi d treatm ent. The Invest igator 
must docum ent outcome of discussion in the source documentation.
6.5.5 COPD Medication Restrictions on the Days of Scheduled Spi[INVESTIGATOR_244810] (see Table 1and 
Table 2). There are restrict ions regarding the subject’s COPD medicat ions prior to the 
spi[INVESTIGATOR_31757]. Please see Section
 [IP_ADDRESS] .
NOTE : Screeni ng (Visi t 1 and Vi sit 2) and Randomizat ion spi[INVESTIGATOR_244811].
Screening Visit [ADDRESS_297975] ions to 
medicat ions (al so refer to Secti on 8.1.3 ) and Visit 1 SARS -CoV -2 naso/oropharyngeal swab 
test (or rapid test) result is negat ive. If the SARS -CoV -2 naso/oropharyngeal swab test (or 
rapid test) resul t will not be available on the day  of Visi t 1, the screening lung funct ion 
Clinical Study Protocol -7.[ADDRESS_297976] be postponed until next visit, the postponed Visit 1, after the SARS- CoV -2 
naso/oropharyngeal) swab test (or rapid test) result is confirmed negative. 
At thepostponed Visit 1, the spi[INVESTIGATOR_244812] -BD, post -BD spi[INVESTIGATOR_96656], 
FeNO and ECG (combined Visit 1 and Visit 2) to be performed. Visit [ADDRESS_297977] -BD spi[INVESTIGATOR_244813] 
1.Preferably, Visit 2 should be scheduled no later than 1 week after Visit 1 but the enrolment 
can be extended to accommodate addit ional wait ing time required to obtain Visit 1 SARS -
CoV -2 naso/oropharyngeal swab test result. The subject must meet the COPD medicat ions 
restri ctions in order to perform the lung assessments. 
Subjects will be asked to withho ld their triple inhaled (ICS/LABA/LAMA) medications on the 
morning o f the screening pre -BD and post -BD spi[INVESTIGATOR_244814] (should be at least 12 
hours prio r to the assessment for twice daily medication and for 24 hours prior to the 
assessment for once daily medicat ions) for the eligibilit y assessment (see Section 5.1, 
inclusio n criterion7). In addit ion, SABA and SAMA should not be used within [ADDRESS_297978]’s usual COPD medicat ions may be 
administered fo llowing com pletion of the screening lung function proc edures.
Treatment Visits 3
-15
Subjects will be asked to withho ld their usual triple inhaled (ICS/LABA/LAMA) medicat ions 
on the m ornings of the scheduled spi[INVESTIGATOR_244815] 12 
hours prior to the spi[INVESTIGATOR_244816] (for m edicat ions that are administered 
twice daily )/24 hours pri or to the assessment (for once daily  medicati ons). Thi s is especially  
important pri or to scheduled spi[INVESTIGATOR_244817] (see Table 1and Table 2) in 
order to maintain the integrit y of planned efficacy analyses around lung funct ion 
improvement. In addit ion, SABA and SAMA should not be used within [ADDRESS_297979]’s usual COPD medicat ions may be administered 
following co mpletion of the post -BD spi[INVESTIGATOR_244818] -BD spi[INVESTIGATOR_96847] (for patients 
participat ing in sputum sub -study ). The IP will be administered at a scheduled visit after the 
pulmo nary lung funct ion assessments.
If the subject has taken their usual triple inhaled (ICS/LABA/LAMA) medications on the 
morning o f the scheduled spi[INVESTIGATOR_244819], the Invest igator/authorized delegate 
shoul d remind the subject of the importance of withholding their usual morning m aintenance 
therapy , and reschedule the visit for another day , within the allowed window. If rescheduling 
is abso lutely not feasible for the subject, spi[INVESTIGATOR_244820] a 
notati on indicat ing that spi[INVESTIGATOR_244821] (ICS/LABA/LAMA) medications. Exception is rando mizat ion visit, which 
must be performed when medicat ions restri ctions are met. 
Clinical Study Protocol -7.[ADDRESS_297980] has taken the rescue SABA and/or SAMA within [ADDRESS_297981], 
spi[INVESTIGATOR_244822] a notation indicating that spi[INVESTIGATOR_244823] 
6 hours of SABA and/or SAMA use.
6.5.[ADDRESS_297982] igator. Timing of the triple inhaled 
(ICS/LABA/LAMA) medicat ions and rescue SABA and/or SAMA use relat ive to the 
unscheduled spi[INVESTIGATOR_244824] d be rec orded.
6.5.7 COPD Medication Restrictions at Centre Visits with Scheduled ECG 
Assessment
The subjects should be instructed not to take their usual triple inhaled (ICS/LABA/LAMA) 
medicat ions pri or to the scheduled ECG assessment. The use of a SABA and/or SAMA sho uld 
be avo ided within 6 hours before the ECG assessments. See Section 8.2.6 .
NOTE: Screening and Rando mization ECG are not allowed without proper medication wash 
out.
6.[ADDRESS_297983] may  be discont inued fro m IP in the fo llowing si tuations:
 Subject decisio n. The subject is at any  time free to discontinue IP, without 
prejudice to further treatment 
 Anadverse event considered to jeopardise the safety  of a subject 
participat ing in the study
 Pregnancy
 Severe non -compliance wi th the Clinical Study  Protocol  
 Lost to follow up
 Development of any study  specific cri teria for discontinuat ion, including:
An anaphylact ic react ion to the IP requiring administration of epi[INVESTIGATOR_238]
A helmint h parasit ic infestation requiring hospi[INVESTIGATOR_059]
Intensive care unit admission wit h intubation or extensive mechanical 
ventilation for a COPD related event
 Any malignancy , except subjects who develop basal cell carcino ma or 
localized squamous cell carcinoma of the skin, provided that the malignancy 
has been excised and determined to have clear margins
 Development of one or more of the fo llowing:
Confirmed ALT or AST increase o f ≥[ADDRESS_297984]
Confirmed ALT or AST increase of ≥[ADDRESS_297985] for more than 2 weeks
Confirmed ALT or AST increase of ≥[ADDRESS_297986] and total bilirubin of ≥[ADDRESS_297987]
ALT or AST of ≥[ADDRESS_297988] with the appearance of fat igue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or 
eosinophilia ( ≥5% based on l ocal laboratory  resul ts)
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 80of 217 Other reasons
Before a decisio n to di scont inue a subject fro m IP is inst ituted, the [COMPANY_008] Study  
Physician should be consulted regardless of the reason for discont inuation.
See the SoA 1.1for data to be collected at the time of IP discont inuat ion and fo llow-up and 
for any  further evaluat ions that need to be completed.
If a subj ect discont inues IP due to a study specific discontinuat ion criterion, thi s shoul d 
always be recorded as ’Development of study  specific wi thdrawal’ on the Discont inuat ion of 
Invest igation Product form in the eCRF.
7.1.[ADDRESS_297989] return the eDiary device at the EOT visit (and at IPD visit for 
subjects choosing option 3 below). If the subject decides to withdraw co nsent, then the reason 
for this must be recorded separately  in the eCRF.
A subject that decides to discont inue IP should always be asked about the reason(s) and the 
presence of any  adverse events. The reason for discontinuing treatment and the date of last IP 
administration should be recorded in the eCRF. Subjects permanent ly discont inuing IP 
administration should be given locally available SoC therapy , at the di scret ion of the 
Invest igator. However, treatment with marketed or invest igational biologics i s not allowed 
until Week [ADDRESS_297990] igator brochure. 
All su bjects who prematurely discontinue IP should return to the site and complete the 
procedures described for the premature IP Discontinuation visit (IPD) at 4 weeks (+/ -5 
days) post last IP administration. Subjects who discontinue treatment should be encourag ed 
to return for all regularly scheduled visits for safety and efficacy assessments.
At the IPD visit the subject will be given three options as to how they  will be fo llowed as 
follows:
Clinical Study Protocol -7.[ADDRESS_297991] should be encouraged to return for all regular clinic visi ts and perform  
all scheduled assessments (excluding IP administration) unt il the EOT visit at Week 
52 (+/ -5 day s). 
2. The subject will be offered fo llow-up on a m onthly  basis via tel ephone calls while 
continuing eDiary  com pletion (no further procedures will be perform ed) unt il the 
subject completes the EOT visit at Week 52 (+/ -5 days). In addit ion to the PRO 
assessments that are performed at home, the subject may also complete the other 
clinic specified PRO assessments (as defined in the SoA 1.1) at home as well. 
3. If the subject cannot or does not wish to comply wit h any o f the opti ons above, (or 
any co mponent of them such as only telephone -based visits wit hout complet ion of  
the eDi ary), the Invest igator will only contact [CONTACT_37326] [ADDRESS_297992] chooses option 2 or 3, the key  information to be collected during the telep hone 
calls are AEs/SAEs, changes in conco mitant m edicati on, healt h care utilizat ion, and COPD 
exacerbation informat ion.
Subjects who init ially choose options 1 or 2 and subsequent ly cannot or do not wish to comply 
with the requi rements of their option can continue with a less intensive option (i.e., subject 
initially choosing opti on 1 can cont inue with options 2 or 3, subjects init ially choosing opti on 
2 can continue with option 3).
7.[ADDRESS_297993] fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_96758].
Before a subject is deemed lost to fo llow-up, the Investigator or desig nee m ust m ake 
every effort to regain contact [CONTACT_96759], certified letter to the subject ´s last known mailing address or local 
equivalent m ethods. These contact [CONTACT_96760]’s 
medical record.
When at least two of the fo llowing methods of contact [CONTACT_244950] [ADDRESS_297994] IP dose:
Clinical Study Protocol -7.[ADDRESS_297995] 3 attempts of either phone calls, faxes or emails; 
oHaving sent 1 registered letter/certified mail;
oOne unsuccessful effort to check the status of the subject using publicly available 
sources, if allowed by  [CONTACT_244951]-up contact.
7.[ADDRESS_297996] m ay withdraw from  the study (e.g., wi thdraw consent), at any  time (IP and 
assessments) at his/her own request, without prejudice to further treatment. A subject who 
considers withdrawing fro m the study  must be info rmed by [CONTACT_244952] m odified 
follow-up opti ons (e.g., telephone contacts, contacts with a relat ive or treating physician, or 
inform ation from medical records) as per Secti on 7.1.[ADDRESS_297997] who withdraws consent will always be asked about the reason(s) and the presence of 
any adverse events (AE).  The Invest igator will fo llow-up subjects as m edically  indicated. A 
withdrawal  visit is essent ial to collect as m uch data as possible for the subject as per EOT visit 
described in SoA, Table 2. The subject will return all study  supplied equipment including 
eDiary.
If the subject withdraws consent for disclo sure of future informat ion, the sponsor may  retain 
and cont inue to use any data collected before such a withdrawal o f consent.
If a subject withdraws fro m the study , he/she m ay request destructi on of  any samples taken, 
and the Investigator must document th is in the site study records.  
If the subject only wit hdraws consent for the retentio n of bio logical samples (bl ood, nasal , 
sputum , urine etc.) for future exploratory  use (e.g., sci entific health -related research), the 
subject will not be withdrawn fro m the study.
Withdrawal o f consent fro m the study  must be ascertained and documented by  [CONTACT_244953] (ICF) or assent form.
7.3.1 Withdrawal Due to Recruitment Completion
When the required number o f subjects are randomized in the study , ongoing subjects in 
screening will not be randomized and will be withdrawn fro m the study . The reason of the 
withdrawal  should be docum ented in the source and eCRF. As with screen failures, no further 
study  related f ollow
-up of  these pati ents is requi red.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 83of 2177.3.2 Discontinuation or Suspension of entire study and Site Closure
If [COMPANY_008] decides to prematurely terminate or suspend the study , the PI, and regulatory  
authori ties shoul d receive wri tten notificat ion of the reaso ns for the premature terminat ion or 
suspension. The PI [INVESTIGATOR_96658]; take necessary measures and document these in the source 
notes.
The sponsor designee also reserv es the ri ght to cl ose the study  site at any  time for any  reason 
at the sol e discreti on of  the sponsor. Study  sites will  be closed upon study  com pletion. A study  
site is considered closed when all required documents and study  supplies have been collected 
and a study -site closure visit has been performed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a stud y site by [CONTACT_17095]:
•Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor's procedures, or GCP guidelines 
•Inadequate recruit ment of parti cipants by  [CONTACT_17062] 
•Discontinuati on of  further study  intervent ion developm ent
8. STUDY ASSESSMENTS AN D PROCEDURES
Study  procedures and their timing and order are summarized in the SoA ( Table 1and Table 
2).  The Investigator will ensure that data are recorded on the eCRFs. The Web Based Data 
Capt ure (WBDC) system will be used for data collection and query handling. 
Due to COVID -19 pandemic, it may not be possible to complete all study  assessments 
according to SoA. Please refer to SoA 
(1.1) and Appendix I for further details. 
The Investigator ensures the accuracy, completeness, legibilit y and timeliness of the data 
recorded and of the provisio n of answers to data queries according to the Clinical Study  
Agreement. The Investigator will sign the completed eCRFs. A copy  of the com pleted 
electroni c CRFs will be archived at the study  site. Addi tional data to assess the imp act of 
COVID -[ADDRESS_297998] reasons for screening failure, as 
applicable.  
The suggested order of assessments to be completed before IP administration should be as 
follows: ePRO, Vi tal Signs, ECG, FeNO, Spi[INVESTIGATOR_244825]. 
During COVID -19 pandemic, the suggested order of screening assessments is: vital signs 
(starting with body  temperature m easurement), ePRO, blood draws and SARS- CoV -2 
naso/oropharyngeal swab (or rapid) testing. Screen ing lung f uncti on assessments and ECG 
can only  be done when there are no restrictions to medicat ions (refer to Section 6.5.5 and 
8.1.3 ) and Visit 1 SARS -CoV -2 naso/oropharyngeal swab test (or rapid test) result is negat ive. 
The am ount of  blood collected from  each subject over the duration of the study  (excl uding 
optional blood samples) will  be approximately  360 mL (including any  extra assessments that 
may be required) and will not exceed [ADDRESS_297999]'s usual COPD symptoms that is beyo nd norm al day-to-day variat ion, is acute in onset, 
lasts 2 or more days (or less if the worsening is so ra pid and profound that the treating 
physician judges that intensificat ion of treatment cannot be delayed), and may warrant a 
change in regular medicat ion and leads to any o f the following: 
Use of systemic corticosteroids for at least 3 day s; a single depot injectable dose of 
corticosteroi ds will  be considered equivalent to a 3 -day course of systemic 
corticosteroi ds 
Use of antibiot ics for at l east 3 days
An inpatient hospi[INVESTIGATOR_244826] (defined as an inpat ient admission ≥24 
hours in the hospi[INVESTIGATOR_307], i n an observat ion area, the emergency department or other 
equivalent healt hcare facilit y depending on the country  and healt hcare system)
Results in death
Clinical Study Protocol -7.[ADDRESS_298000] 1 of the fo llowing:
Hospi[INVESTIGATOR_244827] n for ≥ 24 hours to an observation area, the 
emergency depart ment, or other equivalent healt hcare facilit y (depending on the country  
and healt hcare system) for the COPD exacerbat ion
Death rel ated to COPD or COPD exacerbat ion
A COPD exacerbat ion that does not meet the requirements to be classified as severe will be 
considered moderate if it resul ts in at least 1 of the following:
Use of systemic corticosteroids and/or antibiotics for at least 3 day s 
A single depot injectable dose of corticosteroid s, which will be considered equivalent to at 
least 3 -day course of systemic corticosteroids
[IP_ADDRESS] Duration of COPD Exacerbations
For moderate or severe exacerbat ions, the duration is defined by [CONTACT_244954][INVESTIGATOR_059]
The start date will be defined as the start date of prescribed treatment with a systemic 
corticosteroi d and/or sy stemic ant ibiotic or hospi[INVESTIGATOR_4073] n, which occurs earlier.
The stop date will be defined as the last day  of prescribed treatm ent wi th a systemic 
corticosteroi d and/or sy stemic ant ibiotic or hospi[INVESTIGATOR_2345], which occurs later.
A single depot injectable dose of corticosteroids will be considered equivalent to at 
least 3 -day course of systemic corticosteroids. The corresponding stop date for this 
treatment will consequently be determined as the date of administration plus 2 day s.
If multiple treatm ents are prescribed for the same exacerbat ion, the earliest start date 
and the latest stop date will be used.
For a severe COPD exacerbat ion with no documented corticosteroid or antibiot ics 
treatm ent, hospi [INVESTIGATOR_244828] n/discharge dates, or emergency visit date will be 
used as start/stop dates.
A new COPD exacerbat ion event must be preceded by  [CONTACT_2669] [ADDRESS_298001] 
COPD exacerbat ion (refer to Secti on [IP_ADDRESS] )
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 86of 2178.1.1.3 Approach for Capturing COPD Exacerbations
[IP_ADDRESS].[ADDRESS_298002] the COPD exacerbation that meets the COPD exacerbat ion 
definit ion (refer to Section 8.1.1 ) in the COPD exacerbat ion eCRF (COPDEX).  A ssociated 
symptoms of COPD are considered as symptoms of disease under study  and shoul d not be 
recorded as AEs unless meet condit ions listed in Section 8.3.7 .  The serious COPD 
exacerbation should be recorded in AE/SAE eCRF and in COPDEX. Other COPD related 
SAEs shoul d be recorded on the AE/SAE eCRF.
[IP_ADDRESS].[ADDRESS_298003] ion
 [IP_ADDRESS] .
If symptoms meet a specific thresho ld (i.e., [ADDRESS_298004] 1 other major 
or minor symptom for 2 consecut ive days), the eDiary  generates an alert to the subject and the 
investigat ional site. This alert should generate contact [CONTACT_244955]. The Invest igator then makes the decisio n whether or not to init iate (or 
escalate, as appr opriate) treatm ent for a COPD exacerbat ion. The Invest igator site is 
responsible for document ing the action taken within [ADDRESS_298005] (si te or pati ent). Detaile d 
instructi on will be provi ded in separate guidance. 
Major COPD symptoms : dyspnea, sputum vo lume, and sputum co lor
Minor COPD symptoms : cough, wheeze, sore throat, cold symptoms (rhinorrhea or nasal 
congest ion), and fever without other cause
If COPD exac erbat ion is associated with ePRO worsening alert, symptoms should not be 
reported in the COPD exacerbat ion eCRF. If COPD exacerbat ion is not associated with ePRO 
worsening alert, please refer to section
 [IP_ADDRESS] for further guidance.
[IP_ADDRESS] Investigator Justified COPD Exacerbations
If an event is not associated with ePRO symptom worsening alert as described above (e.g., 
technical issue, subject self -reports sym ptom  worsening/ exacerbati on event, the exacerbat ion 
is ident ified during a visit or phone contact, the exacerbat ion is evaluated and treated at non -
study  centre, or an acute/severe symptom deterioration which is not captured in the ePRO 
system  occurs), the Invest igator s hould interview the subject and evaluate potential worsening 
and duration of the fo llowing symptom s:
Shortness o f breath
Mucus Vo lume
Mucus purulence
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 87of 217Cough
Wheezing
Sore throat
Cold symptom s such as a runny nose or nasal congestion
Fever
Chest Ti ghtness
Other findings
The Investigator should record all pert inent findings (symptom worsening) associated with the 
exacerbation event and their duration in source documents and in the COPD exacerbat ion 
eCRF.
If an exacerbat ion is not associated with worsening of COPD symptom s or i t was not possible 
to capture the symptoms (e.g. patient intubated upon arrival to the emergency department), the 
Invest igator must document the justificat ion for diagnosing and treating the event as an 
exacerbation and record it in the eCRF.
[IP_ADDRESS] COPD Exacerbation visit
COPD Exacerbat ion visit (EXA) may be init iated when pat ient experiences a COPD 
exacerbation. There is no visit window for the EXA visit. The subject should co mplete the 
assessments according to Table 2if he/she experiences an exacerbation during the treatment 
and fo llow-up peri od. If the EXA visit was co mpleted wi thin +/ -5 day s of a scheduled visit, 
the sam e laboratory  assessments do not need to be repeated at the next scheduled visit, unless 
at the PI’s discretion. 
If a subject experience a COPD exacerbation at the time of a regular scheduled visit, the 
subject should co mplete the assessments fro m the scheduled visit. In case of addit ional 
assessments at EXA visit in co mpar ison wit h the regular visit, subject will also need to 
complete those addi tional assessments from  the EXA visit. 
Only for sputum sub -study subjects
Performing COPD Exacerbat ion visit (EXA) for sputum sub -study  patients is essent ial to 
evaluate exploratory  sputum  and nasal sub -study  endpoints during treatm ent phase. Refer to 
Secti on 3.
Patients parti cipating in sputum  sub-study  are required to perform pre -BD and sputum post -
BD spi [INVESTIGATOR_244829], at EXA visits during treatment. Induced sputum is 
preferred however spontaneous sputum is acceptable if pat ient cannot produce induced 
sputum  or if the collect ion of i nduced sputum is not permitted per local Healt h and Safet y 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 88of 217regul ations or guidance during the COVID -19 pandemic. Please refer to applicable sub -study  
manual for more informat ion. 
Patient shoul d withhol d the COPD m edicat ions as instructed in Section 6.5.4 . If withho lding 
COPD m edicat ion is not feasible, the spi[INVESTIGATOR_244824] d be perform ed wi th a notati on 
indicat ing under which condit ions spi [INVESTIGATOR_244830].
8.1.2 Spi[INVESTIGATOR_038]
[IP_ADDRESS] General Requirements
Lung funct ion (FEV1 and FVC) will be measured by [CONTACT_15209][INVESTIGATOR_244831] 
a central  vendor. The sam e equi pment will  be used for sputum  induct ion. Spi [INVESTIGATOR_244832]/European Respi[INVESTIGATOR_96661] (ATS/ERS) guidelines ( Miller et al  2005 ).
The vendor providing central spi[INVESTIGATOR_244833]/ERS recommendations and that the site personnel who will be performing the testing are 
properly cert ified. Spi[INVESTIGATOR_244834] y checks (including mo nitoring of 
unexpectedly  high variabilit y of resul ts) will  be detailed in a separate spi[INVESTIGATOR_244835]. Patients who exhibit unexpectedly  high vari ability of 
FEV1 will be evaluated by [CONTACT_244956] o f variabilit y, necessary  follow-up 
actions, and assessment of continued pat ient eligibilit y. The invest igator will discuss 
unexpectedly  high vari ability with the AZ study  physician. 
Subjects should avo id engaging in strenuous exertion for at least [ADDRESS_298006] ion assessments at the site.
Subjects should avo id eating a large meal for at least 2 hours prior to all lung function 
assessments at the site. 
Subjects should not smoke/vape on the same day(s) prior to the lung funct ion test is 
being performed.
Subjects sh ould withhold their usual maintenance therapi[INVESTIGATOR_96665](s) when lung 
funct ion testi ng is being performed as below:
SABA and SAMA should be withheld at least 6 hours prior to scheduled 
spi[INVESTIGATOR_96666]. 
Twice daily LABA or LAMA -
containing therapi[INVESTIGATOR_244836] d be wi thheld for at l east 
12 hours prior to scheduled spi[INVESTIGATOR_244837].
Once daily  LABA or LAMA -containing therapi[INVESTIGATOR_244838] 
24 hours prior to scheduled spi[INVESTIGATOR_244837].
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 89of 217LTRA should be restricted for at least 24 hours prior to scheduled spi[INVESTIGATOR_244839].
Twice daily theophylline should be wit hheld for at least 12 hours prior to 
scheduled spi[INVESTIGATOR_96620].
Once daily  theophylline for at least 24 hours pri or to scheduled spi[INVESTIGATOR_244837]. 
Twice daily triple inhaled (ICS/LABA/LAMA) medicat ions should be withheld at 
least 12 hours prior to scheduled spi[INVESTIGATOR_96620].
Once daily  triple inhaled (ICS/LABA/LAMA) medicat ions should be withheld at 
least 24 hours prior to scheduled spi[INVESTIGATOR_96620].
Note: If any of the above restri ction are not met, the spi[INVESTIGATOR_244840] d be 
rescheduled within the allowed visit window (See sect ion 6.5.5 ).
As part of the procedure for indu ced sputum  pre-BD and post BD spi[INVESTIGATOR_244841] (see Sect ion 8.8.5 and [IP_ADDRESS] )
. 
Applicable during COVID -[ADDRESS_298007] be performed only when Visit 1 SARS-
CoV -2 naso/oropharyngeal swab test (or rapid test or alternat ive test approved locally) result 
is available and negat ive (refer to footnote a and footnote l under Table 1, section
 1.1and to 
section 6.5.5 .).
SARS -CoV -[ADDRESS_298008] be init iated 
in the morning between 6:00 AM and 11:[ADDRESS_298009] -randomizat ion spi[INVESTIGATOR_96671] ± 1.5 hours of the 
time that the randomizat ion spi[INVESTIGATOR_244842]. For example, if the randomizat ion 
spi[INVESTIGATOR_244843] 8:00 AM, then all subsequent spi [INVESTIGATOR_244844] 6:30 AM and 9:30 AM.
Note: FeNO test should be performed prior to spi[INVESTIGATOR_038] . Please refer to Secti on 8.1.[ADDRESS_298010] Review 
(BTR) process will also be detail ed in the m anual. 
Spi[INVESTIGATOR_96675] (GLI) equations will be used to determine the Predicted 
Norm al Values (PNV) and are pre -programmed int o the spi[INVESTIGATOR_96676] (Quanjer et al 2012 ). 
FEV 1, expressed as percent of the PNV, will be calculated as fo llows:
FEV 1% of PNV = (FEV 1measured/FEV 1PNV) x [ADDRESS_298011]’s usual COPD morning maintenance therapy must not be given unt il spi[INVESTIGATOR_244845]. IP dosing should also be withheld unt il pre -
bronchodilator/post bronchodilator/sputum post -BD spi[INVESTIGATOR_244846].
Record keepi[INVESTIGATOR_007]
A signed and dated copy  of the pre -and post -BD and sputum post -BD spi[INVESTIGATOR_244847]. The printout must be marked wit h the 
study  code, enrolment code, date and time of measurement, visit number. If a printout cannot 
be printed, the mean value of the measurements will be recorded in the subject’s charts. 
[IP_ADDRESS] Post-BD Spi[INVESTIGATOR_244848]-BD spi[INVESTIGATOR_244849] 2 or at postponed Visit 1 (when Visit 1 and 
Visit 2 are combined) (to eval uate inclusio n criterion 5, see Secti on
 5.1), Visit 3, Visit 9, 
Visits 16 (EO T) and IPD. 
Endpoint m aximal  bronchodilat ion will be induced using albuterol (90μg metered dose) or 
salbutamo l (100μg m etered dose) with or without a spacer device up to a maximum of [ADDRESS_298012] SABA inhalat ion. SABA administration 
can start earlier (less than 15 minutes of the final pre- BD spi [INVESTIGATOR_038]) for safet y reasons.
Clinical Study Protocol -7.[ADDRESS_298013] -BD spi[INVESTIGATOR_244824] d be perform ed per schedule in Table 2 (Visit 3, Visit 16, 
IPD and EXA) as part of induced sputum procedures if subject is participat ing in the sputum 
sub-study , after post -BD spi [INVESTIGATOR_038] (where applicable, refer to Section [IP_ADDRESS] ). It is 
conducted solely to ensure patient safet y in inducing sputum and results will neit her be 
captured for the eCRF, nor for study  endpoints. More details will be provided in applicable 
sputum  sub-study  manual .
8.1.[ADDRESS_298014] in 
accordance with the SoA. A single exhalat ion technique recommended by [CONTACT_96766] (Alving et al 2017 )
. Detailed procedure for performing FeNO will be 
described in a separate instruction manual.
The FeNO test will be performed prior to spi[INVESTIGATOR_038] .  
Restrictions on the day  of scheduled FeNO assessment:
The FeNO measurements should not be performed within [ADDRESS_298015] ion.
Subjects should not eat or drink [ADDRESS_298016]. 
Subjects should not use their rescue SABA and/or SAMA medicat ion within 6 hours of 
the measurement.
Inhaled BDs should be withheld for the ef fect duration specific to the BD as described in 
Secti on 6.5.[ADDRESS_298017] dose of 
BD or meal/drink. However, if not possible the visit must be rescheduled wit hin the allowed 
visit window.
The NIOX VERO® Airway Inflammat ion Monitor will be used to measured FeNO. 
Instructi ons for use of this monitor will be provided in a separate user’s manual.   
NIOX VERO® sensors will be replaced as recommended by [CONTACT_3455]. The vendor 
supplying the equipment will be responsible for ensuring that the equipment and procedures 
for the m easurement of FeNO are validated prior to the start of the study . 
Allpost-randomizat ion FeNO assessments should be performed within ± 1.5 hours of the time 
that the rando mizat ion FeNO was performed.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 92of 217Two acceptable FeNO measurements will be performed to establish repeatabilit y; up to 8 
measurements can be performed. After F eNO repeatabilit y is met, i t will not be possible to 
perform  any further FeNO m easurements at that visit.
The sponsor will be unblinded to the FeNO values prior to randomizat ion (Vi sit 2 and any 
repeat testing that is performed during screening, and prior to IP administration) and blinded 
to the subsequent FeNO values post randomizat ion. Sites will be blinded to the FeNO values 
for the whole study  durati on.
8.1.4 COPDCompEx
COPDCo mpEx is a composite endpo int for exacerbat ions (moderate or severe) in COPD. 
COPDCo mpEx co mbines exacerbat ions wi th events defined from pat ient daily diaries. The 
definit ions for both ty pes of  exacerbat ion are as fo llows:
Exacerbations: epi[INVESTIGATOR_1841] l eading to one or m ore of the fo llowing: hospi [INVESTIGATOR_3094],
emergency room  visit, treatm ent wi thsystemic corti costeroi ds, or treatm ent wi th 
antibiotics.
Diary events : defined by  [CONTACT_244957] d and sl ope cri teria using the fo llowing diary  
variables: individual do mains o f the breathlessness, cough, sputum scale, sleep, chest 
tightness and rescue medicat ion use.
The analysis of this endpo int will primarily be time to first COPDCompEx event, but the 
events may also be analysed wit h models addressing event rates or time to recurrent event. 
More details on the derivat ion and analysis o f this variable will be given in the Statist ical 
Analysis Plan (SAP).
8.1.5 Clinically Important Deterioration (CID)
CID is a composite endpo int measuring worsening of the key  clinical features of COPD, 
namely lung funct ion, pati ent-reported outcomes and exacerbat ions. CID i s defined a s 1) a 
decrease of ≥100 mL fro m baseline in trough FEV1, 2) a deterioration in healt h-related qualit y 
of life defined as ≥4-unit increase fro m baseline in SGRQ total score, 3) the occurrence of an 
on-treatment moderate -to-severe COPD exacerbation (defined as an acute worsening of 
COPD symptoms requiring the use of addit ional treatm ent including oral  corti costeroi ds, 
antibiotics, emergency depart ment treatm ent, or hospi[INVESTIGATOR_059]).
8.1.6 Patient Reported Outcomes
Patient reported outcomes (PRO) data will be captur ed electronically using a handheld device 
at hom e and at the site. Site personnel will be trained on the use of this device and detailed 
procedures for using the device will be described in a separate instruction manual.  Subjects 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00 001
CONFIDENTIAL AND PROPRIETARY Page 93of 217will be trained on at hom e use of the eDi ary at Vi sit 2 or Vi sit 1 (if  Visi t 1 and Visi t 2 are 
combined). The site staff will set assessment reminder alarms on the device. Training will 
emphasize the importance of completing the PRO assessments as scheduled to capture the 
subject' s experience and meet the objectives of the study . 
Subjects will co mplete assessments twice daily  and at other timepoints specified in the SoA. 
The Investigator/authorized delegate will check subject’s adherence to the PRO assessment 
schedule as is neces sary to m aintain necessary  to minimize missing data and at each study  
visit. Frequent compliance checks on the ePRO Study  Works portal  will be com pleted by [CONTACT_244958] n criteria 16
and 17 at randomizat ion (Vi sit 3).
[IP_ADDRESS] Major/Minor Symptom Worsening Assessment and Alert System
Symptom s will be assessed each morning for the purposes of a symptom worsening alert. The 
purpose of this alert is to notify  both the subject and the site of a potenti al symptom  worsening 
event that warrants contact [CONTACT_244959]/authorized delegate for 
further evaluat ion.
Each m orning the subject will co mplete 3 questions pertaining to the major symptoms of a 
worsening event (dyspnea, sput um volume, and sputum color). Subject reported worsening o f 
1 or m ore of these symptoms will trigger assessment of the minor symptoms of a worsening 
event (sore throat, cold, fever without other cause, cough, and wheeze). All quest ions will 
have a [ADDRESS_298018] 3 response options (e.g., How breathless have you been in the last 24 hours? 
Less breathlessness than usual, Usual level o f breathl essness, m ore breathl ess than usual) 
whereas quest ions related to the presence or absence of a symptom will have a dichotomous 
response (e.g., Have y ou had a sore throat in the last 24 hours? No, Yes, I had a sore throat).
An alert will be triggered if two or more major symptoms (dysp nea, sputum vo lume, and 
sputum  color) worsen for two consecut ive days or if one major symptom and one minor 
symptom  (e.g., sore throat, cold, fever without other cause, cough, and wheeze) worsen for at 
least two consecutive days. When eit her of these crite ria is m et the subject will be alerted via 
the ePRO device to contact [CONTACT_244960]. Likewise, the 
site will  be alerted to contact [CONTACT_244961]  24-72 hours if he or she has not 
yet contact[CONTACT_244962] e for further evaluat ion.
[IP_ADDRESS] Rescue Medication
Rescue medicat ion usage including reliever inhaler and nebulizer use will be captured twice 
daily . Inhaler usage will be reported as the number of puffs, (i.e., the sum of different 
relievers, if applicable) in a given peri od whereas nebulizer use will be reported as the number 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 94of 217of times. Rescue medication usage at night will be assessed in the morning and rescue 
medicat ion used during the day  will be assessed in the evening.
[IP_ADDRESS] Nocturnal Awakenings
Subjects will be asked to report the occurrence of nocturnal awakenings due to COPD 
symptoms each morning using the ePRO device. A single quest ion with yes/no response 
options will be used.
[IP_ADDRESS] Maintenance Medication
Maintenance medicat ion adherence will be assessed each eveni ng. The subject will be asked if 
they took thei r regul arly scheduled inhaler and instructed not to consider instances of rescue 
inhaler usage when answering this quest ion.
[IP_ADDRESS] St. George’s Respi[INVESTIGATOR_6015] (SGRQ)
The SGRQ is a 50- item PRO instrum ent d eveloped to measure the healt h status of patients 
with airway obstructi on diseases ( Jones et al  1991 ). The questi onnai re is divided into 2 parts: 
part1 consists of 8 items pertaining to the severit y of respi [INVESTIGATOR_244850] 4 
weeks; part [ADDRESS_298019] ivity and psychosoci al impacts of the 
individual’s respi[INVESTIGATOR_244851]. The SGRQ yields a total score and 3 domain scores 
(symptom s, activit y, and impacts). The total score indicates the impact of disease on overall 
healt h status. This total score is expressed as a percentage of overall impairment, in which [ADDRESS_298020] possible health status. 
Likewise, the dom ain scores range from 0 to 100, with higher scores indicat ive of greater 
impairment. Based on empi[INVESTIGATOR_244852], a decrease of 4 units is 
associ ated wi th a minimum  clinically  important difference (MCID). Specific details on the 
scoring algorithms are provided by  [CONTACT_244963] a user m anual ( Jones et al  2009 ). SGRQ 
will be co mpleted using eDiary  in accordance wit h the SoA. If the subject is not able to visit 
the site, SGRQ m ay be com pleted by  [CONTACT_79987]/alternat ive location . Refer to 
Appendix I for details.
[IP_ADDRESS] COPD Assessment Test (CAT)
The CAT i s an [ADDRESS_298021] of COPD on healt h status ( Jones 
et al 2009 ).  The instrument uses semant ic differential six -point response scales which are 
defined by [CONTACT_244964]. Content includes items 
related to cough, phlegm, chest tightness, breathlessness going up hills/stairs, act ivity 
limitation at home, confidence leaving ho me, sleep and energy. A CAT total score is the sum 
of item responses. Scores range from 0- [ADDRESS_298022] on health status. The CAT will be measured at Visits 1, 3, 6, 9, 12, IPD and 16/EOT. If 
Clinical Study Protocol -7.[ADDRESS_298023] at 
home/alternat ive location. Refer to Appendix I for details.
[IP_ADDRESS] Exacerbations of Chronic Pulmonary Disease Tool –Patient -reported Outcome 
(EXACT -PRO) and Evaluating Respi[INVESTIGATOR_238439] (E -RS™: 
COPD) 
The EXACT -PRO is a 14 -item PRO instrum ent devel oped to assess the frequency, severit y, 
and durati on of  COPD exacerbat ions (Jones et al 2011, Lei dy et al  2011 ). The instrument was 
developed for daily , at hom e, administrati on using a handheld electronic device. Respondents 
are instructed to complete the diary  each evening just prior to bedtime and to answer the 
questions while considering their experiences “toda y”. The daily EXACT -PRO total  score has 
a range of [ADDRESS_298024] -PRO can provide informat ion on event 
frequency  and durati on as well as event severit y. 
The E -RS™: COPD is an 11- item PRO developed to evaluate the severit y of respi[INVESTIGATOR_244853] ( Sexton et al 2010, Sexton et al 2011 ) . The E -RS™: COPD is a subset of 
items fro m the EXACT -PRO. Th e E-RS™: COPD was designed to be captured as part of the 
daily  EXACT -PRO assessment. Summat ion of E -RS™: COPD item responses produces a 
total score ranging from 0 to 40, with higher scores indicat ing greater severit y. In addi tion to 
the total score, sympto m domain scores can be calculated for breathlessness (5 items; score 
range: 0–17), cough and sputum (3 items; score range: 0–11) and chest symptoms (3 items; 
score range: 0 –12) by  [CONTACT_244965] a respective domain. As with 
the total score, hi gher domain scores indicate greater severit y.
8.[ADDRESS_298025] has re -consented to home/alternat ive 
location IP administra tion visi ts, it is possible that the HCP can collect clinical safet y 
laboratory  tests in the subject’s home/alternat ive location. Pl ease refer to Appendix I .
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 96of 217The Inv estigator shoul d assess the available results regarding clinically  relevant abnorm alities. 
The l aboratory  resul ts shoul d be signed and dated and retained at centre as source data for 
laboratory  variables.  
For informat ion on how AEs based on laboratory  tests shoul d be recorded and reported, see 
Secti on 8.3.7 .
The  safet y samples (clinical chemistry , hematol ogy and urinalysis) will be performed at a 
central  laboratory . If central  laboratory  kits are not available, the safet y samples can be 
collected and analysed at the local laboratory  at the di scret ion of the PI. However, all 
laboratory  assessments for Vi sit 1, Vi sit 3 and EoT or IPD Vi sit (as per SoA ) must be 
analysed at the central laboratory .
Maintaining the blind to the patient’s blood immunoglobulin, eosinophil, basophil and 
monocyte counts
The sponsor and site will be blinded to the immunoglobulin, eosinophil, basophil and 
monocy te counts from  the central  laboratory  reports except screening visit s (Vi sit 1 and 2), 
any repeat testing that is performed during the screening, and prior to 1stIP administration. 
If the invest igator orders any local safet y laboratory assessments, the requested tests sh ould be 
restri cted to the question at hand. For example, if hemoglobin is desired, the investigator 
shoul d avoi d ordering a com plete bl ood cell count wi th a different ial count.
In cases where the invest igator requires an immunoglobulin, eosinophil, basophi l, or 
monocy te count for m anaging safet y issues, he/she may  order these tests as per regular site 
practi ce. [COMPANY_008] should be notified of all such cases.
Site staff who are directly involved in the patient’s management should remain blinded to any 
blood immunoglobulin, eosinophil, basophil and monocy te counts resul ts included as part of 
an outsi de laboratory  report or el ectronic m edical record. To help ensure this, each 
investigat ional site will designate an individual (e.g. administrator or another ancillary  person) 
not di rectly involved in patient management, to receive and blind any immunoglobulin, 
eosinophil, basophil and mo nocy te counts resul ts pri or to the report being handed over to the 
site staff invo lved in the pat ient’s management and prior to filing the laboratory  report as a 
source document. Similarly, immunoglobulin, eosinophil, basophil and monocy te counts 
resul ts must be redacted from all communications with the sponsor.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 97of 217Table 7 -Laboratory Safety Variables
Hem atology/Hemostasis (Whole Blood) Clinical Chemistry (serum or plasma)
B-Hemoglobin (Hb) S-Alka line phosphatase (ALP)
B-Leukocyte count S-Alanine transaminase (ALT)
B-Leukocyte differential count (absolute count) S-Aspartate transaminase (AST)
B-Platelet count S-Bilirubin, total
B-Hematocrit S-Blood urea nitrogen
B-Mean Corpuscular Volume S-Calcium, total
B-Red blood cell (RBC) count S-Chloride
S-Creatinine
Urinalysis (Dipstick)* S-Creatinine kinase (CK)
U-Hb/Erythrocytes/Blood S-CRP
U-Protein/Albumin S-Gamma -glutamyl transpeptidase (GGT)
U-Glucose S-Glucose
S-Phosphorus
U-Microscopy and culture as required** S-Potassium
S-Sodium
S-Total cholesterol
S-Uric acid
*Urinalysis (Dipstick) central laboratory report will contain results from variables as listed in the laboratory 
manual, however only for variables U -Hb/Erythrocytes/Blood, U -Protein/Albumin and U -Glucose requires 
confirmatio n in laboratory eCRF module if the result is clinically significant. If there are any clinically 
significant results from other variables, it will be the investigator decision to document them in the eCRF as an 
AE. 
**Urine samples will be analyzed locally and sent to the central labora tory only  for microscopy and culture 
analy sis when a positive dipstick result for any parameter is observed.
NB.In case a subject shows an AST orALT ≥3xULN together with total bilirubin ≥2xULN 
please refer to Appendix E for further instructi ons.
[IP_ADDRESS] Pregnancy Test 
The fo llowing tests are applicable to female subjects only  and will  be conducted in accordance 
with the schedule provided in Sect ion 1.1.
 Serum  ß-human chorionic gonadotropin (ß -HCG) –the test done at enrolment 
(Visit 1) only, for WOCBP (analyzed at central laboratory ).
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 98of 217 FSH –the test done at enrolment (Visit 1) only, for female subjects to confirm 
postm enopausal status in women <[ADDRESS_298026] been amenorrhoeic for >[ADDRESS_298027] as WoCBP.                                                                                                                                     
 Urine HCG –the test will be performed at the study site for WOCBP at each 
treatm ent visi t before IP administrati on using a di pstick. Posi tive urine test result 
must be confirmed with serum β -HCG.
8.2.2 Smoking Status
Smoking status will be assessed at every  visit starting from  enro lment (Visit 1) unt il the end of 
the last Follow Up Visit (Week 64) by [CONTACT_244966]’s response to a single y es/no 
question fro m study  personnel: ‘What is y our sm oking status as of t oday , do y ou currently  
smoke? Sm oking status changes during Visit [ADDRESS_298028] Follow Up Visit (Week 
64) will be captured on the eCRF but the subject will be permitted to continue in the study .
8.2.[ADDRESS_298029]’s weight will be 
recorded in kilograms, and height will be recorded in cent imetres. Weight and height 
measurements will be performed in light clothing and with shoes off.
8.2.4 Physical Exa minations
A co mplete physical examinat ion will be performed and include an assessment of the 
following: general appearance , respi [INVESTIGATOR_696] , cardi ovascular, abdom en,skin, head and neck 
(including ears, eyes, nose and throat), lymph nodes, thy roid, musculo skeletal  (including spi[INVESTIGATOR_244854]) and neurological systems. Brief physical examinat ion will also be performed 
and include an assessment of the general appearance, abdomen, cardiovascular and respi[INVESTIGATOR_96682] . For the bri ef physical  examinat ion, only, informat ion on whether the assessment was 
perform ed or not will be recorded.
Physical examinat ion (com plete and bri ef) will  be perform ed at timelines as specified in the 
SoA. Invest igators should pay special attention to clinical signs related to previous serious 
illnesses, as new o r worsening abnormalit ies may qualify  as adverse events, see Secti on 8.3.7
for details.
8.2.5 Vital Signs
Vital signs (body  temperature, pul se, blood pressure and respi[INVESTIGATOR_244855]) will be obtained in 
accordance with the schedule provided in Table 1and Table 2. 
Clinical Study Protocol -7.[ADDRESS_298030] study assessment (at Visit 1 when ICF is 
obtained).
Subject with fever ( ≥ 38°C; ≥ 100.4°F) suspect ed due to COVID -[ADDRESS_298031] ion during 
screening or at randomizat ion should be screen failed (Exclusio n criterion 38).
IP should not be administered if the subject is febrile (≥ 38°C; ≥ 100.4°F) or is 
suspected of having COVID -19. Refer to section 6.1.[ADDRESS_298032] 5 minutes, 
by [CONTACT_244967] (how many times the chest rises) for one minute.
8.2.6 ECG
ECG will be performed in accordance wit h the schedule provided in Table 1and Table 2. The 
equipment will be provided by  a central  vendor .
A 12 -lead di gital electrocardi ogram  (dECG) will be taken in the supi[INVESTIGATOR_23571], after the 
subject has been resting for at least [ADDRESS_298033] (e.g., spi[INVESTIGATOR_244856]).
The Investigator or authorized delegate will be responsible for the overall interpretation and 
determinat ion of clinical significance o f any potential ECG findings. In case of discrepancy 
between the Invest igator's inte rpretati on and that provided by [CONTACT_6632] (if 
applicable), the Invest igator's interpretation will take precedence and should be noted on the 
printout and recorded in the eCRF. A copy  of the ECG will be produced, and qualit y checked 
and kept in case o f further need for re -evaluat ion.
It is highly  recommended that the same machine is used for assessment throughout the 
subject’s participat ion in the study .
ECG evaluat ion will be recorded in the eCRF.
8.2.7 Supplemental Oxygen (O 2)
Oxygen use will be assessed according to the schedule in
 Table 1and Table 2.Use of LTOT 
shoul d be recorded as a concomitant medication in the eCRF.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 100of 2178.2.8 Oxygen Saturation (SpO 2)
Pulse oximetry  will be used to m easure the subject’s oxygen saturation according to the 
schedule in Table 1and Table 2.
8.2.[ADDRESS_298034] X -ray (anteri or-posterior)/CT/MRI 
for other reasons (not study  related) might be acceptable. The outcome of the X -ray/CT/MRI 
must be documented in the patients’ medical records. Study  Physician approval of historical 
X-ray must be obtained pri or to randomizat ion.
8.2.[ADDRESS_298035] does not require a booster (gen erally after 5 -6 years according to 
current guidelines, e.g., CDC 2010 ). If a booster is required, it should be given at Visit 1, or at 
any time prior to randomizat ion. Subjects should receive an annual influenza vaccination in 
the autumn or winter period unless the subject has received it prior to study  start ( refer to 
current CDC guidelines e.g., CDC 2021 -2022) . If the subject has previously received the 
influenza vaccinat ion within the l ast [ADDRESS_298036] has an egg intolerance, the vaccinat ion 
may be omitted. If the PI [INVESTIGATOR_244857], the rationale should be 
clearly  specified. 
See exclusio n criteria 25 f or subjects participating in the sub -study .
COVID -19 Vaccination
COVID -19 vaccines are either nucleic acid vaccines (which can inclu de DNA plasmid and 
mRNA), recombinant vector vaccines (non -replicating viral vectors) or inact ivated virus 
vaccines. DNA plasmid and mRNA vaccines are considered an inact ivated vaccine. 
Reco mbinant vector candidates potentially may be in a new category. Ba sed on available 
publicat ions on mRNA and virus vector anti -SARS CoV -2 vaccines, the immune response 
developed rapi[INVESTIGATOR_244858]. For vaccines that are currently approved under 
emergency use authori zation (EUA), please refer to relevant health authorit y websites for 
Clinical Study Protocol -7.[ADDRESS_298037] (see Table 
6).  
Given the limited long term safet ydata of COVID -19 vaccines and the potential to confound 
the interpretation of safet y resul ts in the study , the fo llowing COVID
-19vaccinat ion 
guidance provi ded in Table 8should be followed depending on the study phase.
Table 8 -COVID -19 Vaccination Guidance
Study Period Vaccine usage 
Patient in
screening/run -in periodIf Covid -[ADDRESS_298038] COVID should be planned in 
advance to ensure the IP dosing/COVID -[ADDRESS_298039] ask if the patient has received or is 
planning to receive a COVID -19 vaccination. This is 
to ensure that the required time interval for IP dosing 
(mentio ned above) is maintained. 
If it is anticipated that a patient will miss two 
consecutive IP administrations, the [COMPANY_008] 
study physician should be contact[CONTACT_244968]. 
The r eason for skippi[INVESTIGATOR_244859] “COVID -19” prefix in medical records 
and COVID -[ADDRESS_298040] of the 
patient, COVID -19 vaccination could be 
administered. Patient should follow schedule of 
assessments; no special adjustments are needed. It is 
advised that subject wait for [ADDRESS_298041] IP 
dose.  
The suggested IP dosing/COVID -19 intervals is summarized in Figure 3.
Figure 3 -COVID -19 Vaccination between IP Dosing
Reporting of COVID- 19Vaccination
COVID- 19 vaccine details including vaccine’s name/manufacturer, route of 
administrati on,and vaccinat ion date should be entered into the eCRF CM module.

Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 103of 217If a patient experiences an AE/SAE associated with COVID -[ADDRESS_298042] thi sinsource document and determine whether the IP should be cont inued, 
skipped, or permanent ly discontinued in accordance with Section 7.1of the CSP.   
8.2.11 Other Safety Assessments
[IP_ADDRESS] Serology
Hepati tis B surface ant igen, hepat itis C antibody , HIV -1 and HIV -2 antibodies will be 
assessed at enrolment (Visit 1) only. All test ing for these will be performed at a central 
laboratory .
Instructi ons for sam ple collect ion, processing, storage, and shipment will be provided in a 
separate laborat ory manual provided to the si tes.
[IP_ADDRESS] SARS -CoV -[ADDRESS_298043] i s applicable only  for new subjects enrolled into the study :
SARS -CoV -2 naso/oropharyngeal swab test, rapid test or alternat ive test (approved by 
[CONTACT_122593]) –done at en rolment (Vi sit 1) only.
The fo llowing test i s applicable for new subjects enrolled into the study  and f or rem aining 
ongoing act ive subjects: 
SARS -CoV -[ADDRESS_298044] –for newly enro lled subjects done at first IP 
administration visit. For remaining ongoing act ive subjects, the test should be done as 
soon as possible, but preferably  at next on -site visit.
SARS -CoV -[ADDRESS_298045] ion, processing, storage, and shipment will be 
included in a separate laboratory  manual provided to the si tes. SARS -CoV -2 serology  data 
will be used to assess individual cases but will not be used for subgroup analyses (e.g. 
serol ogy posi tive/negat ive).
In case of lo ng tu rnaround time of the nasopharyngeal swab test results from central 
laboratory , the si te has the following alternatives:
Perform  naso/oropharyngeal swab test through local lab 
Perform  a rapi d ant igen test or alternat ive tests at the site, provided it is ap proved by  
[CONTACT_244969] -7.[ADDRESS_298046] (or, when appropriate, by  a caregiver, surrogate, or the 
subject's legally  authori zed representative). The Investigator and any  designees are responsible 
for detecting, document ing, and recording events that meet the definit ion of an AE or SAE. 
For informat ion on how to follow -up AEs see Sectio n 8.3.3 .
 
8.3.1 Method of Detecting AEs and SAEs
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended and 
non-leading verbal quest ioning of the subject is the preferred method to inquire about 
AEoccurrences.  
8.3.[ADDRESS_298047]’s last 
visit and he/she considers the event to be reasonably related to the Study  treatm ent or study  
participat ion, the Invest igator must notify the sponsor.
The m ethod of re cording, evaluat ing, and assessing causalit y of AE and SAE and the 
procedures for complet ing and transmitting SAE reports are provided in Appendix B .
 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 105of 2178.3.3 Follow- up of AEs and SAEs
After the init ial AE/SAE report, the Invest igator is required to proactively fo llow each subject 
at subsequent visits/contacts. All SAE/non -serious AEs/AEs of special interest, AEs leading to 
prem ature di scontinuati on will  be followed unt il resolution, stabilization, the event is 
otherwi se explained, or the subject is lost to follow -up. 
Any AEs that are unresolved at the subject’s last AE assessment or other assessment/visit as 
appropriate in the study  are f ollowed up by [CONTACT_13177] a s long as medically indicated, 
but without further recording in the CRF. [COMPANY_008] retains the right to request additional 
inform ation for any  subject wi th ongoing AE(s)/SAE(s) at the end of the study , if judged 
necessary .
8.3.4 Adverse Event Data Collection
The following variables will be collected for each AE;
 AE (verbat im)
 The date when the AE started and stopped
 Whether the AE is serious or not
 Invest igator causalit y rating against the IP(s) (y es or no)
 Action taken with regard to IP(s)
 Select the appropri ate as requi red: AE caused subject’s withdrawal from 
study  (yes or no)
 Outcom e
In addit ion, the fo llowing vari ables will be collected for SAEs:
 Date AE m et cri teria for seri ous AE
 Date Invest igator became aware of serious AE
 Reason of AE being considered se rious 
 Date of hospi[INVESTIGATOR_72913]
 Date of discharge
 Probable cause of death
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 106of 217 Date of death
 Autopsy  performed
 Causalit y assessment in relat ion to study  procedure(s)
 Causalit y assessment to other medicat ion(s)
8.3.5 Causality Collection
The Investigator will assess causal relat ionship between IP and each AE, and answer ‘yes’ or 
‘no’ to the question ‘Do y ou consi der that there i s a reasonable possibilit y that the event may  
have been caused by [CONTACT_33159]?’
For SAEs, causal relat ionship will also be ass essed for other medicat ion and study  procedures. 
Note that for SAEs that could be associated with any  study  procedure the causal relationship is 
implied as ‘yes’.
A guide to the interpretation of the causalit y quest ion is found in Appendix B to the Clinical 
Study  Protocol .
8.3.[ADDRESS_298048] or reported in response to the open question 
from the study  site staff: “Have y ou had any  health probl ems since the previous visit/y ou were 
last asked?” or revealed by  [CONTACT_244970]. When 
collect ing AEs, the recording of diagnoses is preferred (when possible) to recordi ng a list of 
signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms 
that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be 
recorded separately.
8.3.7 Adverse Events Based on Examinations and Tests
The results from the Clinical Study  Protocol  mandated l aboratory  tests, vi tal signs and ECGs 
will be summarised in the CSR. Deterioration as compared to baseline in protocol -mandated 
laboratory  values/vi tal signs/ECG shoul d therefore only be repor ted as AEs if they fulfil any  
of the SAE criteria or are the reason for discont inuation of treatment with the invest igational 
product.
If deteri oration in a laboratory  value/vi tal sign/ECG is associ ated wi th clinical  signs and 
symptoms, the sign or symptom will be reported as an AE and the associated laboratory  
resul t/vital sign/ECG will  be consi dered as addi tional informat ion. Wherever possible the 
reporting Invest igator uses the clinical, rather than the laboratory term (e.g., anaemia versus 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 107of 217low haem oglobin value). In the absence of clinical signs or symptoms, clinically relevant 
deteri orations in non -mandated parameters should be reported as AE(s).
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE. 
When co llecting AEs, the recording of diagnoses is preferred, when possible, to recording a 
list of signs and symptoms. COPD symptoms or signs, such as wheeze, cough, chest tightness, 
dyspnea, breathles sness and phlegm, will be recorded as AEs only when:
The sign or symptom is serious according to definitions, see Appendix B . 
The patient discont inues IP due to th e sign or symptom .
The sign or symptom is new to the patient or not consistent with the patient’s pre -
exist ing COPD history  (defined as within 1 year of Visit 1) as judged by [CONTACT_24338].
Worsening of COPD should be recorded as an AE or SAE only  if itfulfils any  of the above 
criteria. 
[IP_ADDRESS] Adverse Events of Pneumonia Requiring a Confirmed Diagnosis
Events of suspected pneumo nia shoul d be confirmed by  [CONTACT_46917] a new infiltrate on x -
ray within approximately [ADDRESS_298049] 2 of the following signs and symptoms: 
increased cough, increased sputum purulence or production, consistent a uscultatory  findings, 
dyspnea or tachypnea, fever, leukocy tosis, or hy poxemia. 
Events of confirmed diagnoses of pneumonia must be recorded as the AE “Pneumonia 
(confirmed)”. The severe infect ion pages in eCRFs must be completed for infect ions which 
are de fined as SAE, or requiring treatment with systemic ant iviral medicat ions, intravenous 
antibiotics, or medicat ions for helmint h parasit ic infect ion or requiring a permanent 
discontinuat ion of study  drug (refer to section  8.3.8).
8.3.[ADDRESS_298050] (AESI) is an event of scient ific and medical interest 
towards improving the understanding o f the IP. An AESI may be serious or non -serious. For 
this study , AESIs include:
 Serious hy persensi tivity reacti ons
 Malig nancy
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 108of 217 Helmint h infect ions
 Serious infect ionsa
 Guillain Barre Syndrome
 Serious cardiac events
aeCRF 'Severe infection' pages to be completed for infections which are defined as SAE, or requiring treatment 
with sy stemic antiviral medications, intravenous antibiotics, or medications for helminth parasitic infection or 
requiring a permanent discontinu ation of study drug.
8.3.9 Hy’s Law
Cases where a subject shows elevat ion in liver bio chemistry  may require further evaluat ion 
and occurrences o f AST or ALT ≥ 3xULN together with total bilirubin ≥ 2xULN may need to 
be reported as SAEs.  Please refer to Appendix E for further instruction on cases of increases 
in liver bio chemistry  and evaluat ion of Hy’s Law.
8.3.[ADDRESS_298051] ions, use errors, and information supplied by [CONTACT_3455].
NOTE: Addi tional guidance, incl uding expanded definit ions, can be found in Appendix J of 
the protocol. 
The [COMPANY_008] Clinical Study  Medical Device/Device Const ituent Report Form and/or 
Product Complaint Intake Form will be used to collect the de ficiency.
[IP_ADDRESS] Time Period for Detecting Medical Device Deficiencies
Medical device incidents or malfunct ions of the medical device will be detected, 
docum ented, and reported during all periods of the study  in which the medical device is 
used.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 109of 217If the invest igator learns of any medical device deficiency at any t ime after a participant 
has been discharged from the study , and such incident is considered reasonably related to 
a medical device provided for the study , the invest igator will pro mptly notify  the sponsor.
The m ethod of docum enting Medical Device Deficiency is provided in Appendix J .
[IP_ADDRESS] Follow -up of Medical Device Deficiencies
Follow-up applies to all participa nts, including those who discont inue study  intervent ion.
The invest igator is responsible for ensuring that follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the deficiency.
New or updated informat ion will be recorded on the originally co mpleted form wit h all 
changes signed and dated by  [CONTACT_17062].
[IP_ADDRESS] Prompt Reporting of Medical Device Deficiencies to Sponsor
Only deficiencies associated with the device const ituent part of the tezepelumab 
combinat ion product should be reported to the sponsor.
Medical device deficiencies will be reported to the sponsor within 24 hours after the 
investigator determines that the event meets the protocol definit ion of a medical device 
deficiency.
The [COMPANY_008] Clinical Study  Medical Device/Device Const ituent Report Form and/or 
Product Complaint Intake Form will be sent to [COMPANY_008] by  [CONTACT_6968].
Where an SAE has occurred in addit ion to the malfunct ion, the SAE will be recorded in 
the eCRF as detailed in Sect ion 8.4.1 .
The sponsor will be the contact [CONTACT_244971].
[IP_ADDRESS] Regulatory Reporting Requirements for Device Deficienci es
The invest igator will pro mptly report all medical device deficiencies occurring with any 
medical device provided for use in the study  in order for the sponsor to fulfil the legal 
responsibilit y to notify appropriate regulatory  authori ties and other enti ties about certain 
safet y informat ion relating to medical devices being used in clinical studies.
The invest igator, or responsible person according to local requirements (e.g., the head o f 
the medical inst itution), will co mply with the applicable local reg ulatory  requi rements 
relating to the reporting o f medical device deficiencies to the IRB/IEC.
For further guidance on the definit ion of an SAE, see Appendix J of the CSP.
Clinical Study Protocol -7.[ADDRESS_298052] be reported, whether or not considered causally related to the IP, or to the 
study  procedu re(s). All SAEs will be recorded in the CRF.
If any SAE occurs in the course of the study
, then Invest igators or other site personnel must 
inform  the appropri ate [COMPANY_008] representatives within one day i.e., immediately but no 
later than [ADDRESS_298053] igators or other site personnel indicate an AE is serious in the WBDC system, 
an autom ated email alert is sent to the designated [COMPANY_008] representative(s).
If the WBDC system is not available, then the Investigator or other study  site staff must report 
a SAE to the appropriate [COMPANY_008] representative(s) by [CONTACT_756].
The [COMPANY_008] representative(s) will advise the Investigator/study  site staff how to proceed.  
The reference document for definit ion of expectedness/listedness is the Investigator’s 
Broch ure for the [COMPANY_008] IP. 
8.4.[ADDRESS_298054] igator shou ld inform the sponsor within 24 hours of learning of the 
pregnancy. Any cases of pregnancy during the study  period or f ollow up will be recorded in 
the specific eCRF module.
Abnorm al pregnancy outcom es (e.g., spontaneous abortion, foetal death, stillbirth, congenital 
anomalies, ectopi c pregnancy ) are considered SAEs.
Clinical Study Protocol -7.[ADDRESS_298055] iveness of a contraceptive medication.  
Congenital ano malies/birth defects and spontaneous miscarriages should be reported and 
handled as SAEs.  Elect ive abortions without complicat ions shou ld not be handled as AEs.  
The outcome o f all pregnancies (spontaneous miscarriage, elect ive terminat ion, ectopic 
pregnancy, normal birth or congenital anomaly) shoul d be f ollowed up and documented even 
if the subject was discont inued fro m the study .
If any pregnancy  occurs in the course of the study , then the Invest igator or other site personnel 
must inform the appropriate [COMPANY_008] representatives within 1day i.e., immediately but no 
later than [ADDRESS_298056] igator to ensure that all 
relevant informat ion is provided to the [COMPANY_008] Patient Safet y data entry  site wi thin 1 or 5 
calendar day s for SAEs (see Secti on 8.4.1 ) and within 30 days for all other pregnancies.
The same timelines apply when outcome informat ion is available.
The PREGREP module in the CRF is used to report the pregnancy and the PREGOUT is used 
to report the outcome of the pregnancy.
[IP_ADDRESS] Paternal Exposure 
Pregnancy of the subject’s partners will not be considered an AE.  However, the outcome of 
all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal 
birth, or congenital anomaly ) shoul d be f ollowed up and documented in the Pregnancy  Report 
Form  for concepti ons occurring fro m the date of the first administration of IP until 16 weeks 
(5 half -lives) after the last administration o f IP. Consent from the partner must be obtained 
before the Pregnancy  Report Form  is completed.
8.4.3 Overdose
A dose in excess of tezepelumab 700 mg SC administered within a 2 -week peri od is 
considered an overdose.
There i s currently no specific treatment in the event of overdose of IP and possib le symptom s 
of an overdose are not established.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 112of 217An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the relevant 
AE m odule in the CRF and on the Overdose CRF module.
An overdose without associated symptoms is only  reported on the Ov erdose CRF m odule.
If an overdose on an [COMPANY_008] study  drug occurs in the course of the study , then the 
Invest igator or other site personnel inform appropriate [COMPANY_008] representatives 
immediately ,or no later than [ADDRESS_298057] occur within 30 days.
8.4.4 Medication Error, Drug Abuse and Drug Misuse
[IP_ADDRESS] Timelines
If an event of medication error, drug abuse or drug misuse occurs in the course of the study , 
then the Invest igator or other site personnel informs the appropriate [COMPANY_008] 
representatives within one calendar day  ie, immediately but no later than [ADDRESS_298058] igator to ensure that all 
relevant informat ion is completed wi thin 1 (Init ial Fatal /Life -Threatening or follow -up 
Fatal /Life -Threatening) or 5 (other s erious init ial and fo llow-up) cal endar days if there is an 
SAE associated with the medicat ion error (see Sectio n 8.4.1 ) and within 30 days for all other 
medicat ion errors.
[IP_ADDRESS] Medication error
For the purposes of this c linical study  a medicat ion error is an unintended failure or mistake 
in the treatment process for an IMP or [COMPANY_008] NIMP that either causes harm to the 
participant or has the potential to cause harm to the participant.
The definit ion of a Medicat ion Error can be found in Appendix B 8.
[IP_ADDRESS] Drug Abuse
Drug abuse is the persistent or sporadic intentional , non -therapeutic excessive use of IMP or 
[COMPANY_008] NIMP for a pe rceived reward or desired non -therapeuti c effect
The full definit ion and examples o f drug abuse can be found in Appendix B 8
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 113of 2178.4.4.4 Drug Misuse
Drug misuse is the intentional and inappropriate use (by a study participant) of IMP or 
[COMPANY_008] NIMP for medicinal purposes outside of the authorised product informat ion, or 
for unauthorised IMPs or [COMPANY_008] NIMPs, outside the intended use as specified in the 
protocol  and includes deliberate administration of the product by  [CONTACT_244972].
The full definit ion and examples o f drug misuse can be found in Appendix B [ADDRESS_298059] be trained to recognize and treat anaphylaxis 
(Lieberman et al  2010 ). Det ails on anaphylaxis management are provided in
 Appendix G .
Anaphylaxis will be defined as a serious reaction that is rapid in onset and may cause d eath 
(Sampson et al  2006 ). Anaphylaxis t ypi[INVESTIGATOR_244860] 1 of 3 clinical scenarios:
1.The acute onset of a reaction (minutes to hours) with invo lvement of the skin, 
mucosal t issue or both and at least one of the fo llowing: a) respi[INVESTIGATOR_33097]; 
or b) reduced blood pressure or symptoms of end -organ dysfunction. 
2.Two or more of the fo llowing that occur rapi[INVESTIGATOR_96685]: involvement of the 
skin/mucosal t issue, respi[INVESTIGATOR_33097], reduced blood pressure or associated 
symptoms and/or persistent gastrointest inal symptom s.
3.Reduced blood pressure after exposure.
Subjects will have had a pre -assessment (i.e., vital signs and lung funct ion) pri orto IP 
administration. At Visits [ADDRESS_298060] as soon as 
possible after the event, at 60 minutes ± 30 minutes after the event, and at discharge for 
analysis o f serum  tryptase. The sample will be tested at the local lab or central lab where 
applicable.
8.4.6 Independent Data Monitoring Committee
The Independent Data Monitoring Co mmittee (IDMC) is an independent expert advisory  
group commissio ned and charged with the r esponsibilit y of assessing all SAEs (including 
deaths and all hospi[INVESTIGATOR_24509]), non -serious AEs and cardiovascular events. The IDMC will 
Clinical Study Protocol -7.[ADDRESS_298061] no knowled ge of  the 
resul ts presented to the IDMC.
8.4.7 Independent Adjudication Committee
An IAC will assess blinded data to confirm the diagnosis and causalit y of MACE (defined in 
the IAC charter), serious cardiac events, and deaths, as well as diagnosis of malignancie s that 
occur from  rando misat ion until the end of the fo llow-up period.
The IAC will also assess whether cases of ER or urgent care visit s and hospi[INVESTIGATOR_24509], that 
occur from  rando misat ion until the end of the fo llow-up period, are due to a worsening o f 
COPD. 
Details on the adjudicat ion process, including scope of adjudicat ion and the committee 
membership, will be included in the Adjudicat ion Committee Charter/Manual of Operat ions.
8.5 Pharmacokinetics
8.5.1 Collection of Samples to Measure Drug Concentration
Serum samples for determinat ion of tezepelumab will be co llected according to the SoA 
(Table 2).
Samples will  be collected, l abelled, stored, and shipped as detailed in the Laboratory  Manual. 
Samples for determination of tezepelumab concentration in serum will be analyzed by a 
designated third party  on behalf o f [COMPANY_008] using a validated bioanaly tical method. 
Details o f the analy tical method used will be described in a bioanaly tical report.
Samples fro m patients who receive placebo will not be measured init ially but will be retained 
for subsequent analysis if deemed appropriate
Full details o f theanalyt ical method used will be described in a separate Bioanalyt ical 
Validat ion Report.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 115of 2178.5.2 Collection of Samples to Measure for the Presence of ADAs
The presence of ADA will be assessed in serum samples according to the SoA ( Table 2). 
Samples will  be measured for the presence of ADAs for tezepelumab using validated assays. 
Tiered analysis will be performed to include screening, confirmatory , and ti ter as say 
components, and posi tive-negative cut points statistically determined fro m drug-naïve samples 
will be emplo yed. Sam ples confi rmed posi tive for ADA will  be archived for possible testing 
for neutralizing ant ibodies (nAb).
8.5.3 Storage and Destruction of Phar macokinetic/Immunogenicity Samples
The PK and immunogenicit y samples will be retained for future use at [COMPANY_008] or 
designee for a maximum o f [ADDRESS_298062]’s Last Vi sit.
Pharmacokinet ic and immunogenicit y samples may  be disposed of or destroyed or 
anonymized by  [CONTACT_76435]. Addi tional analyses m ay be conducted on the anonymized, pooled 
pharmacokinet ic or immunogenicit y samples to further evaluate and validate the analy tical 
method. Any results fro m such analyses may be reported separately f rom the CSR.
8.6 Pharmacodynamics
Pharmacodynamic parameters will be evaluated using bio markers (see Sect ion
 8.8).
8.[ADDRESS_298063] 
not wish to provide a sample for this research, he/she will st ill be allowed to participate in the 
main study .
The blood sample for genet ic research should be obtained fro m the subjects at Visit 3, as 
outlined in the SoA. 
Clinical Study Protocol -7.[ADDRESS_298064]’s Last Visit, after which 
they will be destroy ed. DNA is a finite resource that may  be used up during analyses. The 
resul ts of any further analyses will be reported either in the CSR itself or as an addendum, or 
separately  in ascient ific report or publicat ion.
No personal details identifying the individual will be available to [COMPANY_008] or designated 
organi zations working wit h the DNA.
8.[ADDRESS_298065] ion
 8.8(for example blood, sputum, nasal, and urine 
samples) will be stored for a maximum of [ADDRESS_298066]’s Last 
Visit, after whi ch they will be destroy ed. The results of this bio marker research will not be 
reported in the CSR but in a n addendum, or separately in a scient ific report or publicat ion. 
The results of this bio marker research may be pooled with bio marker data from other studies 
with the study  drug to generate hy potheses to be tested in future research. Any  residual  
biological samples may be retained for up to [ADDRESS_298067] does not allow samples to be used for future bio marker research 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 117of 217(e.g., s cientific healt h-related research), they  may continue wi th their samples being used for 
the main study . The resul ts of any future analyses will not be reported in the CSR itself but as 
an addendum, or separately  in a scient ific report or publication
8.8.[ADDRESS_298068] ion, processing, storage and shipment will be provided in a 
separate laboratory  manual. The sponsor and site will be blinded to the values except 
screening visit s (Vi sit 1 and 2), any  repea t testing that is performed during the screen visits, 
and prior to IP administration.
8.8.3 Transcriptomics
Who le blood sam ples will be co llected in PAXgene®tubes for ribonucleic acid (RNA) sample 
preparati on in accordance wit h Table 2in the SoA. RNA may be used in the analyses of host 
gene expression and microbio me research using quant itative methods that may include but not 
be limited to RNA microarray s, RNA -Seq and quant itative reverse -transcri ptase polymerase 
chain react ion technol ogies and stored for future analyses. The results of this transcriptomic 
research will not be reported in the CSR but in an addendum, or separately in a scient ific 
report or publicat ion. Instructi on for sam ple collectio n, processing, storage and shipment w ill 
be provided in a separate laboratory  manual.
8.8.4 Nasal Epi[INVESTIGATOR_244861]/or sputum cell transcriptomic samples will be 
obtained, in accordance wit h the schedule provided in Table 2in the SoA, in a subset of 
subjects only part icipating in the sub -study . If sputum  and nasal co llections occur at the same 
visit, nasal sampling should occur befor e sputum  collect ion. If the subject is not able to 
produce sputum (spontaneous or induced) at Visit 3, then the subject should be wit hdrawn 
from the sub -study  only and nasal samples should be discarded. Please note that the subject 
can cont inue in the main study . 
Nasal epi[INVESTIGATOR_125515]/or sputum cell RNA may  be used in the analyses of host gene expressio n 
research using quant itative methods that may include but not be limited to RNA microarray s, 
RNA -Seq and quantitative reverse -transcriptase polymerase chai n react ion techno logies and 
stored for future analyses. 
The results of this transcriptomic research will not be reported in the CSR but in an 
addendum, or separately in a scient ific report or publicat ion. Detailed procedures for 
Clinical Study Protocol -7.[ADDRESS_298069] is not able to 
produce sputum (spontaneous or induced) at Visit 3, then the subject should be wit hdrawn 
from the sub -study  and nasal samples should be discarded. Please note that the subject can 
continue in the main study . For other sub -study  visits, sputum  sub-study  samples will be 
collected if s ub-study  laboratory  kits and supplies are available within visit window. In the 
event of missing supplies, sites should make reasonable effort to collect and process samples 
where feasible, and wit h the approval of Study  Physician. During the COVID -[ADDRESS_298070] ion and processing manual. 
Depending on individual site capabilit y, sputum  processing will fo llow one of two sputum  
processing protocols (full processing or partial processing). Sputum sample processing will 
resul t in the producti on of  cytospin slides (for full sputum processing only), microbio me 
sample, cell pellets for RNA transcriptome, and aliquots of sputum supernatant. The clinical 
sites performing full sputum processing procedures will also generate and record total cell 
count and cell viabilit ydata on thei r sputum  processing worksheets. The microbio me sample, 
cytospin slides, cell pellet for RNA transcriptome and the sputum supernatants will be 
analyzed by a different central laboratory . 
Addit ional local or nati onal regulati ons or gui dance m ust be fo llowed for sputum processing 
during COVID -[ADDRESS_298071] Patient’s 
Last Vi sit. The results of this bio marker research will not be reported in the CSR but in an 
addendum, or separately in a scient ific report or publicat ion.
8.8.6 Nasal Lining Fluid
The nasal lining fluid procedure is a quick and simple technique for sampling nasal secret ions. 
Nasal lining fluid samples will be obtained in accordance wit h the schedule provided in
 Table 
2in a subset of subjects only part icipating in the sub -study, and if nasal lining fluid sampling 
supplies are available. If sputum and nasal co llections occur at the same visit, nasal sampling 
shoul d occur before spontaneous/sputum induct ion. Nasal  lining fluid bio markers will be 
measured to evaluate the pharmaco logy of tezepelumab and to evaluate changes in bio markers 
related to COPD, inflammat ion and the TSLP pathway . Baseline and early  post -dose levels o f 
nasal lining fluid bio markers may  also be used to explore for potential predict ive biomarkers 
of response or exposure to tezepelumab. The specific bio markers that may be analyzed 
include but are not limit ed to cy tokines, chemokines and inflammatory  mediators associ ated 
with COPD and the TSLP pathway . Drug concentrations may  also be m easured in the nasal 
lining fluid samp les, if feasible. If appropriate, urea concentrations may be measured to 
correct for the dilut ion factor of the nasal lining fluid samples. The results of these exploratory  
analyses will not be reported in the CSR but in an addendum, or separately in a sci entific 
report or publicat ion. Detailed procedures for obtaining, processing, storing, transporting and 
analysing the samples will be described in applicable manual.  During the COVID -[ADDRESS_298072] Patient’s Last Visit. The results of this bio marker research will not 
be reported in the CSR but in an addendum, or separately in a scient ific report or publicat ion.
8.8.[ADDRESS_298073] 
Visit. 
8.9 Healthcare Resource Utilization and Health Economics
Healthcare resource utili zation and heal th economics data, associated with medical 
encounters, will be co llected in the CRF by [CONTACT_96773]
-site personnel  for all  
subjects throughout the study . At randomizat ion, Healthcare Resource Utilization (HRU) 
inform ation will be co llected with a ‘one year’ recall period. All the subsequent visits will 
collect HRU informat ion with a recall period of ‘since the last scheduled visit ’. The data may  
be used as input to health econo mic analysis for example cost utilit y analysis or co st 
effect iveness analysis. Protocol -mandated procedures, tests, and encounters are excluded. Any 
resul ts from such analyses may  be reported separately from the CSR.
9. STATISTICAL CONSIDER ATIONS
9.1 Statistical Hypothesis
The null hypothesis is that the exacerba tion rate on tezepelumab is greater than or equal to the 
exacerbation rate on placebo. The alternat ive hypothesis is that the exacerbat ion rate on 
tezepel umab i s less than the exacerbat ion rate on placebo, i.e., 
H0: Rate ratio (tezepelumab vs Placebo) ≥ 1
Ha: Rate ratio (tezepelumab vs Placebo) <1.
9.2 Sample Size Determination 
Original Sample Size
For the primary  endpoint of reducti on in COPD exacerbat ion rate, 141 subjects per treatment 
arm (282 total ) will be randomized to achieve 80% power of detecting a 30% reducti on in 
tezepel umab versus placebo over a fixed time period of 52 weeks. This calculat ion has 
assumed a one -sided 5% alpha level test, an annual placebo rate of 1.6 events/subject/52 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 121of 217weeks, a negat ive bino mial shape parameter of 0.6, and 10% unifo rm drop out. 
In the absence of the interim analysis for fut ility, this design would provide 81.2% power, and 
only 136 subjects per treatm ent arm  woul d be required for 80% power.  
This power statement accounts for the power loss associated with the futi lity interim analysis 
that was originally planned to occur when 182 subjects had been randomized.  In simulated 
resul ts, 1.2% of simulated trials were stopped early for fut ility but would have been successful 
at the final analysis of the primary endpo int had they  been all owed to continue.  Therefore, the 
overall power for this trial account ing for the interim analysis is 80%.  Note that as a result of 
the pause in recruit ment due to COVID -19, the fut ility analysis is now pl anned to occur when 
approximately  30% of  follow-up data are available but the expected power loss will be 
comparable under these condit ions.
The primary  endpoint will also be tested using a one -sided 2.5% al pha l evel test, but the 
sample size has not been determined based on providing powe r for this test.
Updated Sample Size
The sample size has been reassessed due to the potent ial for reduced exacerbation rates due to 
limited person -to-person contact [CONTACT_244973][INVESTIGATOR_244862] -[ADDRESS_298074] (0.7) and dispersio n parameter (0.6) as 
originally assumed, a sample size of 169 subjects per treatment arm (338 overall) will 
maintain the study  power if the placebo exacerbat ion rate is as low as 1.2 
exacerbations/subject -year.
9.2.1 Estim ands
ThePrimary estimand is described as fo llows:
Popul ation -subjects with moderate to very  severe COPD who are randomised and 
receive at least one dose of IP
Variable -annual rate of moderate or severe COPD exacerbat ions up to Week 52
Popul ation-level summary  measure –exacerbation rate ratio of tezepelumab versus 
placebo
Handling of intercurrent events:
oTreatment discont inuat ion: All available data are used regardless of whether 
treatm ent discont inuat ion occurs.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 122of 217oUse of an alternat ive biologic: All  avai lable data are used regardless o f whether 
subject swi tches to an al ternat ive bio logic therapy .
The Supplemental estimand is described as fo llows: 
Popul ation -subjects with moderate to very  severe COPD who are randomised and 
receive at least one dose of I P
Variable -annual rate of moderate or severe COPD exacerbat ions up to Week 52
Popul ation-level summary  measure –exacerbation rate ratio of tezepelumab versus 
placebo
Handling of intercurrent events:
oTreatment discont inuat ion: All available data are used up until randomised 
treatm ent is di scontinued.
oUse of an alternat ive biologic: All  available data are used up until subject 
switches to an al ternative bio logic therapy .
A different approach may be considered depending on the number and pattern of drop-outs.  
Further detail will be provided in the SAP.
Secondary  estimands and est imands to explore the impact of the COVID -19 pandemic may be 
detailed in the SAP.
9.3 Populations for Analyses
For purposes of analysis, the following populat ions are defined:
Population Analysis Set Description
All subjects 
analysis setThis analysis set comprises all enrolled subjects who signed the 
inform ed consent form , including screening failures, and will be 
used for the reporting of disposit ion.
Randomized 
subjects anal ysis 
setThis analysis set comprises all subjects rando mized to study 
treatm ent, i rrespect ive of whether IP was subsequent ly taken, and 
will also be used for the reporting of disposit ion.
Full analysis set 
(FAS)This analysis set comprises all subjects ra ndomized to study 
treatm ent who received at least one dose of IP, irrespect ive of their 
protocol  adherence and cont inued participat ion in the study .
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 123of 217Efficacy analyses will be performed using all subjects in the FAS. 
Subjects will be analyzed according to their randomized treatment 
(including in the case of any discrepancies between rando mized 
and actual treatment at one or more visits).
PK analysis set All subjects who received at least one dose of tezepelumab and 
have at least one detectable serum concen tration post fi rst dose that 
is not affected by  [CONTACT_244974] (e.g., 
disallowed m edicat ion or incorrect study  medicat ion received).
Safety analysis 
setThis analysis set comprises all subjects who received at least one 
dose of IP.
Safety analyses will be performed using all subjects in the safet y 
analysis set. Subjects will be analyzed according to their actual 
treatm ent in the case of any discrepancies between randomized and 
actual treatment. Specifically, a subject randomized to pl acebo 
who has on one or more occasion actually received active 
(tezepelumab) treatment will be assigned to the tezepelumab 
group. A subject who has on no occasion actually  received any 
active (tezepelumab) treatment will be assigned to the placebo 
group.
9.[ADDRESS_298075] measurement on or prior to the date of rando mizat ion will serve as the 
baseline measurement. If there is no value on or prior to the date of rando mizat ion, then the 
baseline value will not be imputed and will be set to missing. The baseline for outcome 
variables based on efficacy  biomarkers is defined as the value recorded at randomizat ion; if a 
measurement is not scheduled to be measured at ra ndomizat ion visit or if the randomizat ion 
visit measurement is missing, the last non -missing value before rando mizat ion will be used as 
baseline instead.
For spi[INVESTIGATOR_96656], laboratory  data and physical examinat ion, baseline will be defined as the latest 
non-m issing assessment prior to first dose.
Absolute change from baseline is co mputed as 
(post -randomization value –baseline value) .
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 124of 217Percent change fro m baseline is computed as 
100 x ((post -randomization value –baseline value) / baseline value) %.
If eit her the post -randomization value or the baseline value is missing, then the abso lute or 
percent change fro m baseline value will also be set to missing.
9.4.2 Calculation or Derivation of Efficacy Variables
[IP_ADDRESS] Exacerbation Rate
The annual COPD exacerbat ion rate will be used as the primary efficacy variable.
A COPD exacerbat ion is defined in Sect ion 8.1.[ADDRESS_298076] d uring the 
treatm ent peri od, the fo llowing rul e will be applied:
The start of an exacerbation is defined as the start date of systemic corticosteroids or 
antibiotic treatment or hospi[INVESTIGATOR_063], w hichever occurs earlier, and the end date is 
defined as th e last day of systemic corticosteroids or antibiotic treatment or hospi[INVESTIGATOR_7954], w hichever occurs later. 
Addit ional systemic corti costeroi d treatm ents, emergency room visits requiring use of 
systemic corticosteroids, or inpat ient hospi [INVESTIGATOR_244863] a new exacerbat ion. In order to be counted as a new 
exacerbation it must be preceded by [CONTACT_2669] [ADDRESS_298077] is approximately 52 weeks; defined as the 
time fro m rando mizat ion to the date of Visit 16, regardless of whether subjects remain on 
rando mized treatment. For a subject lost to fo llow-up or prematurely wit hdrawing fro m the 
study  prior to Vi sit 16, th is will be defined as the time fro m rando mizat ion to the time po int 
after whi ch an exacerbat ion could not be assessed. 
The number of days that the subject experiences an exacerbat ion during the follow -up time, 
including the subsequent 7 days (when a furth er exacerbat ion woul d not be considered a 
separate event (and if wit hin the fo llow-up time) will be subtracted from the fo llow
-up time to 
give the time at risk of exacerbat ion.
In the statist ical analysis, the number of COPD exacerbat ions experienced by a subject during 
their follow-up time will be used as response variable, and the logarithm o f the subject’s 
corresponding time at risk will be used as an offset in the analysis to adjust for subjects having 
different observat ion times during which the events occur.
Clinical Study Protocol -7.[ADDRESS_298078] is 
calculated, and standardized per 52 -week period according to the formula described below.
Annual exacerbation rate=Number of exacerbations*365.25 / (Time at Risk of Exacerbation).
For subjects who prematurely  discontinue treatm ent, efforts will be made to continue 
collect ing the exacerbat ion data until the scheduled Visit 16/EOT at Week [ADDRESS_298079] ical analysis o f exacerbat ion rate for th e primary  estimand, the 
data collected up to Visit 16/EOT will be included for the patients who prematurely 
discontinue treatm ent according to the intent -to-treat principle. For the patients who died 
during the treatment period the exacerbat ion data collec ted up to the date of death will be 
included in the statist ical analysis.
If the cause o f any death is related to COPD or a COPD exacerbat ion, the event will also be 
included in the rate calculat ion as a severe exacerbation.
To examine the sensit ivity of resul ts of the primary  analysis to the underlying assumpt ions, 
sensit ivity analyses may  be perf ormed using different assumptions for missing data following 
study  withdrawal .  Further details will be given in the SAP.
The annual rate of moderate or severe COPD exacerbat ions, excluding those moderate 
exacerbations treated only  with antibiotics, will be used as a supportive endpo int for the 
primary  endpoint.  Thi s supporti ve endpo int includes all severe COPD exacerbat ions and 
moderate COPD exacerbat ions treate d by [CONTACT_244975].  
[IP_ADDRESS] Proportion of Subjects with ≥ 1 COPD Exacerbation
The proporti on of  subjects with ≥ 1 COPD exacerbati on will be a secondary  efficacy variable.  
[IP_ADDRESS] Time to First Exacerbation
Time fro m randomization to the first COPD ex acerbat ion will be a secondary  efficacy 
variable, and is calculated as fo llows:
Start Date of first COPD exacerbation –Date of randomization + 1.
The time to first COPD exacerbat ion for subjects who do not experience a COPD 
exacerbation will be censored at the time point after which an exacerbat ion could not be 
assessed.  For subjects lost to fo llow-up or prem aturely  withdrawing from  the study , the time 
to first COPD exacerbat ion will be censored at the end of the maximum fo llow-up time, as 
described in Section [IP_ADDRESS] .
Clinical Study Protocol -7.[ADDRESS_298080]’s corresponding fo llow-up time will be used as an 
offset in the analysis to adjust for subjects having different observat ion times during which the 
events occur.
Follow-up time is deriv ed as described in Sect ion [IP_ADDRESS] .
Time to first severe COPD exacerbat ion and proporti on of  subjects wi th at least one severe 
COPD exacerbat ion wil l be used as supportive variables to this secondary efficacy variable. 
[IP_ADDRESS] Forced Expi[INVESTIGATOR_1814] [ADDRESS_298081] -randomizat ion visit s up to and including 
the Week 52 visit (Visit 16) will be assessed with ch ange f rom baseline at week [ADDRESS_298082] dose of IP  will be used as baseline FEV 1. 
9.4.3 Calculation or Derivation of Safety Variables
[IP_ADDRESS] Safety Variables
The fo llowing safety  data will  be collected: vital signs, physical examinat ion, 12- lead ECG, 
hematol ogy, clinical chemistry , urinalysis, and reported AEs.
Change from baseline (last measurement prior to first IP administration) to each post -
treatm ent time point wher e scheduled assessments were made will be calculated for relevant 
measurements.  AEs will be summarized by [CONTACT_244976]. 
[IP_ADDRESS] Adverse Events
Adverse events experienced by [CONTACT_244977] (MedDRA).
Adverse event data will be categorized according to their onset date into the fo llowing study  
periods:
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 127of 217 AEs occurring during screening (onset date ≥ Visit [ADDRESS_298083] dose 
of study  treatm ent)
 AEs occurring during treatment (onset date ≥ the first day  of study  treatm ent 
and ≤ the l ast day  of study  treatm ent + 4 weeks)
 AEs occurring during fo llow-up
(onset date > the last day of study treatment + 4 weeks and ≤ the last day  
of study  treatm ent + 16 weeks)
The timing of AEs will be assigned to the period in which they  first occurred. If an AE has a 
missing onset date, then unless the stop date of the AE in dicates otherwi se, this will be 
considered an on -treatm ent event. Similarly , if an AE has a parti al onset date, then unless the 
partial onset date or the stop date indicates otherwise, this will be considered an on -treatment 
AE.
[IP_ADDRESS] Other Significant Adverse E vents
During the evaluat ion of the AE data, an [COMPANY_008] medically qualified expert will review 
the list of AEs that were not reported as SAEs or discontinuat ions due to AEs.
Based on the expert’s judgment, significant AEs of particular clinical importan ce may , after 
consultation wit h the Gl obal Patient Safety  Physician, be considered other significant AEs 
(OAEs) and reported as such in the CSR.
Examples of these are marked hematological and other laboratory  abnorm alities, and certain 
events that led to i ntervent ion (other than those already  classified as serious), dose reduction, 
or significant addit ional treatment.
[IP_ADDRESS] Laboratory Variables
Blood and urine samples for determinat ion of clinical chemistry , hematol ogy and urinalysis 
param eters will  be taken at t he times detailed in the CSP and will be assessed in a central 
laboratory . The parameters outlined in Table 7in Section 8.2.1 , will be co llected. Laboratory 
data will be reported in SI units.
Changes in haematology  and clinical  chemistry  variables between baseline and each 
subsequent on treatment assessment will be calculated as described in Section 8.2.1 .
 There 
will be no imputation for missing values.
Absolute values will be compared to the relevant reference range and classified as low (below 
range), normal (within range or on limit s) or hi gh (above range). The [COMPANY_008] extended 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 128of 217reference ranges will be used for laboratory  variables (where they  exist). All  values (absol ute 
and change) falling outside the reference ranges will be flagged.
Urinalysis data will be categorized as negat ive (0), posit ive (+), or strongly posit ive (++, +++,
or >+++) at each time -point.
For the purposes of hematology , clinical chemistry and urinalysis shift tables, baseline will be 
defined as the latest non -missing assessment prior to first dose, and on -treatm ent will be 
defined as the latest non -missing asse ssment whilst the subject is ongo ing on treatment.
For the liver funct ion tests: AST, ALT, ALP, GGT and total bilirubin, the mult iple of the 
[COMPANY_008] ULN (not extended) range will be calculated for each data point.
Multiple = Value / ULN
i.e., if the AL T val ue was 72 IU/L (ULN 36) then the mult iple woul d be 2.
Subjects who meet any  of the f ollowing cri teria at any point duri ng the study  will be flagged:
 AST ≥ 3x ULN
 ALT ≥ 3x ULN
 TBL ≥ 2xULN
[IP_ADDRESS] ECGs
12 lead digital ECG measurements will be recorded in accordance wi th the protocol , with the 
baseline visit being defined as any time between Visit 1 and Visit 2 inclusive.
The outcome o f the overall evaluat ion is to be recorded as normal/abnormal in the eCRF, with 
any abnormalit ies being recorded as not clinically significant or clinically significant.
[IP_ADDRESS] Physical Examination
Com plete and bri ef physical examinat ions will be performed at time po ints specified in Table 
2.
What is included in the assessment will be dependent on whether the examinat ion is co mplete 
or bri ef, as described in Sect ion
 8.2.4 . For the brief phys ical examinat ion, only  information on 
whether the assessment was performed or not will be recorded.
Each component of the complete physical examination at baseline visit will be recorded as 
norm al or abnorm al. Each com ponent of the physical examinat ions at follow-up will be 
recorded as normal, same as baseline, or new/aggravated.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 129of 217Any new finding(s), or aggravated exist ing finding(s), judged as clinically significant by [CONTACT_24338], will be reported as an AE.
[IP_ADDRESS] Vital signs
Vital signs (pulse, systolic blo od pressure, di astolic blood pressure, respi[INVESTIGATOR_244864]) will be obtained in accordance with the schedule provided in Table 1andTable 
2.
Changes in vital sign variables between baseline and each subsequent scheduled assessment 
will be calculated as described in Sect ion
 9.4.1 . There will be no imputation for missing 
values.
Absolute values will be compared to the relevant reference range and classified as low (below 
range), normal (within ran ge or on limit s) or hi gh (above range). All values (abso lute and 
change) falling outside the reference ranges will be flagged.
Body  mass index (BMI) will be calculated from the height (in meters) and weight (in 
kilograms) as BMI = kg/m2.
9.4.4 Calculation or Derivation of PRO variables
[IP_ADDRESS] SGRQ
Potenti al health status treatm ent benefit s of tezepelumab will be evaluated by  [CONTACT_244978] 52 in SGRQ total scores.  For the responder analysis of 
SGRQ a responder will be defined as an in dividual wi th a ≥ 4-point decrease (improvement) 
in SGRQ total score at Week 52.
9.4.[ADDRESS_298084] saf ety follow-up visit (Week 64).  Main an alyses of the primary , key 
secondary  efficacy object ives and so me supportive summaries will be performed based on 
both the primary and final DBL data. The results produced at the time of primary DBL will be 
used to facilitate further design development for Phase [ADDRESS_298085] of the study  will remain blinded unt il 
primary  database l ock and important protocol deviations ident ified.  
After primary  database l ock, treatm ent all ocati on for sub jects during this study  will beco me 
known to the Sponsor staff and/or designated CRO. The blind will be maintained for the 
Invest igator, invest igational site staff, and for the subject.
Analyses will be performed by [CONTACT_244979]. A c omprehensive stati stical 
analysis plan will be developed and finalized before primary  database l ock and will describe 
the subject populat ions to be included in the analyses, and procedures for accounting for 
missing, unused, and spurious data.
Addit ional analyses assessing the impact of COVID -19 may be incl uded in the SAP.
9.5.1 Multiple Testing Procedure
In thi s Phase 2a study , in order to describe the nature of the benefits wit h tezepelumab and to 
define study  success, the primary  endpoint will be tested using a one -sided 5% si gnificance 
level.  In addit ion, and although not powered, the primary  endpoint will also be tested using a 
one-sided 2.5% al pha in order to strongly  control  type I error.  No addit ional adjust ment for 
multiplicit y will  be implemented.  
9.5.2 Efficacy Analyses
[IP_ADDRESS] Primary Analysis Methods
The primary  efficacy  variable is the annual COPD exacerbation rate and the primary  analysis 
is to compare the annual COPD exacerbation rate of tezepelumab with placebo. Patients will 
be analyzed using the full analy sis set according to randomized treatment.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 131of 217The null hypothesis is that the exacerbat ion rate on tezepelumab is greater than or equal to the 
exacerbation rate on placebo. The alternat ive hypothesis is that the exacerbat ion rate on 
tezepel umab i s less than t he exacerbat ion rate on placebo, i.e.,
H0: Rate ratio (tezepelumab vs Placebo) ≥ 1
Ha: Rate ratio (tezepelumab vs Placebo) < 1
Annual exacerbat ion rate in the tezepelumab group will be co mpared to annual exacerbat ion 
rate in the placebo group using a negat ive binomial model for the primary  analysis. The 
response variable in the model will be the number of COPD exacerbations experienced by a 
patient during the follow -up for exacerbat ions. The model will include covariates of treatment 
group and the stra tificat ion factors (region, and the number of exacerbat ions in the y ear pri or 
to study  entry ). The l ogari thm of the patient’s corresponding time at risk of exacerbat ion will 
be used as an offset variable in the model to adjust for patients having different observat ion 
times during which the events occur.
The COPD exacerbation rate and the corresponding 90% confidence interval (CI) within each 
treatm ent group will be presented. The est imated treatment difference fro m placebo (i .e., the 
absolute difference be tween tezepel umab and pl acebo, and the rate ratio of tezepelumab 
versus placebo), corresponding 90% CI, and 1- sided p -value for the rate ratio will be 
presented. The 95% CI, and 2 -sided p -value for the rate ratio will also be presented. Marginal 
standardiz ation methods will  be used on the m odel estimates for all negative bino mial 
analyses, unless otherwise specified. 
[IP_ADDRESS] Secondary Analysis Methods
Secondary  efficacy endpo ints in this study  are:
Time to first COPD exacerbat ion
Proporti on of  subjects wi th at least 1 COPD exacerbat ion
Rate of severe exacerbat ions
Time to first severe exacerbat ion
Proporti on of  subjects wi th at least one severe COPD exacerbat ion 
Change from baseline in pre -BD FEV 1at week 52
Proporti on of  subjects achieving an MCID of 4 units or more in SGRQ total score over 
52 weeks
Change from baseline in SGRQ at Week 52
Change from baseline in CAT at Week [ADDRESS_298086] COPD exacerbat ion.  
Change f rom baseline in pre -dose/pre -BD FEV 1at Week 52 will be co mpared between 
tezepel umab and placebo using a repeated measures analysis on subjects with a baseline pre -
dose/pre -BD FEV 1and at least one post -randomization pre -dose/pre -BD FEV 1in the FAS. 
The de pendent vari able will be the change from baseline in pre -bronchodilator FEV 1at post -
baseline protocol -specified visits (up to the EOT visit). Treatment group will be fitted as the 
explanatory  variable, and regi on, visit, baseline pre -bronchodilator FEV 1and the interaction 
between visit and treatment will be fitted as covariates. Visit will be fitted as a categorical 
variable, and the variance -covari ance m atrix will be assumed to be unstructured. If the 
procedure does not converge then a compound symmetric variance covariance matrix will be 
used instead. The model is:
Change in FEV 1=Treatment group+ baseline FEV 1+ region + prior exacerbation strata + 
visit + treatment*visit
Changes fro m baseline in SGRQ total score and CAT total score at Week 52 will be ana lyzed 
using a similar model for change from baseline in pre -dose/pre -BD FEV 1; the appropriate 
baseline value will be used in each model.  
Proporti on of  subjects achieving an MCID of [ADDRESS_298087] ion between treatment group and covariates will be described in the SAP. 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 133of 2179.5.4 Safety Analyses
AEs will be summarized by [CONTACT_244980] (treatm ent peri od and foll ow-up period). AEs will be listed for each subject and 
summarized by  [CONTACT_79075] (SOC) and Preferred Term (PT) assigned to the event by  
[CONTACT_61132]. Laboratory  safet y variables will be summarized using standard summary statist ics 
and plots as appropriate. Other safet y variables will be summarized as appropriate. Further 
details will be provided in the SAP.
Laboratory  data for hem atology and clinical  chemistry  will be summarized. The fr equency  of 
changes with respect to normal ranges between baseline and each post -treatm ent tim e point 
will be tabulated. Frequencies of clinically noteworthy  values (defined in the SAP) occurring 
during the clinical study  will also be given. Shift s from  normal to abnorm al between baseline 
and each post -baseline t ime point will be evaluated for urinalysis. Changes in vital signs and 
ECGs will be examined at each visit and at endpoint. Frequencies o f clinically noteworthy  
values (defined in the SAP) occurring during the clinical study  will be presented. Shifts from 
norm al to abnorm al between baseline and fo llow-up will be evaluated for the physical 
examinat ion.
9.5.[ADDRESS_298088] ics by [CONTACT_765]. 
Observed serum concentrations of tezepelumab for each individual will be listed by [CONTACT_765]. The 
PK data collected in this study  may be combined wi th data from  other studi es for popul ation 
PK analysis. The results of such an analysis, if performed, will be reported separately.
The prevalence and incidence o f anti-drug ant ibodies (ADA) will be reported by [CONTACT_6490]. ADA data will be summarized using descriptive statist ics at each visit by [CONTACT_6490]. Sam ples confirm ed posi tive for ADA will be archived for possible testing for 
neutralizing ant ibodies (nAb). The potential effects of ADA status and ADA t iter on 
pharmacokinet ics of tezepelumab will be evaluated. The potential associat ion of 
immunogenicit y with efficacy a nd safet y may be evaluated if appropriate.
9.5.[ADDRESS_298089] ics. Details o f the analyses will be 
described in the exploratory  analyses plan, which will be finalized before the database lock. 
The resu lts will be reported outside the CSR.
9.6 Interim Analyses 
A data cut off for an interim analysis to potentially stop the study  due to futilit y of efficacy 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 134of 217was ori ginally  planned to occur when 182 subjects had been randomized. As a result of the 
pause in re cruitment due to COVID -19, the fut ility analysis is now planned to occur when 
approximately  30% of  informat ion has been achieved.  An Independent Data Monitoring 
Committee (IDMC) will be used.  Futilit y will  be decl ared if the l ower bound of an 80% 
Confide nce Interval for the exacerbat ion rate ratio of tezepelumab vs. placebo is greater than 
0.80. The fut ility boundary and method of assessing fut ility were chosen based on the 
operating characterist ics of ~33% chance of stoppi[INVESTIGATOR_244865] 
~4% chance of stoppi[INVESTIGATOR_244866] o of 0.70.  Full details 
about the fut ility analysis decisio n rules and procedures will be specified in an IDMC charter, 
which will also specify the roles and responsibilit y of t he IDMC members.  Conducting the 
futilit y analysis result s in power loss, but no alpha adjustment is required as there is no 
decisio n rule in place for stoppi[INVESTIGATOR_244867].  
A data cut off for an interim analysis to inform sponsor Phase [ADDRESS_298090] Randomized. The study  will cont inue, even if 
sufficient efficacy is observed to inform an early go for planning purposes. The Ind ependent 
Data Monitoring Committee (IDMC) will be used and a blinding plan will be written to ensure 
that the study  team , investi gational si te staff and pati ents rem ain blinded to subject level 
treatm ent revealing data if an early planning decision is made . As the study will  continue 
regardl ess, no adj ustment to the ty pe I error is required. 
9.6.1 Independent Data Monitoring Committee (IDMC)
An IDMC will be utilized for this study . Details regarding IDMC are provided in Section 
8.4.6 .
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 135of [ZIP_CODE]. REFERENCES
Aithal et al 2011
Clinical Pharmaco logy and Therapeut ics 89(6):[ADDRESS_298091] K. Validat ion of a New Portable Exhaled 
Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma. Pulm Ther. 2017 
Jun;3(1):207- 218. 
Anzalone et al [ADDRESS_298092] 5;50(10):131.
Calvern et al 2012
Calvén J, Yudina Y, Hallgre n O, Westergren -Thorsson G, Davies DE, Brandelius A, Uller L. 
Viral stimuli tri gger exaggerated thymic stromal lymphopoiet in expressio n by [CONTACT_244981] [INVESTIGATOR_2130] : role of endosom al TLR3 and cy tosolic RIG -I-like 
helicases. J Innate Immun. 2012;4(1):[ADDRESS_298093] phenoty pic and activat ion profile in human ty pe 2 innate 
lympho id cells. Blood Adv. 2017 Mar 3 0;1(10):577 -589.
CDC 2010
CDC gui delines 2010, Updated Recommendat ions for Prevent ion of Invasive Pneumococcal 
Disease Am ong Adul ts Using the 23 -Valent Pneumococcal Po lysaccharide Vaccine 
(PPSV23). Centers for Disease Control and Prevention (CDC). Morbidit y and Mortalit y 
Weekly Report .2010 / 59(34);1102 -1106. Available fro m: URL: 
https://www.cdc.gov/vaccines/hcp/acip -recs/vacc -specific/pneumo.ht ml
CDC 2021 -2022
CDC gui delines 2021 -2022, Summary : Prevent ion and Control of Seasonal Influenza with 
Vaccines: Reco mmendat ions of the Advisory  Commi ttee on Immunizati on Practices (ACIP), 
[LOCATION_002], 2021 -2022. Centers for Disease Control and Prevent ion (CDC). Available 
from: URL: https://www.cdc.gov/flu/professio nals/aci p/summary/summary -
recommendat ions.htm
Corren et al 2017
Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffit hs JM, et al. Tezepelumab in adult s 
with uncontrolled asthma. N Engl  J Med. 2017; 377:[ADDRESS_298094] ion decline in chronic obstructive pulmo nary disease. 
Thorax. 2002; 57(10):847- 52.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D524 1C00001
CONFIDENTIAL AND PROPRIETARY Page 136of 217FDA Guidance for Industry (issued July 2009)
FDA Guidance for Industry  (issued July  2009) ‘Drug -induced liver injury: Premarket ing 
clinical evaluat ion’.
GINA 2018
Global Init iative for Asthma (GINA). Global s trategy  for asthm a management and prevent ion 
2018. Available fro m: www.ginasthma.org . 
GOLD 2019
2019 Global Strategy  for Prevent ion, Di agnosi s and Management of COPD, Global Init iative
for Chronic Obstructi ve Lung Disease (GOLD) 2019. Available fro m: 
http://www.goldcopd.org.
Johansson et al 2004
Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey  RF, Motal a C, Ortega 
Martell JA, Platts -Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC. A revised 
nomenclature for allergy for global use: report of the no menclature review co mmittee of world 
allergy  organizat ion. J Allergy  Clin Immunol . 2004; 113:832 –6.
Jones et al [ADDRESS_298095] 2011;139(6):1388 –1394.
Jones et al [ADDRESS_298096] George’s Respi[INVESTIGATOR_96692]. Respir 
Med. 1 991;[ADDRESS_298097] B:[ADDRESS_298098]. Eur Respir J 2009, 34: 648–654.
Kato et al [ADDRESS_298099]  epi[INVESTIGATOR_1663]. J Immunol. 
2007 Jul  15;179(2):1080 -7.
Kemp et al 2008
Kemp SF, Lockey  RF, Sim ons FE; Worl d Allergy  Organizat ion Ad hoc Committee on 
Epi[INVESTIGATOR_96707]. Epi[INVESTIGATOR_238]: the drug of cho ice for anaphylaxis. A statement of 
the World Allergy  Organizat ion. Allergy . 2008; 63(8):[ADDRESS_298100] epit helial cells is controlled by  [CONTACT_244982]. Proc Natl  Acad Sci  U S 
A. 2007 Jan 16;104(3):914 -9.
Leidy et al 2011 
Leidy  NK, Wilcox TK, Jones PW, et al. Standardizing measurement of chronic obstructive 
pulmo nary disease exacerbati ons. Reliabilit y and validi ty of a pati ent-reported diary . Am  J 
Respir Crit Care Med 2011;183(3):323 –329.
Clinical Study Protocol -7.[ADDRESS_298101] ice parameter: 2010 
update. J Allergy Clin Immuno l. 2010 Sep;126(3):477- 80. e1 -42.
Miller et al 2005
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, 
van der Grinten CP, Gustafsson P, Jensen R, Johnso n DC, MacIntyre N, McKay R, Navajas 
D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisat ion of 
spi[INVESTIGATOR_038]. Eur Respi r J. 2005 Aug;26(2):[ADDRESS_298102] jens HAM, Korn S, Lugogo N, et al. Mepolizumab for 
eosinophilic chronic obstructive pulmo nary disease. N Engl  J Med. 2017; 377:[ADDRESS_298103];44(4):1075 -8.
Quanjer et al 2012
Quanjer PH, Stanojevic S, Cole TJ, Baur X, L Hall GL, Culver B, et al. Mult i ethnic reference
values for spi[INVESTIGATOR_96694] 3 -95 year age ra nge: the glo bal lung funct ion 2012 equations.
2012 Dec;40(6):1324-43.
Rodriquez -Roisin R [ADDRESS_298104]. 2000; 
117:398S -401S.
Sampson et al 2006 
Sampson H, Muñoz -Furlong A, Campbell R, Adkinson F, Bock A, Branum A, Brown S, 
Camargo C, Cy dulka R, Galli S, Gi dudu J, Gruchalla R, Harlor A, Hepner D, Lewis L, 
Lieberman P, Metcalfe D, O’Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons 
E, Thom as S, Wood J, Decker W. Second symposium on the definit ion and m anagement of 
anaphylaxis: Summary  report —Second National Inst itute of Allergy  and Infect ious 
Disease/Food Allergy  and Anaphylaxis Network symposium. The Journal of Allergy  and 
Clinical Immuno logy 117.2 (2006): 391 -397.
Sexton et al 2010 
Sexton C, Notte S, Murray  L, Leidy  NK. PRO evidence dossier to support the use of the E -
RS™: COPD to evaluate respi[INVESTIGATOR_29197] s in pati ents wi th COPD. United BioSource 
Corporati on; Bethesda, MD: May  2010. 
Sexton et al 2011 
Sexton C, Leidy NK, No
tte SM, et al. Quant ifying the severit y of respi [INVESTIGATOR_29197] s of 
COPD: reliabilit y and validit y of a patient diary . Pos ter presented at the American Thoracic 
Society Internat ional Meet ing; May 2011: Denver, CO.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 138of 217Singh et al 2014
Singh D, Kolsum U, Bright ling CE, Locantore N, Agusti A, Tal -Singer R. Eosinophilic 
inflammat ion in COPD: prevalence and clinical characterist ics. Eur Resp J. 2014; 44:1697-
1700.
Tanaka et al 2009
Tanaka J, Watanabe N, Kido M, Saga K, Akamatsu T, Nishio A, et al. Hum an TSLP and 
TLR3 ligands promote different iation of Th17 cells with a central memory  phenoty pe under 
Th2-polarizing condi tions. Clin Exp Allergy . 2009; 39(1):89 -100.
Watson and Gauvreau 2014
Watson BM, Gauvreau GM. Thymic stromal ery thropoi etin: a central  regul ator of allergic 
asthma. Expert Opin Ther Targets. 2014; 18:771 -785.
Wedzicha et al 2013 
Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, et al. 
Analysis of chronic obstructive pulmo nary disease exacerbat ions wit h the dual bronchodilato r 
QVA149 co mpared with glycopy rroni um and tiotropi [INVESTIGATOR_1890] (SPARK): a randomized, double -
blind, parallel -group study . The Lancet. 2013;1(3):199 -209.
Ying et al 2008
Ying S, O’Connor B, Ratoff J, Meng Q, Fang C, Cousins D, Zhang G, Gu S, Gao Z, Shamji 
B, Edwards MJ, Lee TH, Corrigan CJ. Expressio n and cellular provenance o f thymic stromal 
lymphopoi etin and chemokines in patients with severe asthma and chronic obstructive 
pulmo nary disease. J Immunol . 2008; 181:2790 -8.
Ziegler et al 2013
Ziegler SF, Roan F, Bell BD , Stokl asek TA, Kitajima M, Han H. The bio logy of thymic 
strom al lymphopoi etin (TSLP). Adv Pharmaco l. 2013; 66:129- 55. 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 139of [ZIP_CODE]. SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS
Appendix A Regulatory, Ethical and Study Oversight Considerations
A 1 Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ionsof Medical  
Sciences (CIOMS) International Ethical Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents 
(e.g., advertis ements) m ust be submitted to an IRB/IEC by  [CONTACT_73004]/IEC before the study  is init iated.  
Any amendments to the protocol will require IRB/IEC and applicable Regulatory  Authori ty 
approval  before implementati on of  changes made to the study  design, except for changes 
necessary  to eliminate an immediate hazard to study  subjects.  
[COMPANY_008] will be responsible for obtaining the required authorisations to conduct the study  
from the concerned Regulatory  Authori ty. Thi s responsibilit y may be delegated to a CRO but 
the accountabilit y remains wi th [COMPANY_008].
The invest igator will be responsible for providing oversight of the conduct of the study at the 
site and adherence to requirements of 21 CFR, ICH guidelines, the IR B/IEC, European 
Regulation 536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regul ations.
Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by [CONTACT_32847] a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of parti cipants and the safet y of 
a study  intervent ion under clinical invest igation are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The sponsor will co mply with country -specific regulatory  requi rements 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 140of 217relating to safe ty reporting to the regulatory  authorit y, Institutional Review Boards 
(IRB)/Independent Ethics Co mmittees (IEC), and investigators.
For all studies except those utilizing medical devices investigator safet y reports m ust be 
prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local 
regul atory  requi rements and sponsor policy and forwarded to invest igators as necessary.
-European Medical Device Regulat ion 2017/745 for clinical device research (if 
applicable), and all other applicable local regulat ions.
An invest igator who receives an invest igator safety report describing a SAE or other 
specific safet y informat ion (e.g., summary or list ing of SAEs) fro m the sponsor will 
review and then file it along wit h the [Investigator’s B rochure or state other documents] 
and will notify the IRB/IEC, if appropriate according to local requirements.
Regulatory Reporting Requirements for Serious Breaches
Prom pt notificat ion by [CONTACT_244983] (potential) serious breach of 
the protocol or regulations is essential so that legal and ethical obligat ions are met.
A ‘serious breach’ means a breach likely to affect to a significant degree the safet y 
and ri ghts of  a parti cipant or the reliabilit y and robustness o f the data generated in the 
clinical study .
If any (potential) serious breach occurs in the course of the study , investi gators or other 
site personnel will inform the appropriate [COMPANY_008] representatives immediately after 
he or she beco mes aware of it.
In certain regions/countri es, [COMPANY_008] has a legal responsibilit y to notify both the local 
regul atory  authori ty and other regul atory  agencies about such breaches.
[COMPANY_008] will comply wit h country -specific regulatory  requi rements rel ating to 
serious breach repo rting to the regulatory  authori ty, IRB/IEC, and invest igators. If 
EU Clinical Trials Regulation 536/2014 applies, [COMPANY_008] is required to enter 
details o f serious breaches into the European Medicines Agency  (EMA) Clinical 
Trial Informati on System  (CTIS) . It is important to note that redacted versions of 
serious breach reports will be available to the public via CTIS.
The invest igator should have a process in place to ensure that:
oThe site staff or service providers delegated by [CONTACT_093]/inst itution are 
able to ident ify the occurrence of a (potential) serious breach
 A (potential) serious breach is pro mptly reported to [COMPANY_008] or delegated party, 
through the contacts (email address or telephone number) provided by [CONTACT_38227].
Clinical Study Protocol -7.[ADDRESS_298105] igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulat ory authori ties. Investi gators 
are responsible for providing information on financial interests during the course of the study 
and for 1 y ear after com pletion of  the study .
A 3 Informed Consent Process
The Investigator or his/her representative will explain th e nature of the study  to the subject or 
his/her legally  authori zed representative and answer all quest ions regarding the study .  
Subjects m ust be informed that their participation is voluntary . Subj ects or thei r legally  
authori zed representative will be r equired to si gn a statem ent of  inform ed consent that meets 
the requirements of [ADDRESS_298106] (HIPAA) requi rements, where applicable, and the IRB/IEC or site.  
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained 
before the subject was enro lled in the study  and the date the written consent was ob tained.  
The authorized person obtaining the informed consent must also sign the ICF.
Subjects m ust be re -consented to the most current versio n of the ICF(s) during their 
participat ion in the study.  
A copy  of the ICF(s) m ust be provi ded to the subject or the subject’s legally  authori zed 
representative.  
If subject declines to participate in any  voluntary  exploratory  genet ic research co mponent of 
the study , there will be no penalt y or loss of benefit to the subject and he/she will not be 
excluded fro m other aspects of the study .
If a subject’s partner beco mes pregnant during the study  from the date o f the first 
administration of IP until 16 weeks (5 half -lives) after the last administration of IP, the partner 
is asked to sign the Adult Study
 Informed Consent Form for Pregnant Partners of Study  
Subjects and provide informat ion about the pregnancy accor dingly .
Subjects who are re -screened are required to sign a new ICF. 
During the COVID- [ADDRESS_298107]'s verbal consent via phone or 
teleconference is obtained before conducting any patient related changes implemented during 
Clinical Study Protocol -7.[ADDRESS_298108]’s re -consent needs to be docume nted in the 
source documents.
The ICF will contain a separate section that addresses the use of remaining mandatory 
samples for optional exploratory  research. The Investigator or authorized designee will 
explain to each subject the object ives o f the exploratory  research. Subjects will be told that 
they are f ree to refuse to participate and may  withdraw thei r consent at any  time and for any  
reason duri ng the storage period. The subject will give a separate agreement to allow any 
remaining specimens to be used for exploratory research. Subjects who decline to participate 
in this optional research will indicate this in the ICF. If a subject withdraws consent to the use 
of donated bi ological samples, the sam ples will be di sposed of/destroy ed, and the acti on 
docum ented.  If samples already have been analyzed at the time of the request, [COMPANY_008] 
will not be obliged to destroy  the resul ts of this research.
A [ADDRESS_298109] records or data 
sets transferred to the sponsor will contain only the identifier; subject names or any  
inform ation which would make the subject identifiable will not be transferred.  
The subject must be informed that his/her personal study -related data will be u sed by  [CONTACT_32855] h local data protecti on law.  The l evel of discl osure must al so be 
explained to the subject.  
The subject must be informed that his/her medical records may be examined by [CONTACT_32856] y Assurance auditors or other aut horized personnel appo inted by  [CONTACT_456], by  
[CONTACT_6667]/IEC members, and by [CONTACT_32857].
A 5 Committees Structure
The safet y of all [COMPANY_008] clinical studies is clo sely monitored on an on -going basis by  
[CONTACT_73006] y.  Issues i dentified will be 
addressed; for instance, this could invo lve amendments to the Clinical Study Protocol and 
letters to Invest igators.
A 6 Dissemination of Clinical Study Data
Any results both technical and lay summaries for this trial, will be submitted toEU CTIS within 
a year from global End of Tri al Date in allparticipating countri es, due to sci entific reasons, as 
otherwi se statistical analysis is not relevant.
A descript ion of this clinical trial will b e available on 
http://astrazenecagrouptrials.pharmacm.com and http://www.clinicaltrials.gov as will the 
summary of the main study  resul ts when they  areavailable. The clinical trial and/or summary  
Clinical Study Protocol -7.[ADDRESS_298110] data relat ing to the study  will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (e.g., laboratory  data).  The Invest igator 
is responsible for verifying that data entries are accurate and correct by  [CONTACT_244984]. 
The Investigator must maintain accurate documentation (source data) that supports the 
inform ation entered in the CRF.  
The Investigator must permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons and provi de di rect ac cess to source data documents.  
The sponsor or designee is responsible for the data management of this study  including qualit y 
checking o f the data.  
Study  monitors will perform  ongoing source data verification to confirm that data entered into 
the CRF by [CONTACT_32861], com plete, and verifiable fro m source 
docum ents; that the safet y and ri ghts of  subjects are being protected; and that the study  is 
being conducted in accordance with the current ly approved protocol and any other stu dy 
agreem ents, ICH GCP, and all applicable regulatory  requirements.  Moni toring details 
describing strategy  (e.g., ri sk-based init iatives in operations and qualit y such as Risk 
Management and Mit igation Strategies and Analyt ical Risk -Based Monitoring), met hods, 
responsibilit ies and requirements, including handling of nonco mpliance issues and monitoring 
techniques (central, remote, or on -site monitoring) are provided in the Monitoring Plan.
Records and documents, including signed ICFs, pertaining to the cond uct of thi s study  must 
be retained by [CONTACT_13177] [ADDRESS_298111] igator’s site.
Data reported on the CRF that are transcribed fro m source documents must be consistent with 
the source documents or the discrepancies must be explained.  The Invest igator may need to 
Clinical Study Protocol -7.[ADDRESS_298112] itutes source data can be found in the monitoring plan.
A 9 Study and Site Closure
The sponsor designee reserves t he right to cl ose the study  site or terminate the study  at any  
time for any  reason at the sole discret ion of the sponsor. The study  may be stopped if, in the 
judgment of [COMPANY_008], trial subjects are placed at undue risk because of clinically 
significant findings that:
• meet individual stoppi[INVESTIGATOR_103414] 
• are assessed as causally related to study  drug 
• are not considered to be consistent with cont inuat ion of the study
Regardless of the reason for terminat ion, all data available for the subject at the time of 
discontinuat ion of fo llow-up m ust be recorded in the CRF. All reasons for discont inuat ion of 
treatm ent m ust be docum ented.
In terminat ing the study, the Sponsor will ensure that adequate considerat ion is given to the 
protecti on of  the subjects’ interests.
Study  sites will be cl osed upon study  com pletion. A study  site is considered cl osed when all 
requi red docum ents and study  supplies have been collected and a study -site closure visit has 
been performed.
The Investi gator may  initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by [CONTACT_244985]:
• Failure of the Invest igator to comply wit h the protocol, the requirements of the 
IRB/IEC or local healt h authorit ies, the sponsor's procedures, or GCP guidelines
• Inadequate recruit ment of parti cipants by  [CONTACT_11856]
• Disconti nuati on of  further study  intervent ion developm ent
A [ADDRESS_298113] a causal  
relationship with this treatment. An AE can therefore be any unfavou rable and unintended sign 
(e.g., an abnormal laboratory  finding), symptom (for example nausea, chest pain), or disease 
temporally  associ ated wi th the use of a m edicinal product, whether or not considered related to 
the medicinal product.  
The term  AE is u sed to include both serious and non -serious AEs and can include a deterioration 
of a pre -exist ing medical occurrence. An AE may  occur at any  time, including screening or 
washout periods, even if no Study  treatm ent has been administered.
B 2 Definitions of Seri ous Adverse Event
A serious adverse event is an AE occurring during any study  phase (i .e., screening, treatm ent, 
follow-up), that fulfils one or more of the following criteria:
Results in death
Is immediately life -threatening
Requi res in -subject hospi [INVESTIGATOR_244868] 
Results in persistent or significant disabilit y or incapaci ty  
Is a congenital anomalyor birth defect
Is an important medical event that may jeopardise the subject or may  require medical  
treatm ent to prevent one of the outcomes listed above
B 3 Life Threatening
‘Life -threatening’ means that the subject was at immediate risk of death from the AE as it 
occurred, or it is suspected that use or continued use of the product would result in the subject’s 
death. ‘Life -threatening’ does not mean that had an AE occurred in a more severe form it might 
have caused death (e.g., hepatit is that resolved without hepat ic failure).
B 4 Hospi[INVESTIGATOR_72917] a serious AE, alt hough the reasons for 
it may be (e.g., bronchospasm, laryngeal oedema).  Hospi[INVESTIGATOR_33094]/or surgical 
operati ons planned before or during a study  are not consi dered AEs if the illness or disease 
Clinical Study Protocol -7.[ADDRESS_298114] drug does not mean that it is an important medical event; medical 
judgement must be used.
Examples of such events are:
Angioedema not severe enough to require intubation but requiring iv hydrocortison e 
treatm ent
Hepatotoxicit y caused by [CONTACT_33153] l (acetaminophen) overdose requiring treatment 
with N-acetylcysteine
Intensive treatment in an emergency room or at home for allergic bronchospasm
Blood dy scrasias (e.g., neutropenia or anaemia requiring blood transfusion, etc.) or 
convulsio ns that do not result in hospi[INVESTIGATOR_72913]
Development of drug dependency or drug abuse
B 6 Intensity Rating Scale:
1. Mild (awareness of sign or symptom, but easily tolerated)
2. Moderate (di scomfort sufficient to cause interference wi th norm al activi ties)
3. Severe (incapacitat ing, with inabilit y to perform  norm al activities)
It is important to dist inguish between serious and severe AEs.  Severit y is a measure of intensit y 
whereas seriousness is defined by  [CONTACT_244986] B 2.  An AE of severe intensit y need 
not necessarily be considered serious.  For example, nausea that persists for several hours may be 
considered severe nausea, but not a SAE unless it meets the criteria shown in Appendix B 2. On 
the other hand, a stroke that results in only a limited degree of disabilit y may be considered a 
mild stroke but would be a SAE when it satisfies the criteria shown in Appendix
 B 2.
B 7 A Guide to Interpreting the Causality Question
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 148of 217When making an assessment of causalit y consi der the foll owing f actors when deciding if there is 
a ‘reasonable possibilit y’that an AE m ay have been caused by  [CONTACT_33641].
Time Course. Expo sure to suspect drug. Has the subject actually  received the suspect drug?  Did 
the AE occur in a reasonable temporal relationship to the administration of the suspect drug?
Consistency with known drug profile . Was the AE consistent with the previous knowle dge of  
the suspect drug (pharmaco logy and toxi cology) or drugs of the same pharmacological class? Or 
could the AE be ant icipated fro m its pharmaco logical  properti es?
De-challenge experience . Did the AE resolve or improve on stoppi[INVESTIGATOR_244869]?
No alternative cause . The AE cannot be reasonably  explained by [CONTACT_244987], other drugs, other host or environmental factors.
Re-challenge experience . Did the AE reoccur if the suspected drug was rein troduced after 
having been stopped? [COMPANY_008] would not normally reco mmend or support a re-challenge .
Laboratory tests. A specific laboratory  invest igation (if performed) has confirmed the 
relationship .
In difficult cases, other factors could be consider ed such as:
Is this a recogni zedfeature of overdose of the drug?
Is there a known mechanism?
Causalit y of ‘related’ is m ade if fo llowing a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’of a causal relationship for the indiv idual case. The expressio n 
‘reasonable possibilit y’ of acausal relationship is meant to convey, in general , that there are facts 
(evidence) or arguments to suggest a causal relat ionship.
The causalit y assessment i s perform ed based on the available data in cluding enough information 
to make an informed judgment. With limited or insufficient informat ion in the case, it is likely 
that the event(s) will be assessed as ‘not related’.
Causal relat ionship in cases where the disease under study  has deteri orated due to lack of effect 
shoul d be classified as no reasonable possibilit y.
B 8 Medication Error, Drug Abuse and Drug Misuse
Medication error
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 149of 217For the purposes of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment process for an IMP or [COMPANY_008] NIMP that either causes harm to the participant 
or has the potential to cause harm to the participant.  
A medication error is not lack of efficacy o f the drug, but rather a human or process related 
failure while the drug is in control of the study  site staff or parti cipant.
Medicat ion error includes situat ions where an error:  
occurred
was identified and intercepted before the participant received the drug
did not occur, but circumstances were recognized that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name [CONTACT_33165] n
Dispensing error e.g., medication prepared incorrectly , even if i t was not actually  given to 
the participant
Drug not administered as indicated, for example, wrong route or wrong site of 
administration
Drug not taken as indicated e.g., tablet disso lved in water when it should be taken as a 
solid tablet 
Drug not stored as instructed e.g., kept in the fridge when it should be at room 
temperature 
Wrong participant received the medicat ion (excluding IWRS errors)
Wrong drug administered to participant (excluding IWRS errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m IWRS - including those which lead to one of the above 
listed events that would otherwise have been a medicat ion error 
Parti cipant acci dentally  missed drug dose(s) e.g., forgot to take medication
Accidental  overdose (will be captured as an overdose)
Parti cipant f ailed to return unused medicat ion or empt y packaging
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 150of 217Errors related to background and rescue medicat ion, or standard of ca re medicat ion in 
open l abel studi es, even if an AZ product 
Medicat ion errors are not regarded as AEs, but AEs may occur as a consequence of the 
medicat ion error
Drug Abuse
For the purpose of this study, drug abuse is defined as the persistent or sporadic intentional, non -
therapeuti c excessive use of IMP or [COMPANY_008] NIMP for a perceived reward or desired 
non-therapeut ic effect.
Any events of drug abuse, with or without associated AEs, are to be captured and forwarded to 
the Data Entry  Site (DES) using th e Drug Abuse Report Form. This form should be used both if 
the drug abuse happened in a study  parti cipant or if the drug abuse invo lves a person not enrolled 
in the study  (such as a rel ative of the study  parti cipant).
Examples of drug abuse include but are not limited to:
The drug is used with the intent of getting a perceived reward (by [CONTACT_244988] 
a person not enrolled in the study )
The drug in the form o f a tabl et is crushed and injected or snorted with the intent of 
getting high
Drug Misuse
Drug misuse is the intent ional and inappropriate use (by  a study parti cipant) of IMP or 
[COMPANY_008] NIMP for medicinal purposes outside of the authorised product informat ion, or for 
unauthori sed IMPs or [COMPANY_008] NIMPs, outside the intended use as specified in the protocol 
and includes deliberate administration of the product by  [CONTACT_244972].
Events of drug misuse, with or without associated AEs, are to be captured and forwarded to the 
DES using the Drug Misuse Report Form. This form should be u sed both if the drug misuse 
happened in a study  parti cipant or if the drug misuse regards a person not enrolled in the study  
(such as a relative o f the study  parti cipant).
Examples of drug misuse include but are not limited to:
The drug is used with the in tention to cause an effect in another person
The drug is so ld to other people for recreational purposes 
The drug is used to facilitate assault in another person
The drug is deliberately administered by [CONTACT_244972]
The drug is split in half because it is easier to swallow, when it is stated in the protocol 
that it must be swallowed whole
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 151of 217Only half the dose is taken because the study  partici pant feels that he/she is feeling better 
when not taking the who le dose
Someone who i s not enrolled in the study  intentionally  takes the drug
Appendix C Handling of Human Biological Samples
C [ADDRESS_298115] igator keeps full traceabilit y of collected bio logical samples from  the 
subjects while in storage at the centre until shipment or disposal (where appropriate).
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment an d keeps documentation of receipt of arrival.
[COMPANY_008] will keep oversight of the entire life cycle through internal procedures, monitoring 
of study  sites, audi ting or process checks, and contractual requirements of external laboratory  
provi ders.
Samplesretained for further use will be stored in the AZ -assigned bi obanks and will be 
registered by  [CONTACT_96787].
If required, [COMPANY_008] will ensure that remaining bio logical samples are returned to the site 
accord ing to local regulations or at the end of the retention period, whichever is the sooner.
C [ADDRESS_298116] withdraws consent to the use of donated bio logical samples, the sam ples will  be 
disposed of /destroy ed, and the acti on documented.  If samples are already  analyzed ,[COMPANY_008] 
is not obliged to destroy  the resul ts of this research.
As collect ion of the bio logical sample(s) i s an integral  part of the study , then the subject i s 
withdrawn from  further study  parti cipat ion.
The Investigator:
 Ensures subjects’ wit hdrawal o f informed consent to the use of donated 
samples is notified immediately to [COMPANY_008]
 Ensures that bio logical samples from that subject, if stored at the study  site, 
are immediately ident ified, disposed of /destroyed, and the action 
docum ented
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 152of 217 Ensures the organizat ion(s) ho lding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed 
of/destroy ed, the acti on docum ented, and the si gned docum ent returned to 
the study  site
 Ensures that the subject and [COMPANY_008] are informed about the sample 
disposal
[COMPANY_008] ensures the organizat ions holding the samples is/are informed about the withdrawn 
consent immediately and that samples are disposed of/ destroy ed and the acti on docum ented and 
returned to the study  site.
C 3 International Airline Transportation Association (IATA) 6.[ADDRESS_298117] SAMPLES
International Airline Transportation Associat ion (IATA) classifies biohazardous agents into 3 
categori es(https://www.iata.org/whatwedo/cargo/dgr/Documents/infectious -substance -
classification -DGR56- en.pdf .).For transport purposes the classificat ion of infect ious substances 
according to risk groups was removed fro m the Dangerous Goods Regulat ions in the 46th edition 
(2005). Infect ious substances are now classified either as Category  A, Category B or Exem pt. 
There is no direct relationship between Risk Groups and Categories A and B.
Category A Infectious Substances are infect ious substances in a form that, when exposure to it 
occurs, is capable of causing permanent disabilit y, life- threatening or fatal  disease in otherwise 
healt hy humans or animals. Category  A pathogens are e.g., Ebola, Lassa fever virus:
 are to be packed and shipped in accordance wit h IATA Instruction [ADDRESS_298118] ious substances that do not meet the criteria f or 
inclusio n in Category  A. Category  B pathogens are e.g., Hepatit is A, B, C, D, and E viruses, 
Hum an immunodeficiency virus ty pes 1 and 2. They  are assigned the following UN number and 
proper shippi[INVESTIGATOR_72919]:
 UN 3373 –Biological Substance, Category  B
 are to be packed in accordance with UN3373 and IATA 650
Exempt -all other materials wit h minimal risk of containing pathogens
 Clinical trial samples will fall into Category  B or exempt under IATA 
regul ations
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241 C00001
CONFIDENTIAL AND PROPRIETARY Page 153of 217 Clinical trial samples will routinely be packed and transported at ambient
 Temperature in IATA 650 compliant packaging 
(https://www.iata.org/whatwedo/cargo/dgr/Documents/infect ious-
substance -classificat ion-DGR56 -en.pdf.)
 Biological samples transported in dry  ice requi re addi tional dangerous 
goods specifica tion for the dry -ice content
 IATA co mpliant courier and packaging materials should be used for 
packing and transportation and packing should be done by  [CONTACT_244989], as applicable
 Samples routinely transported by  [CONTACT_244990] a 
safe and appropriate way  to contain any  risk of infecti on or contaminat ion 
by [CONTACT_244991]/containment materials at all 
times. The IATA [ADDRESS_298119] or rail transport is used.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 154of 217Appendix D Genetics
D 1 Use/analysis of DNA
Genet ic variat ion may impact a subject’s response to therapy , susceptibilit y to, and severi ty and 
progression of disease.  Variable response to therapy  may be due to geneti c determinants that 
impact drug absorption, distribut ion, metabo lism, and excret ion; mechanism  of action of the 
drug; di sease et iology; and/or mo lecular subt ype of the disease being treated.  Therefore, wher e 
local regulati ons and IRB/IEC allow, blood samples will be collected for DNA analysis fro m 
consent ing subjects.
[COMPANY_008] intends to collect and store DNA for genet ic research to explore how genetic 
variat ions may affect clinical parameters, risk and p rognosi s of diseases, and the response to 
medicat ions.  Genetic research may lead to better understanding of diseases, better diagnosis of 
diseases or other improvements in healt h care and to the discovery  of new diagnosti cs, 
treatm ents or m edicat ions.  
In addit ion, collect ion of DNA samples from populat ions wit h well described clinical 
characterist ics may lead to improvements in the design and interpretation of clinical trials and, 
possibly , to geneti cally guided treatment strategies.
Genet ic research may consist of the analysis o f the structure of the subject ´s DNA, i.e., the ent ire 
geno me. 
The results of genet ic analyses may be reported in the clinical study  report (CSR) or in a separate 
study  summary .
[COMPANY_008] will store the DNA samples in a secure storage space with adequate measures to 
protect confident iality.
D [ADDRESS_298120] fulfil all the inclusio n criteria described in 
the main body  of the Clinical  Study  Protocol  and provi de inform ed consent for the genet ic 
sampling and analyses.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 155of 217Exclusion criteria
Exclusio n from this genet ic research may be for any o f the excl usion criteria specified in the 
main study  or any  of the fo llowing:
 Previous allogeneic bone marrow transplant
 Non-leukocyte depleted whole blood transfusio n in [ADDRESS_298121] ion is preferred to avoid introducing bias through 
excluding subjects who may wit hdraw due to an adverse event (AE), such subjects would be 
important to include in any genet ic analysis. If for any reason the sample is not drawn at 
rando mizat ion visit, it may be taken at any  visit until  the last study  visit. Only  one sample shoul d 
be co llected per subject for genetics during the study. Samples will be co llected, labelled, stored, 
and shipped as detailed in the Laboratory  Manual.
Coding and storage of DNA samples
The processes adopted for the coding and storage of samples for genet ic analysis are important to 
maintain subject confident iality.  Samples will be stored for a maximum o f 15years, from the 
date of l ast subject l ast visi t, after whi ch they  will be destroy ed.  DNA is a finite resource that is 
used up during analyses. Samples will be stored and used until no further analyses are possible or 
the maximum storage time has been reached.
An addit ional second code will be a ssigned to the blood either before or at the time of DNA 
extracti on repl acing the information on the sample tube. Thereafter, the sample will be 
ident ifiable only by [CONTACT_33160], unique number. This number is used to ident ify the sample and 
corresponding da ta at the [COMPANY_008] genet ics laboratories, or at the designated organization.  
No personal details identifying the individual will be available to any person ([COMPANY_008] 
employee or desi gnated organi zations working with the DNA).
The link between the subject enrolment/randomization code and the second number will be 
maintained and stored in a secure environment, with restricted access at [COMPANY_008] or 
designated organizat ions. The link will be used to ident ify the relevant DNA samples for 
Clinical Study Protocol -7.[ADDRESS_298122] and the original filed at the study  
centre. The Principal Investigator(s) is responsible for ensuring that consent is given freely and 
that the subject understands that they  may freely  withdraw from  the genet ic aspect of the study at 
any time.
Subject data protection
[COMPANY_008] will not provide individual genoty pe resul ts to subjects, any  insurance com pany, 
any emplo yer, their family members, general physician unless required to do so by  [CONTACT_2371].
Extra precautions are taken to preserve confident iality and prevent genetic data being linked to 
the identi ty of the subject. Regul atory  authori ties may requi re access to the relevant files, though 
the subject’s medical informat ion and the genetic files would remain physically separate.
Data management
Any genoty pe data generated in this study  will be stored at a secure system at [COMPANY_008] 
and/or design ated organi zations to analyze the samples.
[COMPANY_008] and its designated organizat ions may share summary results (such as genet ic 
differences fro m groups of individuals with a disease) fro m this genetic research with other 
researchers, such as hospi[INVESTIGATOR_600], academic organizat ions or health insurance co mpanies.  This can 
be done by [CONTACT_244992], where they can be combined with the 
resul ts of similar studi es to l earn even m ore about healt h and disease.  The researchers can only 
use this informat ion for health -related research purposes.  Researchers may  see summary  resul ts, 
but they  will not be able to see individual subject data or any  personal  identifiers.  
Some or all  of the clinical datasets from the main study  may be merged wi th the genet ic data in a 
suitable secure environment separate from the clinical database.
Statistical methods and determination of sample size
Clinical Study Protocol -7.[ADDRESS_298123] ical 
Analysis Plan may be prepared where appropriate.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 158of 217Appendix E Actions Required in Cases of Increases in Liver Biochemistry 
and Evaluation of Hy’s Law
E 1 Introduction
This Appendix describes the process to be fo llowed in order to ident ify and appropriately report 
Potenti al Hy’s Law (PHL) cases and Hy’s Law (HL) cases. It is not intended to be a 
comprehensive gui de to the m anagement of el evated liver biochemistries. Specific guidance on 
managing liver abnormalit ies can be found in Section 7.1of the Clinical  Study  Protocol .
During the course of the study  the Invest igator will remain vigilant for increases in liver 
biochemistry . The Investi gator i s responsible for determining whether a subject meets potential 
PHL cri teria at a ny po int during the study .
All sources of l aboratory  data are appropri ate for the determinat ion of PHL and HL events; this 
includes samples taken at scheduled study  visit s and other visits including central and all local 
laboratory  evaluat ions even if co llected outsi de of the study  visits; for exam ple, PHL cri teria 
could be m et by  [CONTACT_96724]  a central  laboratory  and/or elevated TBL from  a local 
laboratory .
The Investigator will also review Adverse Event data (for example, for AEs that may indicate
elevations in liver biochemistry ) for possible PHL events.
The Investigator participates, together with [COMPANY_008] clinical project representatives, in 
review and assessment of cases meet ing PHL criteria to agree whether HL criteria are met. HL 
criteria are met if there is no alternat ive explanation for the elevat ions in liver biochemistry  other 
than drug induced liver injury (DILI) caused by [CONTACT_244993] (IMP).
The Investigator is responsible for recording data pertaining to PHL/ HL cases and for reporting 
AEs and SAEs according to the outcome of the review and assessment in line wit h standard 
safet y reporting processes.
E 2 Definitions
Potential Hy’s Law (PHL)
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥ 3x Upp er Limit of 
Norm al (ULN) together with Total Bilirubin (TBL) ≥ 2xULN at any po int during the study  
following the start of study  medicat ionirrespect ive of an increase in Alkaline Phosphatase 
(ALP).
Hy’s Law (HL)
Clinical Study Protocol -7.[ADDRESS_298124] or ALT ≥ 3x ULN together with TBL ≥ 2xULN, where no other reason, other than the 
IMP, can be found to explain the combinat ion of increases, e.g., elevated ALP indicating 
cholestasis, viral hepat itis, another drug.  
For PHL and HL the elevat ion in transaminases must precede or be coincident w ith (i.e., on the 
same day ) the el evati on in TBL, but there is no specified timeframe within which the elevat ions 
in transaminases and TBL must occur.
E 3 Identification of Potential Hy’s Law Cases
In order to i dentify  cases of PHL i t is important to perform a comprehensive review of laboratory  
data for any  subject who m eets any of the fo llowing i dentificat ion criteria in iso lation or in 
combinat ion:
 ALT ≥ 3×ULN
 AST ≥ 3×ULN
 TBL ≥ 2×ULN
When a subject meet any  of the PHL i dentificat ion criteria, in isol ation or in co mbinat ion, the 
central  laboratory  will immediately  send an alert to the Invest igator (and also to the [COMPANY_008] 
representative).  
The Investigator will also remain vigilant for any  local  laboratory  reports where the PHL 
ident ificat ion criteria are met, where this is the case the Investigator will:
 Notify  the [COMPANY_008] representative
 Request a repeat of the test (new blood draw) by  [CONTACT_244994]
 Com plete the appropri ate unscheduled laboratory  CRF m odule(s) wi th the ori ginal 
local laboratory  test resul t
When the identificat ion criteria are m et from central  or local laboratory  resul ts the Invest igator 
will wit hout del ay:
 Determine whether the subject meets PHL criteria (see Appendix E 2Definit ions 
within this Appendix for definit ion) by [CONTACT_244995] m all previous 
visits (including both central and local laboratory  resul ts)
E 4 Follow -Up
E 4.1 Potential Hy’s Law Criteria Not Met
Clinical Study Protocol -7.[ADDRESS_298125] does not meet PHL criteria the Investigator will:
 Inform  the [COMPANY_008] representative that the subject has not met PHL criteria.
 Perform  follow-up on subsequent laboratory  resul ts according to the guidance 
provi ded in the Clinical Study  Protocol .
E 4.2 Potential Hy’s Law Criteria Met
If the subject does meet PHL criteria the Invest igator will:
Determine whether PHL criteria were met at any  study  visit prior to starting Study  treatm ent 
(See Section 8.3.10 Safet y Reporting)
Notify  the [COMPANY_008] representative who will then inform the central Study  Team  
Within [ADDRESS_298126] igator will report the case as an SAE of 
Potenti al Hy’s Law; seri ous cri teria ‘Im portant m edical event’ and causalit y assessment 
‘yes/related’ according to CSP process for SAE reporting
For subjects that met PHL criterial prior to starti ng IMP, the Invest igator is not required 
to submit a PHL SAE unless there is a significant change in the subject’s condit ion
The [COMPANY_008] Study  Physician contacts the Investigator, to provide guidance, discuss and 
agree an approach for t he study subjects’ fo llow
-up (including any  further l aboratory  testing) and 
the continuous review o f data. Subsequent to this contact [CONTACT_48887]:
Moni tor the subject until liver biochemistry  parameters and appropriate clinical symptoms 
and signs return to norm al or baseline levels, or as long as medically  indicated. Com pletes 
follow-up SAE Form as required. 
Invest igate the aetiology o f the event and perform diagnostic investigat ions as discussed 
with the Study  Physician. This includes deciding w hich the tests available in the Hy’s law 
lab kit should be used.
Com plete the three Liver CRF Modules as information becomes available 
E 5 Review and Assessment of Potential Hy’s Law Cases
The instructions in this sect ion shoul d be fo llowed for all  cases whe re PHL cri teria are m et.
As soon as possible after the biochemistry  abnormalit y was ini tially detected, the [COMPANY_008] 
Study  Physician contacts the Invest igator in order to review available data and agree on whether 
there is an alternat ive explanat ion for meeting PHL criteria oth er than DILI caused by  [CONTACT_2203], 
to ensure timely analysis and reporting to health authorities within [ADDRESS_298127] and TBL elevations, a 
determinat ion of whether the alternat ive explanat ion is an AE will be made and subsequent ly 
whether the AE meets the criteria for a SAE:
 If the alternat ive explanat ion is notan AE, record the alternative explanation on the 
appropriate CRF.
 Ifthe alternat ive explanat ion is an AE/SAE:  update the previously submitted Potential 
Hy’s Law SAE and AE CRFs accordingly wit h the new information (reassessing event 
term; causalit y and seri ousness cri teria) fo llowing the AZ standard processes.
If it is agreed that there is no explanat ion that would explain the ALT or AST and TBL 
elevations other than the IMP:
 Send updated SAE (report term ‘Hy’s Law’) according to [COMPANY_008] standard 
processes.  
The ‘Medically  Important’ seri ous cri terion shoul d be used if no other serious 
criteria apply.
As there is no alternat ive explanation for the HL case, a causalit y assessment of 
‘related’ should be assigned.
If there is an unavo idable delay, of over 15 calendar days in obtaining the informat ion necessary  
to assess whether or not the case meets the criteria for HL, then it is assumed that there is no 
alternat ive explanat ion unt il such time as an informed decisio n can be made:
 Provi des any  further update to the previously submitted SAE of Potential Hy’s Law, 
(report t erm now ‘Hy’s Law case’) ensuring causalit y assessment i s related to IMP and 
seriousness cri teria is m edically important, according to CSP process for SAE 
reporting. 
 Continue fo llow-up and review according to agreed plan. Once the necessary  
supplementary  informat ion is obtained, repeat the review and assessment to determine 
whether HL criteria are still met. Update the previously submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review 
amending the reported t erm if an al ternat ive explanat ion for the liver biochemistry  
elevations is determined.
Clinical Study Protocol -7.[ADDRESS_298128] resul ts need to be 
recorded in the eCRF.
Hy’s Law lab kit for central labora tories
Addit ional standard chemistry  and 
coagul ation testsGGT
LDH
Prothrombin t ime
INR
Viral hepati tis IgM ant i-HAV 
IgM and IgG anti -HBc
HBsAg
HBV DNA
IgG anti -HCV
HCV RNA* 
IgM ant i-HEV
HEV RNA
Other viral infect ions IgM & IgG anti-CMV
IgM & IgG anti -HSV
IgM & IgG anti -EBV
Alcoho lic hepat itis Carbohydrate deficient transferrin (CD -
transferrin)
Autoimmune hepatit is Antinuclear antibody (ANA)
Anti-Liver/Kidney  Microsom al Ab (Anti -
LKM)
Anti-Smooth Muscle Ab (ASMA)
Metabo lic diseases alpha-1 -antitrypsin
Cerul oplasmin
Iron
Ferri tin
Transferrin
Transferrin saturation
* HCV RNA is only tested when IgG anti -HCV is positive or inconclusive
References
Aithal et al 2011 , Clinical Pharmaco logy and Therapeutics 89(6):806 -815.
FDA Guidance for Industry  (issued July  2009) ‘Drug -induced liver injury: Premarket ing clinical 
evaluat ion’
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 163of 217Appendix F Maintenance Therapy Equivalence Table
Inhaled Corticosteroids dose conversio n tables shoul d be used to assess Inclusio n 7.
ICS component Conversion Factor
(i.e. multiply dose by X)Minimum acceptable 
daily dose (mcg)
Fluticasone propi[INVESTIGATOR_16847] 1 >250
Fluticasone propi[INVESTIGATOR_96701] 1.14 >220 (per actuation)
Fluticasone furoate 2.5 ≥100 (metered)
≥92 (delivered)
Budesonide (metered/delivered dose) 0.63/0.78 >400 (metered)
>320 (delivered)
Budesonide (nebulized) 0.5 >0.5 m g (2 ml  ampules)
Beclo methasone 0.5 >500
Beclo methasone (Trimbow) 1.25 400 (m etered)
348 (delivered dose)
Beclo methasone extra- fine particles 
and HFA (Fostair, QVAR)1.04 (m etered dose)
1.25 (dose per actuation)>250 (metered dose)
>200 (per actuation)
Ciclesonide 1.56 >160
Mometasone furoate 1.14 >220 (metered)
>200 (per actuation)
Fluniso lide 0.25 >1000
Triamcino lone 0.25 >1000
Sources: GOLD 2018; GINA 2018 
Example conversio n
Converting budesonide (delivered dose) to flut icasone propi[INVESTIGATOR_16847] (in mcg): 
ICS component Conversion Factor
(i.e. multiply dose by X)Minimum acceptable 
daily dose (mcg)
Budesonide (metered/delivered dose) 0.63/0.78 >400 (metered)
>320 (delivered)
For a budesonide dose of 160 mcg, use a conversio n factor of 0.78
160 mcg of budesonide x 0.78 = 124.8 mcg fluticasone propi[INVESTIGATOR_244870] (m cg) for Budesonide (delivered dose) must be higher than 
320m gdaily for subject to be eligible for the study (320mcg daily  dose is not acceptable).
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 164of 217Appendix G Anaphylaxis: Signs and Symptoms, Management
G 1 Introduction
As wi th any antibody , allergic reactions to dose administration are possible. The World Healt h 
Organizat ion (WHO) has categorized anaphylaxis into [ADDRESS_298129] inguishable: immuno logic [IgE -mediated and non -IgE-mediated (e.g., IgG and immune
complex mediated) and nonimmuno logic (Johansson et al 2004 ). The clinical criteria for 
defining anaphylaxis for this study  are listed in Appendix G 2. A gui de to the si gns and 
symptoms and management of acute anaphylaxis is provided in Appendix
 G 3. Appropri ate 
drugs, such as epi[INVESTIGATOR_238] , antihistamines, corticosteroids, etc., and medical equipment to treat 
anaphylactic reactions must be immediately available at study sites, and study  personnel shoul d 
be trained to recognize and treat anaphylaxis according to local guidelines. 
If an anap hylact ic react ion occurs, a blood sample will be drawn fro m the subject as soon as 
possible after the event, at 60 minutes ± 30 minutes after the event, and at discharge for analysis 
of serum  tryptase.
G 2 Clinical Criteria for Defining Anaphylaxis and Immune 
Complex Disease
Anaphylaxis
In adults, anaphylaxis is highly likely when any one of the fo llowing 3 cri teria is fulfilled:
1. Acute onset of an illness (minutes to several hours) with invo lvement of the skin, 
mucosal t issue, or both (e.g., generalized hives, pruri tus or fl ushing, swollen lips -
tongue -uvula).
AND AT LEAST ONE OF THE FOLLOWING
(a) Respi[INVESTIGATOR_33097] (e.g., dyspnea, wheeze
-bronchospasm, stridor, 
hypoxemia).
(b) Reduced blood pressure (BP) or associated symptoms of end -organ dysfunct ion 
(e.g., hy potoni a [collapse], syncope, incont inence).
2. Two or more of the fo llowing that occur rapi[INVESTIGATOR_11312] a likely allergen for 
that subject (minutes to several hours):
(a) Involvement of the skin -mucosal t issue (e.g., generalized hives, itch -flush, swollen 
lips-tongue-uvula).
(b) Respi[INVESTIGATOR_33097] (e.g., dyspnea, wheeze- bronchospasm, stridor, 
hypoxemia).
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 165of 217(c) Reduced BP or associated symptoms (e.g., hy potonia [collapse], syncope, 
incont inence).
(d) Persi stent gastrointestinal symptoms (e.g., crampy  abdominal pain, v omiting).
3. Reduced BP after exposure to known allergen for that subject (minutes to several 
hours): Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease fro m 
that subject’s baseline.
Immune Complex Disease
Immune com plex disease or Hy perse nsitivity Type III i s evoked by  [CONTACT_96793]-
antibody  or anti gen-antibody -complement com plexes on cell surfaces, with subsequent 
involvement of breakdown products of complement, platelets, and polymorphonuclear 
leukocy tes, and development of v asculi tis; serum  sickness and nephri tis are commo n.
G 3 Signs and Symptoms and Management of Acute Anaphylaxis
Anaphylaxis is an acute and potentially lethal mult i-system  allergic reacti on in which som e or all  
of the fo llowing signs and symptoms occur: 
Diffus e ery thema
Pruri tus
Urticaria and/or angioedema
Bronchospasm
Laryngeal edema
Hypotensi on
Cardi ac arrhy thmias
Feeling of impending doom
Unconsciousness
Shock
Other earlier or concomitant signs and symptoms can include:
Itchy  nose, ey es, pharynx, genitalia, palms, and so les
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 166of 217Rhinorrhea
Change in voice
Metallic taste
Nausea, vo miting, di arrhea, abdominal cramps and bloating
Lightheadedness
Headache
Uterine cramps
Generalized warmt h
G [ADDRESS_298130] , breathing, ci rculation, and adequacy  of mentati on.
2. Administer epi[INVESTIGATOR_96702]  5-15 minutes, in appropriate doses, as 
necessary , depending on the presenting signs and symptoms of anaphylaxis, to control 
signs and symptoms and prevent progress ion to more severe symptoms such as 
respi [INVESTIGATOR_36645], hypotension, shock and unconsciousness.
Possibly appropriate, subsequent measures depending on response to epi[INVESTIGATOR_238]
(a) Place subject in recumbent posit ion and elevate lower extremit ies.
(b) Establish an d maintain airway .
(c) Administer oxy gen.
(d) Establish venous access.
(e) Norm al saline IV for fluid replacement.
Specific measures to consider after epi[INVESTIGATOR_96703], where appropriate
(f) Consider epi[INVESTIGATOR_96704] n.
(g) Consider H1 and H2 ant ihistamines.
(h) Consider nebulized β2 agonist [e.g., albuterol (salbutamo l)] for bronchospasm 
resistant to epi[INVESTIGATOR_238].
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 167of 217(i) Consider systemic corticosteroids.
(j) Consider vasopressor (e.g., dopamine).
(k) Consider glucagon for subject taking β -blocker.
(l) Consider atropi[INVESTIGATOR_96705].
(m) Consider transportation to an emergency  depart ment or an intensive care facilit y.
(n) For cardi opulm onary arrest during anaphylaxis, high -dose epi[INVESTIGATOR_244871], if necessary .
Adapted from: Kemp et al 2008
Kemp SF, Lockey  RF, Sim ons FE; Worl d Allergy  Organizat ion Ad hoc Committee on 
Epi[INVESTIGATOR_96707]. Epi[INVESTIGATOR_238]: the drug of cho ice for anaphylaxis. A statement of the 
World Allergy  Organizati on. Allergy. 2008; 63(8):[ADDRESS_298131] Pressure
CRF Case Report Form (electronic/paper)
CRO Contract Research Organization
CSR Clinical Study Report
CT Scan Computed Tomography Scan
CTIS Clinical Trial Information System
CTT Clinical Trial Transparency
DAE Discontinuation of Investigational Product due to Adverse Event
dECG Digital electrocardiogram
DILI Drug induced liver injury
DNA Deoxyribonucleic acid 
eCRF Electronic case report form
EC Ethics Committee, synonymous to Institutional Review Board (IRB) and 
Independent Ethics Committee (IEC)
ECG Electrocardiogram
EGPA Eosinophilic granulomatosis with polyangiitis
EOT End of Treatment 
ePRO Electronic Patient Reported Outcome 
ER Emergency Room
E-RS™: COPD Exacerbations of Chronic Pulmonary Disease Tool –Respi[INVESTIGATOR_244872] -7.[ADDRESS_298132] -PRO Exacerbations of Chronic Pulmonary Disease Tool –Patient -reported 
Outcome
FAS Full Analysis Set
FeNO Fractional Exhaled Nitric Oxide
FEV [ADDRESS_298133]
HIV-1/2 Hum an immunodeficiency virus -1/2
HL Hy’s Law
HRU Healthcare resource utilization
IATA International Air Transport Association
ICH International Conference on Harmonization
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 171of 217Abbreviation or special 
termExplanation
ICI International Co -ordinating Investigator (If a study is conducted in 
several countries the International Co -ordinating Investigator is the 
Investigator coordinating the Investigators and/or activities 
internat ionally). 
ICF Infor med Consent Form 
ICS Inhaled Corticosteroids
IDMC Independent data monitoring committee
IEC Independent ethics committees
IFU Instructions for Use
Ig Immunoglobulin 
IHC Immunohistochemistry
IL-[ADDRESS_298134]
IND Investigation New Drug (application)
IP Investigational Product 
IPD Investigational Product Discontinuation
IRB Institutional Review Board
ISF Investigator Site File
IUD Intrauterine device
IUS Intrauterine system
ITT Intent -to-Treat
IV Intravenous
IWRS Interactive Web Response System
LABA Long -Acting β2 -Agonist
LAMA Long -Acting Muscarinic Antagonists
Clinical Study Protocol -7.[ADDRESS_298135]
NIPPV Noninvasive positive -pressure ventilation
O2 Oxygen
OAE Other Significant Adverse Event
OCS Oral Corticosteroids
PD Pharmacodynamic
PGx Genetic research
PHL Potential Hy’s Law
PI [INVESTIGATOR_244873](s)
PNV Predicted Normal Value
PRN Pro Re Nata (as needed)
PRO Patient Reported Outcome
PT Preferred Term
Clinical Study Protocol -7.[ADDRESS_298136]. George’s Respi[INVESTIGATOR_244874] -nucleotide polymorphism
SoA Schedule of Activities 
SoC Standard of Care
SOC System Organ Class
SOP Standard Operating Procedure
SpO [ADDRESS_298137]
V Visit
W Week
WBC White blood cell
WBDC Web Based Data Capture
WOCBP Women of Childbearing Potential
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 175of 217Appendix I Coronavirus (COVID -19) Pandemic Guidance 
During the COVID- [ADDRESS_298138] ively enrolled subjects in the screening period will be 
screen failed and rando mizat ion visits will be temporarily placed on ho ld until the pandemic 
norm alizes, and AZ approves the continuat ion of the study . Sputum  and nasal samples will not 
be co llected fro m subjects in treatment until the pandemic normalizes and AZ approves th e 
continuat ion of sampling. Sputum and nasal sampling will be performed, if allowed per local 
regul ations and guidance.
Please Note: Changes below should only be implemented during the COVID -[ADDRESS_298139]’s ho me, or at an alternat ive 
location. During the ca ll, subject should be instructed to contact [CONTACT_244996], if subject 
experiences any  COVID -19 symptom s or was exposed to someone diagnosed with COVID- 19. 
For rem ote visits (phone call and/or virtual visits), the COVID- 19 screening questionnaire shou ld 
be conducted as a part of study  visit assessments. Pati ent COVID -19 screening should include:
Symptom  history
Exposure to someone diagnosed with COVID -[ADDRESS_298140] 14 day s
Recent travel including to countries with CDC Level 2 or higher travel warning or 
equivalent or known COVID -19 hot spots
Unexplained fever, cough, shortness of breath, chills, muscle pain, headache, sore throat 
and/or new loss of taste or smell within the past [ADDRESS_298141] ionnaire:
1.Have you experienced unexplained fever, cough, shortness of breath, chills, muscle pain, 
headache, sore throat, and/or new loss of taste or smell wit hin the past 14 day s?
2.Have you been in conta ct wi th anyone who is sick or with symptoms (refer to question 1) 
in the last 14 day s? 
3.Have you been exposed to someone diagnosed with COVID -[ADDRESS_298142] 14 days?
4.Have you been practicing social distancing over the last 14 days? 
(refer to region/ci ty/country  regul ations)
5.Have you traveled in the last 14 days, if so where? 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 176of 217(recent travel including to countries/regions with CDC Level 2 or higher travel warning 
or equivalent or known Covid- 19 hot spots)
6.Have you been in iso lation or quarantin e for any  reason in the past 14 day s?
7.Have you been diagnosed with Covid- 19 at any  time, if so where and when? 
Sites m ay use thei r own versio n of questionnaire per local guidance. Responses are not 
considered as part of clinical trial data and are not rec orded in RAVE. The site will determine the 
appropriate course of action based on the responses to questionnaire. Subject reporting 
symptoms should be referred for further evaluat ion as per invest igator judgment. Visit should be 
cancelled or re -scheduled, i f needed as judged by  [CONTACT_244934]. 
I [ADDRESS_298143] On -Site Visits (where applicable)
Due to l ocal travel  restri ctions and/or site restrict ions, patients may  not wish to or m ay not be 
able to go to the study  site for study visits and related proced ures. If an on -site visi t is not 
possible, it is reco mmended to have a home administration of IP by a qualified HCP, provided 
this is acceptable wit hin local regulat ion/guidance. This is to ensure safety o f the study  subjects 
and minimum disruption to IP a dministration that may occur during the COVID -19 pandemic. 
NOTE: Before init iating consent for home IP administration visit, the subject must have 
received at least the first [ADDRESS_298144] by  [CONTACT_244997] -19 symptom s before 
initiating ho me visit. Refer to I 1.
At minimum, during ho me vis it the qualified HCP is expected to:
Collect vital signs (visit should start with temperature measurement)
Collect adverse events reported since last contact [CONTACT_1155]
Collect informat ion about new or changes in concomi tant medications since last contact 
[CONTACT_1155] 
Com pletion of SGRQ and CAT (if applicable)
ePRO com pliance check (if applicable)
Collect informat ion about any worsening of underlying COPD symptoms/COPD 
exacerbations since last contact [CONTACT_1155]
Collect smoking status
Collect informat ion on healt hcare resources utilization
Perform  physical examinat ion (if applicable)
Measure oxygen saturation (SpO 2) (if applicable)
Collect use o f Suppl emental  O2status (if applicable)
Urine Pregnancy (dipst ick) prior to IP administration (if applicable)
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 177of 217If possible, co llect blood and urine samples according to the SoA 
Administer IP. Please refer to the IP home administration instructions for use during 
COVID -19 pandemic for more information
Observe the subject for one hour after IP administration for the signs or symptoms of any 
acute drug reactions 
Docum ent the visi t. The form  of contact [CONTACT_210068] d be docum ented in the m edical records
Laboratory assessments during home visit
If safet y blood sam ples are being co llected, they may  be obtained wi thin 1- hour post IP 
administration, to allow addit ional time for processing of the safety  samples at si te according to 
the laboratory  manual .
If PK and/or A DA samples are being co llected, they have to be obtained prior to IP 
administration. If it is not possible, these samples are not required to be collected during the 
home visit. 
I 3 Visit at an Alternative Location (where applicable) 
Study  visit s including a dministrati on of  IP and study  assessments according to the SoA can take 
place at an al ternat ive location away fro m infect ion risk zones, or cl oser to subjects’ ho mes, 
provi ded thi s is acceptable within lo cal regulat ion and guidance. 
Site must contact [CONTACT_244998] -19 symptom s before 
initiating visit at an alternat ive location. Refer to I 1.
Central  lung f unction assessments at alternat ive location is not implemented in COURSE study .
I 4 Phone call and/or virtual visits to replace on -site visits (where 
applicable)
During the COVID -[ADDRESS_298145] aced by [CONTACT_244999]/alternative location 
visits may be repl aced by a phone call and/or a virtual visit. 
Having a phone call and/or a virtual visit with the subject will allow collection of information
regarding:
Assessment of COVID-19 symptoms (refer to I 1)
Collect adverse events reported since last contact [CONTACT_1155]
Collect informat ion about new or change s in concomi tant medications since last contact 
[CONTACT_245000] -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 178of 217Com pletion of SGRQ and CAT (if applicable)
ePRO com pliance check
Collect informat ion about any worsening of underlying COPD symptoms/COPD 
exacerbations since last contact [CONTACT_1155]
Collect smoking status
Collect informat ion on healt hcare resources utilization
Measure oxygen saturation (SpO 2) (if applicable)
Collect use of Supplemental O 2status (if applicable)
Docum ent the visi t. The form  of contact [CONTACT_210068] d be docum ented in the m edical records
I 5 Re-consenting of subjects during the COVID -19 pandemic 
COVID -19 addendum to ICF (SoA,
 Table 2) must be obtained pri or to starti ng any procedures 
according to Appendix
 A 3. The standard informed consent process in the trial should be 
followed. However, if the subject may  not be able to visit the site due to COVID -[ADDRESS_298146] was enrolled in this study , coronavirus disease 2019 (COVID -19) has 
emerged as a worl dwide pandemic disease with significant public healt h implicat ions. 
[COMPANY_008]’s decisio n was to place enro lment temporarily on ho ld unt il the pandemic 
norm alizes as not all screening assessments required for the evaluat ion of subject eligibilit y 
could be done. Subj ects al ready randomized were allowed to continue wit h study  but alterna tive 
options were given to minimize the risk of subject exposure to COVID -19.
However, [COMPANY_008] is not aware of any current evidence suggest ing that tezepelumab eit her 
increases the susceptibilit y to COVID -[ADDRESS_298147] ion rates (e.g. travel 
restri ctions) may inhibit the abilit y of subjects to attend study  visits. Necessary  healthcare 
responses at sites to the pandemic (e.g. addit ional infect ion control measures) may  also inhibi t 
the abilit y of a clinical site to effect ively and properly conduct the study . Stud y visit attendance 
for dosing and for clinical assessments are crit ical for the sci entific value of the study .
To ensure the safet y of the subject and site staff, at every  visit will foll ow these gui delines:
All subjects will have a COVID -[ADDRESS_298148] ion 
based on the responses to the questions. 
Naso/oropharyngeal swab testing (or rapid test) for severe acute respi[INVESTIGATOR_82326] e 
coronavirus 2 (SARS -CoV -2) is requi red at screening Visit [ADDRESS_298149] ion into 
the study . 
Testing for SARS -CoV -[ADDRESS_298150] ion may 
and should be performed, if required, by [CONTACT_245001]. If SARS -CoV -2 
testing is conducted, a negative result should be obtained before conducting visit 
assessments if required by [CONTACT_245002]
If, a subj ect is not able to attend their scheduled study  visit at the si te, al ternative visit 
options are available. 
All site staff shoul d wear personal protective equipment in accordance with local or 
national guidelines.
Moreover, Invest igators should not enrol subjects unless they  have reasonable confidence that 
throughout the duration of the study :
Subjects will be able to attend study  visits, including rem ote vi sits, whilst avoi ding contact 
[CONTACT_245003] -19 pati ents (e.g. hospi[INVESTIGATOR_244875]); 
and
The site will be able to conduct the study  effect ively and safely , considering rel evant 
national and local factors; and
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 180of 217Subjects agree to alternate site visits or home visits as an alternat ive to on- site visi ts (if all owed 
by [CONTACT_73022]), if pandemic restrictions are in place.
Conclusion
Given the limited addit ional risks to the study  popul ation related to COVID -19, from study 
participat ion, beyo nd those they  woul d experi ence in every day life, the mi tigations descri bed 
above are considered sufficient to ensure a favourable benefit -risk balance.
Appendix J Medical Device AEs, ADEs, SAEs, SADEs, [LOCATION_003]DEs and 
Medical Device Deficiencies: Definitions and Procedures for 
Recording, Evaluating and Follow -up
This appendix supports the activit ies described in section 8.3.10
The definit ions and procedures detailed in this appendix are in accordance wit h 
International Organi zation for Standardizat ion [ZIP_CODE] and European Medical Device 
Regulation (MDR) 2017/745 for clinical device research (if applicable). 
Both the invest igator and the sponsor will comply with all local reporting 
requi rements for m edical  devices.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 181of 217The detecti onand docum entati on procedures described in this protocol apply  to all  
sponsor m edical devices provided for use in the study . See secti on 6.1.[ADDRESS_298151] of 
sponso r medical devices.
J 1 Definition of Medical Device AE and ADE
Medical Device AE and ADE Definit ion
An AE is any  untoward m edical occurrence in a clinical study  parti cipant, users, or other 
persons, temporally associated with the use of study intervent ion, wheth er or not 
considered related to the medical device. A Medical Device AE can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory  finding), symptom, 
or disease (new or exacerbated) temporally  associ ated wi th the use of a med ical device. 
This definit ion includes events related to the medical device or comparator and events 
related to the procedures invo lved.
An adverse device effect (ADE) is defined as an AE related to the use of a medical device. 
This definit ion includes any AE result ing from insufficient or inadequate instructions for 
use, depl oyment, implantation, installat ion, or operation, or any malfunction of the 
investigat ional medical device as well as any  event resul ting fro m use error or from 
intentional misuse of th e medical  device.
J 2 Definition of Medical Device SAE, SADE and [LOCATION_003]DE
A Medical Device SAE is any Medical Device adverse event that:
a.Led to death
b.Led to serious deterioration in the healt h of the participant, that either resulted in:
A life-threatening illness or injury. The term “life -threatening” in the definit ion of 
“serious” refers to an event in which the participant was at risk of death at the time of the 
event. It does not refer to an event, which hypothetically might have caused death if it 
were more severe.
A permanent impairment of a body  structure or a body  function.
Inpat ient or prolonged hospi[INVESTIGATOR_3094]. Planned hospi [INVESTIGATOR_95658] a pre -exist ing 
condi tion, or a procedure required by [CONTACT_760], without serious deterioration in healt h, 
is not considered an SAE.
Medical or surgical intervent ion to prevent life -threatening illness or injury  or perm anent 
impairment to a body  structure or a body  function.
Chronic disease (MDR 2017/745).
c.Led to fetal distress, fetal death, or a congenital anomaly or birth defect
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 182of 217SADE definition
A serious adverse device effect (SADE) is defined as an adverse medical device effect that 
has resulted in any o f the consequences characteristic of an SAE (e.g. needle st ick requiring 
surgi cal interventi on or battery  leakage chemical burn causing scaring).
Any medical device deficiency that might have led to an SAE if appropriate action had not 
been taken, intervent ion had not occurred, or circumstances had been less fortunate.
Unanticipated SADE ([LOCATION_003]DE) definition
An unant icipated serious adverse device effect ([LOCATION_003]DE) (also ident ified as UADE in 
[LOCATION_002] Regulat ions 21 CFR 813.3), is defined as a serious adverse medical device 
effect that by  [CONTACT_5942], incidence, severit y, or outcom e has not been i dentified in the cur rent 
versio n of the risk analysis report (see Section 2.3).
J [ADDRESS_298152] ions, use errors, and inadequacy in the information supplied by [CONTACT_245004].
J 4 Recording and Follow -up of AE and/or SAE and Medical 
Device Deficiencies
AE, SAE, and Medical Device Deficiency Recording
When an AE/SAE/medical device deficiency occurs, it is the responsibilit y of the 
investigator to review all documentatio n (e.g., hospi[INVESTIGATOR_1088], laboratory  reports, 
and diagnostics reports) related to the event.
The invest igator will then record all relevant AE/SAE/medical device deficiency 
inform ation in the participant’s medical records, in accordance with the in vestigator’s 
norm al clinical pract ice and on the appropriate form.
It is notacceptable for the invest igator to send photocopi[INVESTIGATOR_10914]’s medical 
records to Sponsor in lieu of complet ion of the AE/SAE/medical device deficiency form.
There m ay be instances when copi[INVESTIGATOR_244876]. In this case, all part icipant identifiers, with the exception o f the participant number, 
will be redacted on the copi[INVESTIGATOR_244877] n to Spons or.
The invest igator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical informat ion. Whenever possible, the diagnosis (not the individual 
signs/symptom s) will be documented as the AE/SAE.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 183of 217For m edical device d eficiencies, it is very  important that the invest igator describes any 
corrective or remedial act ions taken to prevent recurrence of the deficiency.
A remedial act ion is any action other than routine maintenance or servicing o f a medical 
device where such action is necessary to prevent recurrence of a medical device 
deficiency. This includes any amendment to the medical device design to prevent 
recurrence.
Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE/SAE/m edical device 
deficiency reported during the study  and assign it to one of the following categories: 
Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal disco mfort and 
not interfering wit h every day act ivities.
Moderate: An event that caus es sufficient discomfort and interferes wit h norm al everyday 
activit ies.
Severe: An event that prevents normal every day activi ties. An AE that is assessed as severe 
shoul d not be confused wit h an SAE. “Severe” is a category  used for rating the intensit y of
an event; both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definit ion of an SAE, notwhen it is rated as severe.
Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and each 
occurrence of each AE/SAE/medical device deficiency.
A “reasonable possibilit y” of a relationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relat ionship, rather than a relat ionship, cannot be ruled out.
The invest igator will use clinical judgment to determine the relat ionship.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal rel ationship of the event to study  intervent ion administration 
will be considered and invest igated.
The invest igator will also consult the IB in his/her assessment.
For each AE/SAE/medical device deficiency , the investi gator must document in the medical 
notes that he/she has reviewed the AE/SAE/medical device deficiency and has provided an 
assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the invest igator has minimal 
inform ation to include in the init ial report to Sponsor. Howev er, it is very  important that the 
investigator always make an assessment of causalit y for every  event before the init ial 
transmissio n of the SAE data to Sponsor.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 184of 217The invest igator may change his/her opi[INVESTIGATOR_3078] n of causalit y in light of fo llow-up inform ation 
andsend an SAE fo llow-up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  reporting 
requi rements.
Causalit y of ‘related’ is m ade if fo llowing a review of the relevant data, there i s evidence for 
a ‘reasonable possibilit y’ of a causal relat ionship for the individual case. The expressio n 
‘reasonable possibilit y’ of a causal relationship is meant to convey, in general, that there are 
facts (evidence) or arguments to suggest a causal re lationship.
The causalit y assessment i s perform ed based on the available data including enough 
inform ation to m ake an informed judgment. With no available facts or arguments to suggest 
a causal relat ionship, the event(s) will be assessed as ‘not related’.
Follow -up of AE/SAE/Medical Device Deficiency
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by [CONTACT_19514]/or causalit y of the AE/SAE/medical device deficiency as fully as 
possible. This may include addit ional laboratory  tests or invest igations, histopathological 
examinat ions, or consultation with other health care professio nals.
If a participant dies during participation in t he study or during a recognized fo llow-up 
period, the invest igator will provide Sponsor with a copy of any post -mortem findings 
including histopathology .
New or updated informat ion will be recorded in the originally co mpleted form.
The invest igator will su bmit any  updated SAE data to Sponsor within [ADDRESS_298153] completed to Q1 2024.
Secti on 2.3Benefit/Risk Assessment ,Added “Use of tezepel umab has been demonstrated to 
show an important benefit in asthma in a phase 2b and phase 3 study .”
Secti on 2.3Benefit/Risk Assessment , Added “Tezepel umab has been well tolerated with an 
acceptable safet y profile and no safet y signals in sub jects with severe, uncontrolled asthma 
ident ified in the completed studies to date. ”
Secti on
 2.3Benefit/Risk Assessment , Added “No seri ous allergic reacti ons or anaphylact ic 
reacti ons consi dered rel ated to tezepelumab were reported in the Phase [ADDRESS_298154] of 
this study , in conjunction wit h the performance o f the [COMPANY_008]’s routine
pharmacovigilance act ivities.”
Secti on
 4.1Overall Design , Added “Extension of the screening/run -in for any  other reason 
will be allowed only  upon approval  of the [COMPANY_008] Study  Physician (refer to section 
5.4)”
Secti on 4.1Overall Design , Added “
Subjects who have a blood eosinophil count <[ADDRESS_298155] f or blood eosinophils is 
perform ed not earlier than 4 weeks from the previo us testing. In case o f recent treatment 
with systemic corti costeroi ds, an interval o f ≥[ADDRESS_298156] dose is recommended. ”
Secti on 4.3Justificat ion for Dose , “Based on the efficacy  and safet y data, as well as 
exposure -response analysis, of the Phase 2b asthma study  CD-RI-MEDI9929- 1146, 210 mg 
Q4W SC was selected as the optimal dose of tezepelumab for adult and adolescent patients 
with severe asthma and is  tested in the Phase 3 studies in severe asthma” updated to “Based 
on the efficacy and saf ety data, as well as exposure -response analysis, of the Phase 2b 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 186of 217asthma study  CD-RI-MEDI9929- 1146, 210 m g Q4W SC was selected as the optimal dose 
of tezepel umab for adul t and adolescent pati ents wi th severe asthma and is  confirmed in the 
Phase 3 studies i n severe asthma”
Secti on 5.1Inclusion Criteria and Sect ion [IP_ADDRESS] Pregnancy Test , Added “Until FSH is 
docum ented to be wi thin menopausal range, treat the subject as WoCBP”.
Secti on 5.1Inclusion Criteria , Inclusio n 7 –Added “ See appendix F for ICS dose 
conversio n table.”
Secti on
 5.
2Exclusion Criteria , Exclusio n 22 -“Receipt of any marketed (eg, omalizumab) 
or any  invest igational mo noclonal  orpolyclo nal antibody  therapy  (eg, gamma gl obulin) 
taken for any  reason wi thin 6 m onths or 5 half -lives prior to Visit 1, whichever is longer.” 
updated to “Receipt of any marketed (eg, omaliz umab) or any  investi gational m onoclonal or 
polyclo nal antibody  therapy  (eg, gamma gl obulin) taken for any  reason wi thin 4 m onths or 
5 half -lives prior to Visit 1, whichever is longer.”
Secti on
 6.1.2 Medical Devices , Added Section 6.1.2 –Medi cal Devices: regarding sponsor 
manufactured medical device use in this study  and all medical device deficiencies should be 
docum ented and reported by [CONTACT_245005].
Secti on 6.5Concomitant Therapy , Table 5 –“Prohibited if taken for any  reason wi thin 6 
months or 5 half -lives (whichever i s longer) pri or to Visit 1 and during the study  (even if 
the subject has discont inued IP).” updated to “Prohibited if taken for any reason within 4 
months or 5 half -lives (whichever is lo nger) prior to Visit 1 and during the study (even if 
the subject has discont inued IP).”
Secti on
 8Study  Assessments and Procedures , 
Updated “The amount of blood collected 
from each subject over the duration of the study  (excluding optional blood samples) will be 
approximately  285 mL (including any  extra assessments that may be requi red) and will  not 
exceed 450 mL” to “The amount of blood collected fro m each subject over the duration of 
the study  (exc luding opti onal blood sam ples) will be approximately 360 mL (including any  
extra assessments that may be required) and will not exceed 450 mL”
Secti on 8.2.10 Vaccination Restrictions, Updated CDC guidelines reference fro m “2018 -
2019” to “2021
-2022”
Secti on 8.3Collect ion of Adverse Events, Add ed “The definit ions of medical device -related 
safet y events, can be found in Appendix J. Medical Device deficiencies are covered in 
section 8.3.10”
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 187of 217Secti on 8.3.7 Adverse Events Based on Examinat ions and Tests , Updated “COPD 
exacerbation should be recorded as an AE or SAE only if it fulfils any o f the above criteria” 
with “Worsening of COPD should be recorded as an AE or SAE only  if it fulfils any  of the 
above criteria.”
Secti on 8.3.10 Medical Device Deficiencies, Added Section 8.3.10 -definit ions of medical 
device deficiency and requirements to f ulfil regulatory  reporti ng obligat ions worldwide and 
investigator’s responsibilit y for detecti on and documentati on of  events m eeting the 
definit ion of device deficiency occurring during the study .
Secti on 8.4.4 Medicat ion Error , 
Removed “Medication errors with AZ IP are collected in all 
studi es where m edicat ion error is possible.  Refer to the PSSR or other appropriate project 
docum ent for specific considerat ions for collect ion of medicat ion errors. For guidance, refer 
to AZ SOP ‘Reporting of Individual Safet y Events in Clinical Studies’”
Secti on 8.5.1 Collection of Samples to Measure Drug Concentration , Added “Samples fro m 
patients who receive placebo will not be measured init ially but will be retained for 
subsequent analysis if deemed appropriate”
Secti on
 9.5Statistical Analyses , Replaced “All analyses of the primary  and secondary  
objectives will be performed based on the primary DBL data” with “Main analyses o f the 
primary , key  secondary  efficacy object ives and some supportive summaries will be 
perform ed based on both the primary  and final DBL data. The results produced at the time 
of primary  DBL will be used to facilitate further design development for Phase 3 only. 
Although no changes ar e ant icipated in conclusio ns given the primary  DBL occurs after all 
subjects complete the planned treatment period, any discrepancies in the conclusio ns 
between the two DBLs will be discussed in the CSR. The CSR will be produced fo llowing 
the final DBL.”
Section
 10References , 
Updated CDC 2010 guidelines link to
“https://www.cdc.gov/vaccines/hcp/acip -recs/vacc -specific/pneumo.html ”
Secti on 
10References , Rem oved ref erence for 2018- 2019 CDC guidelines and added 
refer ence for 2021 -2022 CDC guidelines.
Appendix
 A 1Regul atory  and Ethical Considerat ions, Added “The invest igator will be 
responsible for providing overs ight of the conduct of the study  at the si te and adherence to 
requi rements of 21 CFR, ICH guidelines, the IRB/IEC, European Regulat ion 536/2014 for 
clinical studies (if applicable), European Medical Device Regulation 2017/745 for clinical 
device research ( if applicable), and all other applicable local regulat ions.”
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 188of 217Appendix A 1Regul atory  and Ethical Considerat ions, Added “European Medical Device 
Regulation 2017/745 for clinical device research (if applicable), and all other applicable 
local regulati ons”
Appendix A 7Data Qualit y Assurance , Updated study  docum ents retention period from “15 
years” to “25 y ears”
Appendix C 3International Airline Transportation Associat ion (IATA) 6.2 Guidance 
Docum ent, Updat ed IATA classificat ion link to 
https://www.i ata.org/whatwedo/cargo/dgr/Documents/infect ious-substance -classificat ion-
DGR56 -en.pdf.
Appendix H Abbrevia tions, Added “ADE: Adverse Device Effect”, “SADE: Serious 
Adverse Device Effect” and “[LOCATION_003]DE: Unant icipated Serious Adverse Device Effect”.
Appendix J Medical  Device AEs, ADEs, SAEs, SADEs, US ADEs and Medical Device 
Deficiencies: Definit ions and Procedures for Recording, Evaluating and Fo llow-up, Added 
Appendix J –Medical Device AEs, ADEs, SAEs, ADEs, US ADEs and Medical Device 
Deficiencies: Definit ions and Procedures for Recording, Evaluating and Fo llow-up
Appendix K Protocol  Amendment Hi story, Added Appendix K –Moved protocol 
amendment history  to Appendix K.
Versi on 5.0, 15Mar 2021
Changes to the protocol are summarized below.
Secti on 1.1SoA, Table 1: removed ‘if applicable’ fro m ‘Chest x -ray (if applicable)’ to 
clarify chest x -ray is a mandatory  assessment.
Secti on 1.1SoA, Table 1, Footnote f, Footnote l, Section 4.1Overall Design, Section 5.4
Screen Failures and Re -Screening, Secti on 6.5.5 COPD Medicat ion Restri ctions on the 
Days of Scheduled Spi[INVESTIGATOR_244878] s, Section
 8Study  Assessments and 
Procedures, Section [IP_ADDRESS] General Requirements, [IP_ADDRESS] SARS -CoV -2 testing, 
Appendix I 6Benefit -risk assessment of starting recruitment during COVID -19 Pandemic: 
added ‘naso/orophary ngeal’ and ‘or rapid test’ to permi t flexibili ty with the method of 
SARS -CoV -[ADDRESS_298157] ion [IP_ADDRESS] SARS -CoV -2 Testing: clarified 
local ve rsus central  testing. Due to l ong turnaround times for central laboratory  SARS -CoV -
[ADDRESS_298158] been ma de to 
allow the option of SARS -CoV -2 testing to be performed locally.  
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 189of 217Secti on 1.1SoA, Table 1, Footnote a, Section 4.1Overall Design, Screening Period 
(Enrolment and Run -in), Section 6.5.5 COPD Medicat ion Restri ctionson the Days of 
Scheduled Spi[INVESTIGATOR_244879], Section 8Study  Assessments and Procedures: 
revised to clarify  assessments that m ust be done at Visit 1 and which assessments can be 
postponed based on the ty pe of  SARS -CoV -
2 testing performed. 
Secti on 1.1SoA, Table 1, Footnote g, Section 5.2Exclusio n Cri teria (Exclusio n 40), 
Secti on
 8.2.[ADDRESS_298159] X -ray: added ‘Under special circum stances, a recent ly done historical 
chest X -ray (anteri or-posterior and lateral)/CT/MRI for other reasons (not study related) 
might be acceptable. The outcome of the X -ray/CT/MRI m ust be docum ented in the 
patients’ medical records. Study  Physician a pproval  of histori cal chest X -ray must be 
obtained prior to randomization.’ This is to minimize the need for a subject who recently 
had a chest X -ray done for non -study  related reasons having to repeat a chest X -ray 
assessment during screening in the study (to limit radiat ion exposure).
Secti on 1.1SoA, Table 1, Footnote k, Section
 4.1Overall Design, Appendix I 1Pre-visit 
assessment during COVID -19 pandemic, I 6Benefit -risk assessment of re -starting 
recrui tment duri ng COVID
-19 Pandemic: extended the timeframe for complet ion of the 
COVID -19 screening assessment from 'wit hin 24 hours' to ‘within 72 hours’ prior to eve ry 
study  visit (except rem ote visits). The extensio n to [ADDRESS_298160] with subjects on the weekend may not be possible. 
Secti on 1.1SoA, Table 2, NOTE: revised the suggested order of assessments to be 
completed pri or to IP administrati on to, ‘ePRO, Vital signs, ECG, FeNO, spi[INVESTIGATOR_244880].’ Added clarificat ion, ‘Applicable during COVID -19 pandemic: Vital si gns, 
ePRO, ECG, FeNO, spi[INVESTIGATOR_244881]’ to be consistent with Table 1, Footnote f 
order of assessments. Vital signs should be performed first to ensure that the patient does 
not have a fever before performing other assessments.
Secti on 1.1SoA, Table 2, Sputum cell pellet: revised wording to ‘cell counts and/or RNA 
transcri ptomic profiling’ to allow flexibilit y due to parti al sputum  processing
Secti on 1.1SoA, Table 2, Footnote f, Section [IP_ADDRESS] Post-PD Spi[INVESTIGATOR_96656] : rem oved ‘X’ for 
post-BD spi[INVESTIGATOR_244882] -BD spi [INVESTIGATOR_244883]-study  section. Also for footn ote f, ‘post -BD’ removed a nd added clarificat ion to 
pre-BD spi [INVESTIGATOR_244884] i t will be performed at EXA visit as part of induced sputum 
procedures ‘during treatment phase’. 
Secti on 1.1SoA, Table 2, Footnote k, Section 8.8.[ADDRESS_298161] ion, Secti on
 8.8.6 Nasal 
Lining Fluid: rephrased statement regarding spu tum and nasal sample collect ion during the 
COVID -19 pandemic to the fo llowing, ‘During the COVID -[ADDRESS_298162] ki ts are available,’ since [COMPANY_008] approves the 
continuat ion of sampling as the study  has resum ed recrui tment.
Secti on 1.2Synopsis, Section 4.1Overall Design: removed ‘During the COVID -[ADDRESS_298163] ease refer to Appendix I,’ from 
Secti on 1.2, and removed ‘During COVID -19 pandemic, sputum samples will not be 
collected from subjects in treatment phase unt il the pandemic normalizes and AZ approves 
the continuat ion of sampling. Please refer to Appendix I,’ fro m Secti on 4.1, since 
[COMPANY_008] approves the continuat ion of sampling as the study  has resumed recruitment.
Secti on
 1.1SoA, Table 2, Footnote q: added ‘(in treatment or in fo llow-up)’ to cl arify that 
the SARS -CoV -[ADDRESS_298164] ives and Endpoints, Section 4.1Overall Design: 
updated study  rando mization fro m approximately ‘282’ to ‘338’ subjects due to sample size 
reassessment as a suggestion of the IDMC fo llowing interim analysis to account for a 
possible decrease in COPD exacerbat ions related to the COVID pandemic and social 
distancing.
Secti on 1.2Synopsis, Section
 3Object ives and Endpoints: updated the estimated date of 
last subject completed to Q2 [ADDRESS_298165] ives: added clarificat ion ‘during treatment phase’ to the obj ective ‘to evaluate the 
effect of tezepelumab on sputum bio markers, sputum cell counts and sputum microbio me, 
in subjects parti cipat ing in sub -study , at baseline, end of treatment, and at the start of all 
exacerbations.’ 
Secti on
 1.3Schema, Figure 1: revised sample size to ‘169’ per treatment arm per sample 
size revisio n in Sect ion 9.2.
Appendix I 1Pre-visit assessment during COVID -19 pandemic: added clarificat ion, 
‘During the call, subject should be instructed to contact [CONTACT_245006] -site study  visit, if 
subject experiences any  COVID -19 symptom s or was exposed to someone diagnosed with 
COVID -19’.  
Secti on 4.1Overall Design, Screening Period (Enrolment and Run -in): 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 191of 217added cl arificati on to the 35 -day run-in can be extended by: ‘wait ing time required to obtain 
Visit 1 SARS -CoV -2 naso/oropharyngeal swab test (or rapid test) result’ and ‘28 days for 
patients receiving COVID -19 vaccine during screening’. 
Added clarificat ion to the 35 -day run-in can be extended by: ‘28 days for wait ing time 
requi red to receive central lab kits’ if central laboratory  kits are unavailable. 
Secti on 4.1Overall Design, Rando mizat ion, Treatm ent and Fo llow-up: added cl arificat ion 
on requirements of signing COVID -19 addendum to informed consent prior to starting 
alterative opti ons of  on-site IP administrati on; option of phone call visit is included in the 
main informed consent 
Secti on 5.2Exclusion Criteria:
updated Exclusio n 5: removed ‘or screening perio d’ to be consistent with Section 5.4.  Also 
added cl arificati on, ‘Note: Refer to Ex clusion cri teria [ADDRESS_298166] ion with maintenance 
systemic steroid treatment.’ 
updated Exclusio n 19: added ‘systemic’ to ‘Use of sy stemic immunosuppressive 
medicat ion’ to further clarify .
updated Exclusio n 24: ‘Chronic use o f macro lide or other antibio tics for prophylact ic use of 
COPD exacerbat ion if duration of treatment is < 9 mo nths prior to enrolment (Visit 1) or re -
screening visit. If the patient was previously on prophylact ic treatment but is no longer 
taking it, the patient cannot be randomized u ntil [ADDRESS_298167] dose. Chronic 
macro lide or other antibiotic therapy is allowed provided the patient has been on a stable 
dose/regimen for ≥ 9 m onths pri or to enrolment (Visit 1) or re -screening visit and have had 
at least [ADDRESS_298168] ic treatment.’ This reference 
was updated from randomization to enrolment visit to correct inconsistency between 
Inclusio n 6 and Exclusio n 24.
updated Exclusio n 39: added ‘naso/oropharyngeal’ and ‘or posit ive rapid ant igen test ’ to 
SARS -CoV -2 testing methods, to be consistent with other protocol updates concerning 
allowable methods of testing.
added Exclusio n 41 ‘Receipt of any COVID -19 vaccine 28 days prior to date of 
rando mizat ion.
Secti on 6.1.2 Preparation/Handling/Storage/Accountabilit y: 
added ‘The subject received COVID -[ADDRESS_298169] ion 8.2.10, Table Table 8cannot be fo llowed,’ to be consistent with 
COVID -[ADDRESS_298170] ics of the IP to specify  more details related to appearance and 
clarity of the IP.
Secti on 6.3Measures to Minimize Bias: Updated vendor name [CONTACT_245013], fro m  to  due to company  name [CONTACT_48599].
Secti on 6.5Concomitant Therapy :
Added ‘fo llow-up peri od’ to paragraph describing subject’s usual pre -study  triple inhaled 
therapy , to align wit h Section 6.5.1.
Added for eCRF entry , ‘COVID -19 vaccine gi ven at any  time’, to align with Table Table 6
revisio ns.
Table Table 6–Allowed, Restri cted, and Prohibited Medicat ions: 
systemic corticosteroids (tablets or inject ions), revised details to ‘Allowed to treat a COPD 
exacerbation or an AE where there is no alternat ive treatment available, for no more than 14 
days’ to further clarify the restrict ions on use of systemic corticosteroids.
added ‘COVID -19 vaccinations’ restrict ions 
replaced ‘any’ wit h ‘systemic’ in Systemic immunomodulators and immunosuppressive 
medicat ion and rem oved ‘maintenance systemic steroid treatment’ from ‘any  
immuno modulators and immunosuppressive medication (including but not limited to 
methotrexate, cy closporine, any  experimental  anti-inflammatory  therapy )’. Also in details, 
added ‘refer to Sy stemic corti costeroi ds (tabl ets or inject ions) for further restrict ions’. This 
is to further clarify the restrict ions on use of systemic corticosteroids.
Secti on
 7.3Withdrawal  from the Study , Secti on 8.8.1Storage, Re -use and Destruction of 
Biomarker Sam ples: For the statement that indicates, if the subject only wit hdraws consent 
for retenti on of  biological samples for future exploratory  use, it has been revised to include 
a broadened definit ion of future use. 
Secti on [IP_ADDRESS] COPD Exacerbat ion Visit: added section ‘Only for sputum sub -study  
subjects: Perf orming COPD Exacerbat ion visit (EXA) for sputum sub -study  patients is 
essent ial to evaluate exploratory  sputum  and nasal sub -study  endpoints during treatm ent 
phase. Refer to Section 3. Patients participat ing in sputum sub -study  are requi red to perform  
pre-BD and sputum post -BD spi[INVESTIGATOR_244885], at EXA visits during 
treatm ent. Induced sputum is preferred however spontaneous sputum is acceptable if pat ient 
[COMPANY_003]
[COMPANY_003]
Clinical Study Protocol -7.[ADDRESS_298171] ion of induced sputum is not
permitted per local Healthy and Safet y regulati ons or gui dance during the COVID -19 
pandemic. Please refer to applicable sub -study  manual for m ore informat ion.’ for 
clarificati on.
Secti on [IP_ADDRESS] Post-BD Spi[INVESTIGATOR_038] : updated to allow SABA administration to start earlier 
(less than 15 minutes of the final pre- BD spi [INVESTIGATOR_038]) if needed for safety  reasons.
Secti on [IP_ADDRESS] Sputum Post -BD Spi[INVESTIGATOR_038] , Section 8.8.[ADDRESS_298172] ion, Secti on 8.8.6 Nasal Lining 
Fluid:: added ‘applicable’ to manual to allow for full or partial processing manual. 
Secti on 8.2.1 Clinical Safety Laboratory Assessments: added language to allow for local 
laboratory  testing of safet y samples (clinical chemistry , hematol ogy and urinalysis) at the 
discreti on of  the PI [INVESTIGATOR_244886]. Also indic ated that all 
laboratory  assessments for Vi sit 1, Vi sit 3, and EoT or IPD Visit (as per SoA) must be 
analysed at the central laboratory . Also, added sub -section ‘Maintaining the blind to the 
patient’s bl ood immunogl obulin, eosinophil, basophil and mo nocy tecounts’ with 
procedures to mit igate unblinding.
Secti on 8.2.5 Vital Signs, [IP_ADDRESS] Vital signs: removed ‘pre -dose’ fro m vital signs 
descript ion as vital signs assessments are also required at follow -up visi ts.
Secti on 8.2.10 Vaccinatio n Restrictions: updated section name [INVESTIGATOR_39736] m ‘Pneumococcal and 
Annual Influenza Vaccination’ to ‘Vaccinat ion Restri ctions’ and added sub -section 
‘COVID Vaccinat ion’ to include COVID -[ADDRESS_298173] ions.
Secti on [IP_ADDRESS] Maternal Exposure, [IP_ADDRESS] Paternal Exposure, B 2Definit ions of Serious 
Adverse Event: revised wording related to congenital ano malies (‘congenital ano maly’ 
instead of ‘congenital abnormalit y’) to be consistent with wordin g provi ded in new clinical 
study  protocol  template.
Secti on 8.8.[ADDRESS_298174] ion
added new guidance for partial sputum processing, ‘Depending on individual site capa bility, 
sputum  processing will fo llow one of two sputum processing protocols (full processing or 
partial processing). Sputum  sample processing will result in the production of cy tospin 
slides (for full sputum processing only ), microbi ome sample, cell pelle ts for RNA 
transcri ptom e, and ali quots of sputum  supernatant. The clinical sites performing full sputum 
processing procedures will also generate and record total cell count and cell viabilit y data 
on their sputum processing worksheets.’
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 194of 217added cl arificati on, ‘For other sub -study  visit s, sputum  sub-study  samples will be co llected 
if sub -study  laboratory  kits and supplies are available within visit window. In the event of 
missing supplies, sites should make reasonable effort to collect and process samples wher e 
feasible, and with the approval of Study  Physician.’ 
Secti on 8.8.6 : added clarificat ion for nasal lining fluid samples that will be obtained in 
accordance with the schedule provided in Table 2 in a subset of subjects only participating 
in the sub -study , ‘if nasal lining fluid sampling supplies are available.’
Secti on 9.2Sample Size Determinat ion: revised into two sections, ‘Original Sample Size’ 
and ‘Updated Sample Size’ and added ‘The sample size has been reassessed due to the 
potenti al for reduced exacerbat ion rates due to limited person -to-person contact [CONTACT_245007] [INVESTIGATOR_244887] -[ADDRESS_298175] (0.7) and dispersio n parameter (0.6) as originally  assumed, a sample size of 
169 subjects per treatment arm (338 overall) will maintain the study  power if the place bo 
exacerbation rate is as low as 1.2 exacerbat ions/subject -year.’
Secti on 9.2.1 Estimands: presentation of the primary  and supplemental estimands has been 
updated t o more clearly specify the [ADDRESS_298176] imand has been amended 
(previously  addressed by  [CONTACT_63689] -treatm ent estimand detailed in the SAP only). 
Secti on
 [IP_ADDRESS] Forced Expi[INVESTIGATOR_21581] 1 Second: removed, ‘If the Visit [ADDRESS_298177] non- missing pre -bronchodilator value 
before Visit 3 will be used as baseline instead.’ to be consistent with Section 9.4.1.  
Appendix A 7Data Qualit y Assurance: Added clarificat ion describing detai ls of mo nitoring 
strategy , including rem ote m onitoring.
Appendix F Maintenance Therapy Equivalence Table: added to support Inclusio n 7 
criterion assessment. 
Appendix H Abbreviat ions: added ‘EUA: Emergency Use Authorizat ion’ as newly 
referenced in Sect ion 8.2.10.
Throughout CSP:
removed references associating ba seline assessments with Visit 3. The association has been 
redefined as fo llows, “rando mization” or “rando mization visit” for efficacy related 
assessments, and “first IP administration” for safety related assessments, to remove 
ambiguit y. 
Clinical Study Protocol -7.[ADDRESS_298178] 2020
Changes to the protocol are summarized below.
Secti on 1.1SoA, Table 1:
Added pre -visit assessment: telephone assessment of possible COVID -19 symptoms, to 
visits 1 and 2. Also, added footnote k ‘During the COVID -[ADDRESS_298179] be 
contact[CONTACT_244922] -19 screening assessments within 24 hours prior to every 
study  visit (except rem ote visits). Refer to Appendix I for details.’ This is to minimize the 
risk of subject performing study  visits with active COVID -[ADDRESS_298180] ion.
Added study  procedure: COVID -19 addendum to ICF (if applicable). Also, added footnote 
m ‘During re -consent ing of subjects during the COVID -[ADDRESS_298181] be fo llowed. Refer to Appendix I for further details’. This is to minimize 
the risk of enro lling subject who do not agree to any alternat ives when on -site visi t is not 
possible due to COVID -19 pandemic’.
Added laboratory  assessment: SA RS-CoV -[ADDRESS_298182] to Visit 1. Also, 
added footn ote l ‘Central  laboratory  SARS -CoV -[ADDRESS_298183] be 
available and negat ive prior to performing screening lung function assessments and ECG 
(refer to 1.1footnote a)’. This is to minimize the risk of subject complet ing lung funct ion 
assessments with act ive COVID -19 infection.
Footnote a: updated to ‘The screening lung funct ion asse ssments and ECG m ust be 
postponed unt il the Visit [ADDRESS_298184] -BD 
spi[INVESTIGATOR_038], FeNO and ECG (combined Visit 1 and Visit 2) to be performed. Visit [ADDRESS_298185] result. Lung assessments can only be done if there are no 
restri ctions to medicat ions (refer to Section 6.5.5 and 8.1.3 ).’ This is to minimize the risk of 
subject complet ing lung function assessments with active COVID -19 infection.
Footnote c: removed ‘Sponsor and’ fro m ‘the Sponsor and sites will be blinded to the FeNO 
values for the who le study  durati on’ and added ‘The sponsor will be blinded to the FeNO 
values except at screening visit, at any  repeat testing that i s perform ed duri ng the screening 
Clinical Study Protocol -7.[ADDRESS_298186] (IP) administration at Visit 3.’ Sponsor only 
needs to be blinded to the FeNO values after randomizat ion. 
Footnote f: added ‘IMPORTANT: Applicable during COVID -19 pandemic: the suggested 
order o f assessments: vital signs, ePRO, blood draws and SARS -CoV -[ADDRESS_298187] result is available and negat ive.’  This 
is to minimize the risk of subject complet ing lung funct ion assessments with active COVID -
[ADDRESS_298188] ion.
Footnote g: updated to specify that for all subjects enro lled during COVID-[ADDRESS_298189] X -ray assessment 
prior to randomizat ion. This is to minimize the risk of enrolling subjects with COVID -19 
pneumo nia or other lung pathology .
Secti on 1.1SoA, Table 2:
Added pre -visit assessment applicable during COVID -19 pandemic: telephone assessment 
of possible COVID -19 symptoms, to every  visit. Also, added footnote p ‘ During the 
COVID -[ADDRESS_298190] be contact[CONTACT_244922] -19 screening 
assessments within 24 hours prior to every  study  visit (except rem ote visi ts). Refer to 
Appendix I for details.’ This is to minimize the risk of subject performing study  visits with 
active COVID -[ADDRESS_298191] ion.
Added assessment applicable during COVID -19 pandemic: SARS -CoV -[ADDRESS_298192] to 
Visit 3 and footnote q to cl arify that ‘SARS -CoV -[ADDRESS_298193] should be done as 
soon as possible but preferably at the next site visit’. This is to determine whether subjects 
have been prev iously infected wi th SARS -CoV -2 for safet y reasons (e.g. assessment of 
adverse events during study  parti cipat ion). 
Footnote c: removed ‘Sponsor and’ fro m ‘the Sponsor and sites will be blinded to the FeNO 
values for the who le study  durati on’ and added ‘Th e sponsor will be blinded to the FeNO 
values except at screening visit, at any  repeat testing that i s perform ed during the screening 
period and pri or to Invest igational Product (IP) administration at Visit 3.’ Sponsor only 
needs to be blinded to the FeNO v alues after randomizat ion. 
Footnote k: updated to clarify that during the COVID- 19 pandemic, sputum and nasal 
sampling will not be collected from subjects in treatment phase unt il the pandemic 
norm alizes and AZ approves the continuat ion of sampling. 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 197of 217Adde d footnote r: ‘Randomizat ion transact ion in IWRS should be completed after 
confirmat ion of subject eligibilit y’. This is to further clarify  the order of assessments and 
prevent randomizat ion in error.
Secti on 1.2Synopsis: updated the estimated date of last subject completed to Q4 [ADDRESS_298194] occurred due to putting recruit ment on hol d during COVID -19 pandemic.
Secti on 4.1Overall design: 
Added ‘Pre -visit assessment during COVID -19 pandemic: Subjects must be contact[CONTACT_245008]- 19 symptom s within 24 hours pri or to every  
study  visit (except rem ote visits). Please refer to Appendix I for details’. This is to minimize 
the risk of subject complet ing study  procedures wi th active COVID -19 infection.
Screening Period (Enrolment and Run -in): removed ‘Run -in Visit 2 should be init iated no 
later than 1 week after Enrolment at Visit 1’ and added ‘The screening lung funct ion 
assessments and ECG must be postponed until the Visit [ADDRESS_298195] -BD spi [INVESTIGATOR_038], FeNO and ECG (combined Visit 1 and 
Visit 2) to be perform ed. Visi t [ADDRESS_298196] resul t.’
Secti on 4.1Overall design and Section 5.1Inclusion 6: Added a note f rom section 5.4on 
how historical COPD exacerbations should be reported in case of re -screening, for further 
clarificati ons. 
Secti on 5.1Inclusion 12: removed wit h versio n 4.[ADDRESS_298197] aced 
with Exclusio n criterion 40.
Secti on 5.2Exclusion Criteria: added Exclusio n criterion [ADDRESS_298198] ion.
Secti on 5.2Exclusion Criteria: added Exclusio n criterion [ADDRESS_298199] ive COVID -19 infection.
Secti on 5.2Exclusion Criteria: added Exclusio n criterion [ADDRESS_298200] X -ray performed during the screening period which shows 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 198of 217abnorm alities or evi dence o f COVID -19 pneumo nia that p recludes the patient’s abilit y to 
complete the study . 
Secti on 5.4Screen Failures and Re -screening: Added situations, applicable during COVID -
[ADDRESS_298201] be screen failed: 
‘Judgement by  [CONTACT_245009]- [ADDRESS_298202] can be re -
screened within 2 to 4 weeks upon approval of the AZ Study  Physician (exclusion criterion 
38)’. 
‘Subject who had positive SARS -CoV -[ADDRESS_298203] ion, upon approval of the A Z Study  Physician (exclusio n criterion 39)’. 
Secti on 5.4Screen Failures and Re -screening: Remo ved ‘and only  once’ under re -screening 
requi rements as subject screen failed due to COVID -[ADDRESS_298204] for any reason will be allowed only  upon approval  of the AZ Study  
Physician.
Secti on 6.1.2 Preparation/handling/storage/accountabilit y, Dose Administrati on – added 
situations, applicable during COVID -19 pandemic, when IP should not be administered: if 
the subject has suspected or confirmed act ive COVID- [ADDRESS_298205] ion.
Secti on 6.4Com pliance to IP: added ‘with the reason for drug interruption’ to ‘The date and 
time of all IP administrations, as well as any missed doses with the reason for drug 
interruption, shoul d be recorded in the appropriate sect ion of the eCRF’ to further clarify 
eCRF reporti ng requirements.
Secti on 6.5.5 COPD Medication Restrictions on the Days of Scheduled Spi[INVESTIGATOR_244888]: updated instructions for Screening Visit 1 and Visit 2 to ‘the screening lung 
funct ion assessments must be postponed until the Visit [ADDRESS_298206] result is available and negative (refer to SoA Table 1)’ At the postponed Visit 1, 
the spi[INVESTIGATOR_244889] w pre -and post -BD spi [INVESTIGATOR_244814] (combined 
Visit 1 and Visi t 2) to be perform ed. Vi sit [ADDRESS_298207] m eet the COPD m edicat ions restri ctions in order to perform the lung assessments.’ 
Clinical Study Protocol -7.[ADDRESS_298208] ion. 
Secti on 6.5.7 COPD Medication Restrictions at Centre Visits with Scheduled ECG 
Assessment: removed ‘Medicat ions do not have to be wit hheld for the ECG performed at 
any time between Visit 1 and Visit 2 inclusive’ as medicat ion wash out during enro lment is 
a requirement.   
Secti on 8 Study  Assessments and Procedures: added ‘During COVID-19 pandemic, the 
suggested order of screening assessments is: Vital signs (starting with body  temperature 
measurement), ePRO, blood draws and SARS -CoV -[ADDRESS_298209] result is available and negat ive’. This is to 
minimize the risk of subjects complet ing study  assessments with COVID -[ADDRESS_298210] ion.
Secti on [IP_ADDRESS]   Spi[INVESTIGATOR_038], General Requirements: added sub -section ‘Applicable during 
COVID -19 pandemic: The screening lung function assessments must be performed only 
when Visit [ADDRESS_298211] result is available and negat ive (refer 
to footnote a and footnote l under Table 1, sect ion  1.1and to section 6.5.5 ). SARS -CoV -[ADDRESS_298212] be obtained before conducting visit assessments’ This is to minimize 
the risk of a subject complet ing lung function assessments with ac tive COVID -[ADDRESS_298213]-BD Spi[INVESTIGATOR_038] : added ‘postponed’ to ‘Visit 1’ for clarificat ion. 
Secti on 8.1.3 FeNO: removed vis it [ADDRESS_298214] of visits prior to randomizat ion, for whi ch the 
FeNO values will be unblinded for the sponsor. 
Secti on 8.1.4 COPDCompEx: added ‘systemic’ replacing ‘ oral’ to corti costeroi ds to further 
clarify medicat ion type. Also, rem oved ‘wheeze’ as a diary  variable as i t is not used in the 
analysis of COPDCo mpE x.
Secti on [IP_ADDRESS] St. George’s Respi[INVESTIGATOR_96692] (SGRQ) and Section [IP_ADDRESS] COPD 
Assessment Test (CAT): Removed ‘during the COVID -19 pandemic due to local 
restri ctions’ and added reference to Appendix I . 
Secti on 8.2.5 Vital Signs: added instructi ons that ‘body  temperature shoul d be done as the 
first study assessment (at Vi sit 1 when ICF i s obtained)’ and ‘Subject with fever ( ≥ 38°C; ≥ 
100.4°F) suspected du e to COVID -19 infection during screening or at rando mizat ion (Vi sit 
3) should be screen failed (Exclusio n criterion 38). IP should not be administered if the 
Clinical Study Protocol -7.[ADDRESS_298215] is febrile ( ≥ 38°C; ≥ 100.4°F) or is suspected of having COVID- 19.  Refer to section 
6.1.2 ’. 
Secti on 8.2.[ADDRESS_298216] scan or MRI: section tit le update to ‘Sect ion 8.2.[ADDRESS_298217] ion was updated to ‘a chest X -ray done during the screening period before 
rando mizat ion visit (Visit 3) is required to ensure there are no abnormal radio logical 
findings as per exclusion criterion 14 and exclusio n criterion 40.’ This is to minimize the 
risk of enrolling subjects with COVID -19 pneumo nia.
Secti on [IP_ADDRESS] SARS -CoV -2 testing: added a new section to describe tests that are 
applicable during the COVID -[ADDRESS_298218] ion: 
updated to clarify  spontaneous sputum  may also be used as a secondary  option for outcom e 
measures if induced sputum is not permitted per local regulatio ns or gui dance during 
COVID -19 pandemic.
added ‘addit ional local or nati onal regulat ions or guidance must be fo llowed for sputum  
processing during COVID -19 pandemic’.
Secti on 9.3Populat ions for Analyses: revised PK analysis set descript ion from ‘all subjects 
who received at least one dose of tezepelumab and have PK blood samples…’ to ‘all 
subjects who received at least one dose of tezepelumab and have at least one de tectable 
serum  concentrati on post first dose…’ to be consistent with other studies in tezepelumab 
clinical program.
Appendix H Abbreviat ions: added SARS -CoV -2 (Sever e Acute Respi [INVESTIGATOR_244890] 20 and CDC (Centers for Disease Control and Prevent ion)
Appendix I Coronavirus (COVID -19) Pandemic Guidance: 
Clarified that sputum and nasal samples will not be collected fro m subjects in treatment 
until the pandemic normalizes and AZ approves the continuat ion of sampling. Sputum and 
nasal sampling will be performed, if allowed per local regulations and guidance.
Added a new se ction I 1to describe the pre -visit assessment applicable during COVID -[ADDRESS_298219] ion I 6to describe the benefit/risk assessment of re -starting recruit ment 
during COVID -[ADDRESS_298220] been made.
Versi on 3.0, 26 May 2020
Changes to the protocol are summarized below.
Secti on 1.1 SoA, Tabl e 1:
Footnote b: clarified that screening phase can be extended up to 14 days to meet FeNO 
restri ctions (refer to section 5.4).
Footnote c: clarified that the sponsor and site will be blinded to the FeNO values for the 
whole study  durati on to minimize the possibilit y that changes in FeNO levels might unblind 
the subject, ie indicate to th e site/sponsor that the subject was on tezepelumab rather than 
placebo. 
Footnote j: added that inact ive/killed vaccinat ions e.g. influenzae should be wit hheld 3 
weeks prior to EOT visit for patients in the sub study  (if no safet y concerns) as it might 
influence exploratory  sputum  analysis.
Secti on 1.1 SoA, Tabl e 2:
Added ‘Healt hcare resource utilizat ion’ to Follow up visits [ADDRESS_298221] a 
typographical error in the SoA. 
Footnote b: clarified that exacerbation (EXA) visit is an optional visit and m ay be init iated 
when pat ient experiences COPD exacerbat ion.’
Footnote c: clarified that the sponsor and site will be blinded to the FeNO values for the 
whole study  durati on to minimize the possibilit y that changes in FeNO levels might unblind 
the subject, ie indicate to the site/sponsor that the subject was on tezepelumab rather than 
placebo.
Footnote e: clarified that during COVID -19 pandemic, spi[INVESTIGATOR_244891].
Footnote k: clarified that during COVID -[ADDRESS_298222] consented to the sub study  until the pandemic stabilizes 
and AZ approves the continuat ion of sampling. This is to limit the possibilit y of COVID -19 
spread to subjects and site staff.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 202of 217Footnote l: clarified that during COVID -19 pandemic: IP administration can be performed 
at the subject’s ho me or alternat ive location along with study  assessments. This step is taken 
to limit subject exposure to COVID -19. Also, the laboratory  asses sments can be co mpleted 
post IP administration, to allow addit ional time for processing of the safet y samples at si te 
according to the laboratory  manual . 
Added Footn ote m : to cl arify that during re -consenting of trial subjects during the COVID -
19 pandemic , local/regional guidelines m ust be fo llowed wi th regard to verbal informed 
consent. Pl eases refer to Appendix I . Also, added ‘COVID -19 addendum to ICF (if 
applicabl e)’ as assessment to Table 2.
Added Footn ote n: to cl arify that during the COVID -[ADDRESS_298223] exposure to COVID -
19.
Added Footn ote o: These assessments can be replaced by  a phone visit during COVID -19 
pandemic. Please refer to Appendix I . This is to limit the possibilit y of COVID- 19 spread to 
subjects and site staff.
Secti on 1.2Synopsis and Section 3 Objectives and Endpoints: Evaluat ing the effect of 
tezepel umab on the frequency, duration and severity  of EXACT -PRO defined events has 
been added a s an expl oratory  object ive (with the rate of EXACT -PRO defined 
exacerbations and the EXACT -PRO defined exacerbat ion rate ratio (tezepelumab vs 
placebo) as the outcome variable and measure respectively). Previously  these data were 
being recorded but not ana lysed.
Secti on 1.2 Synopsis and Section 4.1Overall design, Section 6.3 Measures to minimize 
Bias: Corrected ty po in the target of subjects based on eosinophils co unt to: approximately  
20% of the subjects with ≥300 eosinophils/ μL, 40% of the subjects between ≥150 to <300 
eosinophils/μL and a maximum o f approximately  40% of  the subjects with <150 
eosinophils/μL at enrolment.’ 
Secti on 1.2 Synopsis, Overall design and Section 4.1 Overall design: clarified that ‘During 
the COVID -19 pandemic, sputum and nasal samples will not be collected fro m subjects in 
treatm ent phase, unt il the pandemic normalizes, and AZ approves the continuat ion of 
sampling. Please refer to Appendix I .’ This is to limit the possibilit y of COVID- 19 spread to 
subjects and site staff.
Secti on
 4.1Overall design: 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 203of 217Screening Period (Enrolment and Run -in): added ECG as assessment that cannot be 
perform ed during screening wit hout m eeting wash -out requirement due to ECG device 
settings to ‘If the subject does not meet the COPD medicat ions restri ctions at Visit 1, the 
lung funct ion assessments (Spi[INVESTIGATOR_038] , FeNO) and ECG should be postponed and 
perform ed no l ater than one week after Visit 1.’.
Randomization, Treatment and Fo llow-up: cl arified that ‘If allowed by [CONTACT_5737]/regional 
guidance during the COVID- [ADDRESS_298224] an on -site visi t and 
on-site IP administration can be replaced with home/alternat ive location IP administration. 
Patient m ust si gn the COVID -19 addend um to info rmed consent form  prior to starting these 
alternat ive options. If obtaining signed addendum is not feasible, patient can fo llow 
alternat ive options after verbal consent ing. Please refer to Appendix I for details.’ These 
steps are being taken to limit subject exposure to COVID -19 with clinic visit s.
Randomization, Treatment and Fo llow-up: cl arified that COPD exacerbat ion visit (EXA) is 
optional visit.
Secti on 4.1Overall Design, Section 9.2Sample Determinat ion,
 9.6Interim Analysis: The 
futilit y analysis was originally planned to occur when 182 patients had been 
rando mized. As a result of the pause in recruit ment due to COVID -19, the futil ity analysis 
is now planned to occur when approximately 30% of informat ion has been achieved.  This 
time point has been chosen on the recommendat ion of the Independent Data Monitoring 
Committee (IDMC) chair.
Secti on
 5.1Inclusion 6: updated to clarify that in case of re -screening, historical COPD 
exacerbation fro m period wi thin 2 to 52 weeks prior to re -screening Visit 1 should be 
included.
Secti on 5.1Inclusion 8 and 18: updated to clarify that CAT score only based on ePRO 
questionnaire should be used for assessing pat ient eligibilit y.
Secti on 5.1 Incl usion 19: updated to cl arify that only  screening Visi t 1 pre -BD result can be 
used for assessing FEV1 screening variabilit y due to spi [INVESTIGATOR_244892] ‘Stable 
FEV1 during the screening period, defined as a change in pre -BD FEV1 ≤400 mL and/or 
≤25% com pared to baseline pre -BD (Vi sit 1) assessment’ (i .e. Incl usion [ADDRESS_298225] not changed).
Secti on
 5.4Screen Failures and Re -screening:
Updated to clarify  in which si tuations, the screening may be extended wit hout pri or 
approval  form [COMPANY_008] Study  Physician and added that ‘Extensio n of the screening 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D524 1C00001
CONFIDENTIAL AND PROPRIETARY Page 204of 217period for any  other reason will be allowed only upon approval of the [COMPANY_008] Study  
Physician.’
Added clarificat ion that ‘Subje cts wi th respi [INVESTIGATOR_103415] (excluding pneumo nia) NOT 
requi ring ant ibiotics or antiviral medicat ion during the screening period: May  remain in 
screening and the screening period may  be extended up to [ADDRESS_298226] to meet 
FeNO restrictions.’
Added guidance on how to proceed with re- screening of subjects that were screened failed 
due to the COVID -19 pandemic and were re -screened once since re -screening is only 
allowed once. 
Secti on 6.1.2 Preparation/handling/storage/accountabilit y, Dose Administrati on – added 
“Please Note: During the COVID- 19 pandemic, if allowed by [CONTACT_5737]/regio nal guidelines, IP 
preparati on and administration may be performed at the subje ct’s ho me/alternat ive location 
by a qualified HCP. Please refer to Appendix I for further details” at the end of the sect ion 
to accommodate for home/alternat ive location visit s. Thi s opti on is being incl uded to limi t 
subject exposure to COVID -19 with clini c visi ts.
Secti on 6.5Concomitant Therapy  Table
 Table 6: 
SABA and SAMA co mbination products are added as ‘Allowed for rescue medicat ion and 
treatm ent of acute COPD exacerbat ion and prohibited if administered as maintenance 
medicat ion or in a scheduled dose’ as patients might be on SABA and SAMA co mbinat ion 
produ ct. 
For om alizumab, denosumab or any  other m onocl onal or polyclo nal ant ibody  therapy , 
added cl arificati on that m edicati ons are prohibited during the study  even if the subject has 
discontinued IP.
For cl arificati on, added Immunom odulators as prohibited med ication to ‘Any 
Immunomodulators and immunosuppressive medication (…)’. Also, updated restrictions 
condi tions: medicat ions [ADDRESS_298227] ive/killed vaccinat ions, added restrict ion ‘3 weeks prior to EOT visit for sub -study  
subjects o nly’ as it might influence exploratory sputum analysis.
Secti on
 6.5.5 COPD Medication Restrictions on the Day s of Scheduled Spi[INVESTIGATOR_244888]: 
For cl arifica tion, added note that screening (Visit 1 and Visit 2) and randomization (Visit 3) 
spi[INVESTIGATOR_244893].  
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 205of 217For cl arificati on added FeNO in various places in the section to include wit h scheduled 
Spi[INVESTIGATOR_31757]. 
Secti on 6.5.7 COPD Medication Restrictions at Centre Visits with Scheduled ECG 
Assessment: For clarificat ion added note that screening and rando mizat ionECG are not 
allowed wit hout proper medicat ion wash out due to ECG device settings. 
Secti on 8 Study  Assessment and Procedures: Added ‘Due to COVID -19 pandemic, it m ay 
not be possible to complete all study  assessments, such as spi[INVESTIGATOR_96656], according to SoA. 
Please refer to SoA and Appendix I for further details.’ This is added to limit the risk of 
COVID -[ADDRESS_298228] and site staff.
Secti on 8 Study  Assessments and Procedures: Added ‘Addit ional data to assess the impact 
of COVID -19 pandemic will be collected.’ 
Secti on
 [IP_ADDRESS] Duration of COPD Exacerbations: 
For cl arificati on, updated COPD exacerbation start date: ‘The start date will be defined as 
the start date of prescribed treatment with a systemic corticosteroid and/or sy stemic 
antibiotic or hospi[INVESTIGATOR_4073] n, which occurs earlier.’ by [CONTACT_245010][INVESTIGATOR_4073] n.
For cl arificati on, updated COPD exacerbation stop date: ‘The stop date will be defined as 
the last day  of prescribed treatm ent wi th a systemic corti costeroi d and/or sy stemic ant ibiotic 
or hospi[INVESTIGATOR_2345], which occurs later.’
Secti on [IP_ADDRESS].2 Symptom Reporting: added clarificat ion that ‘If COPD exacerbat ion is 
associ ated wi th ePRO worsening alert, symptoms should not be reported in the COPD 
exacerbation eCRF. If COPD exacerbat ion is not associ ated wi th ePRO worsening alert, 
please refer to section [IP_ADDRESS] for further guidance’
Secti on
 [IP_ADDRESS] Spi[INVESTIGATOR_96656], General  Requi rements: Added that ‘During the COVID -19 
pandemic, spi[INVESTIGATOR_244894].’ This is to provide guidance on how to proceed with respect to 
Schedule of Act ivities during the COVID -19 pandemic.
Secti on 8.1.6 Patient Reported Outcomes: Added clarification that subject can be trained at 
home use of eDiary also at Visit 1, if Visit 1 and Visit 2 are combined.
Secti on [IP_ADDRESS] St. George’s Respi[INVESTIGATOR_96692] (SGRQ): added clarificat ion ‘If the 
subject is not able to visit the site during the COVID -[ADDRESS_298229] at hom e/alternative l ocati on.’
Clinical Study Protocol -7.[ADDRESS_298230] (CAT): added clarificat ion ‘If the subject is not able 
to visit the site during the COVID -[ADDRESS_298231] at home/alternat ive location.’
Secti on 8.2.2 Clinical Safety Laboratory Assessments: added clarificat ion ‘During the 
COVID -[ADDRESS_298232] has re- consented to hom e/alternative l ocati on IP 
administration visits, it is possible that the HCP can co llect clinical safet y laboratory  tests in 
the subject’s ho me/alternat ive location.’ This change i s to minimize the subject's risk of 
COVID -19 exposure with clinic visits.
Secti on 8.3.2 Time Period and Frequency  for Collecting AE and SAE Informat ion:  
Clarified that Adverse Events and Serious Adverse Events have to be collected from the 
time of informed con sent and throughout the duration of the study . The AE/SAE collection 
requi rements have not changed.
Secti on 8.7.1 Optional Exploratory Genet ic Sample, Section
 8.8.1 Storage, Re -use and 
Destruction of Bio marker Samples: For clarification added that the results of any analyses 
will not be reported in the CSR itself but as an adde ndum, or separately  in a scient ific report 
or publicat ion for clarificat ion.
Secti on 8.8.4 Nasal Epi[INVESTIGATOR_244895]: added clarificat ion
‘During the COVID -[ADDRESS_298233] ion: Added that during the COVID -[ADDRESS_298234] 
and site staff exposure to the virus.
Secti on 8.8.6 Nasal Lining Fluid: Added that during the COVID -[ADDRESS_298235] 
and site staff exposure to th e virus.
Secti on 9 Statistical considerat ions: For clarificat ion of the analysis plan added that 
additional estimands (Secti on 9.2.1 ) and addit ional analyses (Section
 9.5) to assess the 
impact of COVID -19 will be detailed in the SAP.
Appendi x
 A 3Inform ed Consent Process: Added ‘During the COVID -[ADDRESS_298236] fo llow local/regi onal gui delines wit h regard to informed 
consen t. It i s critical that where wri tten re -consent cannot be obtained, and local and 
regional guidance all ows, the subject's verbal consent via phone or teleconference is 
obtained before conducting any  patient related changes implemented during COVID -[ADDRESS_298237]’s re -consent needs to be documented in the source 
docum ents.’ This step i s taken to minimize the risk of subject exposure to COVID -19 with 
site visi ts.
Appendix H Table of Abbreviations: For clarificat ion added COVID -19 and TPV.
Appendix I Coronavirus (COVID -19) Pandemic Guidance: Added Appendix I to describe 
in more detail the changes m ade during the COVID -[ADDRESS_298238] been made.  
Versi on 2.0, 16 December 2019
Changes to the protocol are summarized below.
Secti on 1.1, SoA –Table 1- Schedule of Assessments: corrected visit windows days.
Secti on 1.1,
 SoA –Table 1- Schedule of Assessment, footn otes:
‘a’: Updated to clarify  that Vi sit [ADDRESS_298239] ion assessments (Spi[INVESTIGATOR_244896]) should be postponed and done within a week 
after Visi t 1. At the postponed visit, spi[INVESTIGATOR_244897] [ADDRESS_298240] BD Spi [INVESTIGATOR_038]. The rem aining Table 1 (Vi sit 1 and Visi t 2) 
assessments should be done at Visit 1, if co mbined Visit 1 and Visit 2 spi[INVESTIGATOR_244898].
‘b’: Updated to align with changes made in Section 5.4as pati ents wi th respi [INVESTIGATOR_244899] -in period may  be extended up to 14 day s to allow the 
completion of therapy  if deemed suitable by  [CONTACT_11856]. 
‘c’: Added ‘Visit 1’ to clarify that sponsor is also unblinded to FeNO values fro m enrolment 
(Visit 1) when Visi t 1 and Visi t 2 are combined; added ‘The site will be blinded to the 
FeNO values for the whole study  durati on,’ to clarify  that si tes do not have acc ess to FeNO 
central  resul ts for the whol e study  durati on.
‘g’: Added Magnet ic Resonance Imaging (MRI) to ‘If a historical (not older than 6 months) 
chest x -ray (posteri or/ anteri or and lateral) is not available, historical (not older than 6 
months) Co
mpute d Tom ography  (CT) scan/ MRI is acceptable,’ as an acceptable historical 
MRI coul d repl ace chest x -ray during screening. 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 208of 217'f': The order of assessments during the screening period was changed fro m 'The suggested 
order of assessments in the clinic should occ ur as follows: Patient Reported Outcomes 
(PRO), Vi tals, ECG, bl ood draw, FeNO and spi[INVESTIGATOR_244900] 'The suggested order of 
assessments in the clinic: Vital Signs, ECG, FeNO, spi[INVESTIGATOR_244901],' as the 
blood sam pling is not required if the patient does not meet spi[INVESTIGATOR_244902] y criteria. 
‘h’: Added ‘immunoglobulin’ as sponsor and site are blinded to immunoglobulin results 
from the central  laboratory  resul ts except at screening visits, for any  repeat testing that is 
perform ed during the screening and at Vi sit 3 pri or to IP administrati on.
‘j’: Updated to clarify that ‘Pneumococcal vaccination can be done at Visit 1 or at any  time 
prior to randomizat ion’ and ‘Annual influenza vaccinat ion can be done at any  other time 
throughout the study  (except for within ±7 days o f IP administration) at the discretion of 
Invest igator’ and added reference to Section 8.2.10 .
Secti on 1.1, SoA –Table 2 -Schedule of Assessments:
Removed Heal thcare resource utilizat ion assessment fro m COPD Exacerbat ion (EXA) visit 
as data i s not to be captured in the case report form.
Under sect ion ‘Subset of Subjects Participat ing in Sputum and Nasal Lining Fluid/Epit helial 
Cells Sub Studies Only’ added assessment ‘Sputum post -BD spi [INVESTIGATOR_038]’ that i s part of the 
sputum  sub-study  and is conducted to ensure patient safet y during the induc tion as 
described in Section [IP_ADDRESS] and in the sputum manual.
'NOTE' was updated from 'The suggested order of assessments to be completed before IP 
administration s hould be as fo llows: ePRO, Vi tal Signs, ECG, Bl ood draws, FeNO, and 
Spi[INVESTIGATOR_038]' to 'The suggested order of assessments to be completed prior IP administration: 
ePRO, Vital Signs, ECG, FeNO, Spi[INVESTIGATOR_244903]' to be consi stent wi th Table 1 
footnote'f'. 
Secti on
 1.1, SoA –Table 2- Schedule of Assessments, footnotes:
‘b’: Added missing reference to Section [IP_ADDRESS] .
‘c’: Updated to clarify  that sponsor i s also unblinded to FeNO values fro m enrolment (Visit 
1) when Visit 1 and Visit 2 are combined. Also, added ‘The site will be blinded to the 
FeNO values for the whole stud y durati on’ to cl arify  that the si tes shoul d not have access to 
FeNO central results. 
‘f’: Footnote f is removed fro m IPD visit as pre -and post -BD spi [INVESTIGATOR_244904], and not only for subjects in the sub study . 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 209of 217‘g’: Ame nded to clarify that ‘sponsor and site will be blinded to the immunoglobulin, 
eosinophil, basophil and mo nocy te counts from  the central laboratory  reports except 
screening visit s (Vi sit 1 and 2), any  repeat testing that is performed during the screen visit s, 
and at Visit 3 prior to IP administration.’
‘h’ was removed as footnotes ‘g’ and ‘h’ were merged.
‘k’: Amended to clarify that if subject is not able to produce sputum (spontaneous or 
induced) at Visit 3, then subject should be wit hdrawn fro m the sub -study  and nasal samples 
shoul d be discarded. 
Secti on 1.2Synopsis: Added Internat ional coordinating invest igator details.
Secti on 1.[ADDRESS_298241] ives:
Removed ’Physical examinat ions’ from Safety Endpoints/Variables as specific details from 
the assessment will not be captured in the case report form.
Added ‘participat ing in sub -study’ in ‘To evaluate the effect of tezepelumab on sputum  
biomarkers, sputum cell counts and sputum microbio me in subjects participat ing in sub -
study  at baseline, end of treatment, and at the start of all exacerbat ions’ to specify the 
subgroup.
Secti on 1.2 Synopsis, Section
 4.1Overall design, Section 6.3Measures to minimize Bias: 
Updated the target of subjects based on eo sinophils count to include approximately 20% of 
the subjects with >300 eosinophils/μL as ‘Approximately 20% of the subjects will be 
targeted to have >300 eosinophils/μL, 40% of the subjects between ≥150 to 300 
eosinophils/μL and a maximum o f approximately  40% of the subjects with <150 
eosinophils/μL at enrolment’ to improve distribut ion of subjects across the range of baseline 
eosinophils levels. 
Secti on 2.1Synopsi s and Secti on [IP_ADDRESS] :
 Updated fro m ‘proporti on of  subjects wi th at least 
4 uni ts changed in SGRQ’ to ‘proportion of subjects with at least 4 units decrease in SGR Q’ 
to clarify  the clinically  significant change.
Secti on 4.1Overall design: 
Changed sect ion heading from ‘Screening Period’ to ‘Screening Period (Enrolment and 
Run-in)’ and added description of enro lment and run -in visits based on Table 1.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 210of 217Removed ‘I n case of an exacerbat ion within 2 weeks of rando mizat ion; run -in period can be 
extended to allow for recovery ,’ as instructions on how to manage a COPD exacerbat ion are 
provi ded in Sect ion 5.4Screen Failure and Re -screening.
Added ‘If the subject does not meet the COPD medicat ions restri ctions at Visit 1, the lung 
funct ion assessments (Spi[INVESTIGATOR_038] , FeNO) should be postponed and performed no later than 
one week after V isit 1. At the postponed visit, spi[INVESTIGATOR_244905] [ADDRESS_298242] BD Spi[INVESTIGATOR_038]. The remaining Table 1 (Visit 1 and 
Visit 2) assessments shoul d be done at Vi sit 1, if combined Visi t 1 and Visi t 2 spi [INVESTIGATOR_244906].’ clarificat ion from Table 1 footnote ‘a’.
Added ‘COPD disease state’ in ’Acceptable Documentation for COPD disease state and 
Historical COPD Exacerbat ions and Background Therapy’ to clarify that the section defines 
the acceptabl e docum entati on for COPD disease.
Changed sect ion heading from ‘Treat ment’ to ‘Rando mizat ion, Treatment and Fo llow-up’ 
to align wit h sect ion content. 
Removed ‘If the EXA visit was completed within +/ -5 days of as scheduled visit, the same 
assessment d
oes not need to be repeated at the next scheduled visit, unless at the PI’s 
discreti on’ and added instead reference to Section [IP_ADDRESS] COPD Exacerbat ion Visit.
Secti on 5.1Inclusion criteria:
#5: Added ‘(Visit 1 if Visit 1 and 2 are combined)’ as the inclusio n is applicable at Visit 1 if 
Visit 1 and Visi t 2 are combined. 
#6: A dded reference ‘See Sect ion 4.1for requi red source documentation for this inclusio n.’
#7: Rem oved the reference, ‘Equivalent ICS doses as detailed in Appendix F’ as Appendix 
F was removed as data included in the Appendix were fro m GINA Asthma guidance 2018 
and were not in congruence wit h ICS doses for COPD. 
#7: Added ‘ If an Investi gator deci des to swi tch a subject who is on an ICS in a separate 
single device to a fixed -dose com binat ion device therapy, this should be done at Visit [ADDRESS_298243] remain at the same dose and schedule as used in the 3 months 
prior to Visit 1 (provided dose and regimen are locally  approved for COPD)’ from Table 5 
for Background (m aintenance) COPD m edicat ions details pertain to Inclusio n #7.
#12: Added Magnet ic Resonance Imaging (MRI) and correct double negative wording as it 
shoul d read that ‘Chest x -ray, com puted tom ography  (CT) scan or Magneti c Resonance 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 211of 217Imaging (MRI) of the chest/lungs m ust not show suspected lung pathology  that precl udes 
the pati ent’s abilit y to complete the study .’
#19: Added ‘pre -BD’ to clarify  that stabl e pre -BD FEV1 i s expected during the run -in 
period; updated the run -in period baseline pre -BD defin ition from ‘Visi t 1’ to ‘Visi t 1 if 
visits are combined or Visit 2’ as Visit 1 or Visit 2 pre -BD FEV1 result can be used as 
baseline.
Secti on 5.2Exclusion criteri a: 
#1: Added ‘as judged by  [CONTACT_244938]’ to clarify that patients with clinically important 
pulmo nary disease other than COPD in Invest igator’s judgement should not be enrolled if it 
may put the patient at risk or negatively affect the outcome of the stud y.
#6: Changed fro m ‘History  of clinically  significant infect ion (excluding pneumo nia), acute 
upper or lower respi[INVESTIGATOR_103415], requiring ant ibiotics or antiviral medicat ion within 14 
days pri or to enrolment (Visit 1) or during the screening period bas ed on the l ast day  of 
antibiotic/ant iviral treatment or hospi[INVESTIGATOR_244799], whatever occurred later or during the 
enrolment and screening’ to ‘History  of clinically significant infect ion (excluding 
pneumo nia), acute upper or lower respi[INVESTIGATOR_244907], requiring antibiot ics or antiviral 
medicat ion within 14 days pri or to enrolment (Visit 1) or 14 days prior to randomizat ion 
(Visit 3), based on the l ast day  of antibiotic/ant iviral treatm ent or hospi [INVESTIGATOR_244908], 
whatever occurred later,’ as patients wi th respi [INVESTIGATOR_244909] h screening 
as per updated Section 5.4.
#16: Added reference to Section 6.5.1 .
#20: Added ‘immunoglobulin’ to ‘Receipt of immunoglobulin or blood products within 30 
days pri or to enrolment (Visit 1)’ as we assess the effect of tezepelumab on total serum 
immunogl obulins in exploratory  analy sis.
#24: Updated to ‘Patients who received ≥6 m onths of ant ibiotics treatment (including 
macro lides or other antibiot ic) in the previous year must have a hearing assessment 
perform ed as per l ocal standard of care wi thin 3 months prior to randomizat ion’ to further 
clarify when the hearing assessment is applicable.
#32: Added ‘wit h or without ongoing treatment’ to further clarify that patients with 
evidence of active liver disease even on ongoing treatment should be excluded.
Secti on 5.3.2 Alcoho l, Tobacco and Other and Section
 8.2.2 Smoking Status: Removed 
‘Any  changes in sm oking status between Visit 1 (enrolment) and Visit 3 (randomizat ion) 
will result in screen failure’ as change of smoking status is acceptable through out the study .
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 212of 217Secti on 5.3.2 Alcoho l, Tobacco and Other and Section [IP_ADDRESS] General requirements: Added 
‘Subjects should not smoke on day (s) pri or to l ung f unction assessments at the site’ to 
clarify that current smokers should withho ld smoking unt il the lung assessments are 
completed.
Secti on 5.4Screen Failures and Re -screening: Updated ‘Subjects with respi[INVESTIGATOR_244907] 
(excluding pneumo nia) requiring ant ibiotics or antiviral medicat ion within 14 days prior to 
Visit 1 or during the run -in period: May remain in screening and the run -in period may be 
extended up to [ADDRESS_298244] igator’ to allow pat ients with respi [INVESTIGATOR_244910] -in window. 
Secti on 6.1.2 Preparation/Handling/Storage/Accountabilit y, Dose administrati on: Added 
clarificati on that ‘IP shoul d be equilibrated to room temperature for at least 60 minutes prior 
to administration ’ and that ‘The second inject ion shoul d be administered immediately  after 
the first inject ion.’
Secti on 6.3Measures to Minimise Bias, Rando mization and Blinding: Added ‘ or re -
screening Visit 1’ to reflect that number of historical exacerbat ions should be revised in 
case of re -screening.
Secti on
 6.5Table 5 Allowed, Restricted and Prohibited Medicat ions: 
‘Background (maintenance) COPD medicat ions’ details: updated fro m ‘The dose of 
background (maintenance) COPD medicat ions (ICS/LABA/LAMA) should be stable 3 
months prior to V1 and throughout the study’ to ‘The dose of ICS should be stable 3 months 
prior to V1 and throughout the study’ as only ICS stable dose is required 3 months prior to 
V1 and throughout the study .
‘Muc olytics’ details: removed ‘Allowed if not containing ephedrine’ as ‘ Medicat ions 
containing ephedrine’ were added to Table 5 as prohibited medications.
‘Antitussive prn’ details: removed ‘Allo wed if not containing ephedrine and/or opi[INVESTIGATOR_244911]/or other bronc hodilator’ from as Medications containing ephedrine’ were added to 
Table 5 as prohibited medicat ions.
Updated from ‘Ant ihistamines prn not containing ephedrine or bronchodilators’ to 
‘Antihistamines prn’ and removed fro m details ‘Allowed if not containing ephedrine or 
bronchodilators’ as ‘Medications containing ephedrine’ were added to Table 5 as prohibited 
medicat ions.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 213of 217Added ‘Dermal topi[INVESTIGATOR_8826], intra -articular, nasal steroids, topi[INVESTIGATOR_244912]’ to cl arify other allowed medi cations.
Added ‘Immunoglobulin and blood products’ as prohibited medications within 30 days 
prior to enrolment (Visit 1) as per Exclusio n 20 and throughout the treatment period.
added ‘Medicat ions containing ephedrine’ as prohibited medicat ions from Visit 3 
throughout the treatment period.
for ‘Allergen immunotherapy ,’ added ‘run -in’ to ‘Allowed, if on stable therapy for at least 2 
months prior to date of Visit 1 with no ant icipated change during the run -in and the 
treatm ent peri od’ to cl arify that no chang e is ant icipated al so during the run -in.
‘Inactive/killed vaccinat ions’ details: changed from ‘wit hin 5 days before and after any IP 
dosing visit ’ to ‘within 7 days before or after any  IP dosing visit’ to correct inconsistency 
between Table 5 and Table 1 f ootnote ‘j’.
‘Long term oxygen therapy  (LTOT)’ status changed from ‘Prohibited’ to ‘Restricted’ and 
details were added, ‘During the treatment phase, any  increase in maintenance oxy gen 
therapy  up to 4 L/min is allowed, based on invest igator’s judgement’ in order to clarify  that 
the increase in maintenance oxy gen therapy  may be all owed under specific circumstances.
Added ‘Investigational non- biologic products’ as prohibited medicat ions wi thin 30 days or 
5 half -lives, whichever is lo nger pri or to Visit 1 and d uring the study as already prohibited 
per Excl usion Criterion 22.
Secti on 6.5.5 , COPD Medicat ion Restri ctions on the Days o f Scheduled Spi[INVESTIGATOR_244913]: 
Updated the screening sect ion to cl arify that for subject who does not meet the COPD 
medicat ions restri ctions at Visit 1, the spi[INVESTIGATOR_244914] d be postponed no later than [ADDRESS_298245] 
BD Spi [INVESTIGATOR_038]. The rem aining Table 1 (Vi sit 1 and Visi t 2) assessments shoul d be done at 
Visit 1, if  combined Visit 1 and Visit 2 spi[INVESTIGATOR_244915].’
Removed ‘preferably’ from ‘(preferably  should be at l east 12 hours prior to the assessment 
for twice daily  medicat ion and for 24 hours prior to the assessment for once daily 
medicat ions)’ as there is a requirement to withho ld triple inhaled medications at l east 12 
hours for twice daily medicat ions and for 24 hours for once daily medicat ions.
To sub -section ‘Treatment Visits 3 -15’ and to Sectio n [IP_ADDRESS] ,
 added ‘or sputum post -BD 
spi[INVESTIGATOR_244916] s (for pati ents parti cipat ing in sputum sub -study’ to cl arify that f or subj ect 
Clinical Study Protocol -7.[ADDRESS_298246] -BD assessment.
Added ‘The spi[INVESTIGATOR_244917] m edicat ion washout i s not allowed during the 
screening period (between Visit 1 and Visit 2 inclusive) and at Randomization Visit 3’ to 
clarify the medicat ion conditions for the screening and randomizations visits. 
Secti on 7.1Discont inuat ion of Study  Treatm ent: added ‘eosinophilia ( ≥5% based on local 
laboratory  resul ts)’ as sponsor and site staff are blinded to central lab results after IP 
administration at Visit 3. 
Secti on 7.3.2 , Discont inuat ion or suspensio n of entire study  and sit e closure – Updated the 
title of this sect ion and added addit ional co mments about site closure. The rationale for this 
change i s to specify  the condi tions for closure of sites during and after study  com pletion.
Secti on [IP_ADDRESS] ‘Duration of COPD exacerbat ions’: Added reference to Section
 [IP_ADDRESS] .
Secti on [IP_ADDRESS].1 ‘COPD Exacerbat ion eCRF’:
Removed ‘The invest igator should record all pert inent findings and symptoms associated 
with the exacerbation event and their duration in source documents and in the COPD 
exacerbation’ as symptoms reporting are properly described in Section [IP_ADDRESS].2 Symptom 
Reporting. 
Added: ‘The invest igator should record the COPD exacerbation that meets the COPD 
exacerbation definit ion (refer to Section 8.1.1) in the COPD exacerbat ion eCRF 
(COP DEX)’ to clarify when COPD exacerbat ion shoul d be reported in COPDEX.
Updated the rule for reporting the serious COPD exacerbat ion, ‘The serious COPD 
exacerbation should be recorded in AE/SAE eCRF and in COPDEX. Other COPD related 
SAEs shoul d be recorded o n the AE/SAE eCRF’ to clarify the rules. 
Secti on [IP_ADDRESS].2 ‘Symptom reporting’: Added timeframe of [ADDRESS_298247] igator 
to document the action taken after an e
-diary  alert has been tri ggered.
Added ‘Section [IP_ADDRESS] -COPD Exacerbat ion visit’: To describe the COPD exacerbat ion 
(EXA) visit from SoA Table 2.
Secti on [IP_ADDRESS] General requirements: 
Added restrictions for subjects not to smoke/vape on the same day (s) pri or to the l ung 
funct ion test is being performed; 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 215of 217Added referen ce to Secti on [IP_ADDRESS] .  
Secti on [IP_ADDRESS] Post-BD Spi[INVESTIGATOR_038] : The revised t ext reads, ‘Endpoint maximal 
bronchodilat ion will be induced using albuterol (90μg metered dose) or salbutamo l (100μg 
metered dose) with or without a spacer device up to a maximum o f [ADDRESS_298248] SABA inhalation ’ to cl arify SABA administrati on 
details for Post -BD spi[INVESTIGATOR_038].’
Added Sect ion ‘[IP_ADDRESS] Sputum post -BD Spi[INVESTIGATOR_038] ’: Sputum  post -BD spi[INVESTIGATOR_244824] d 
be perform ed pe r schedule in Table 2 (Visit 3, Visit 16, IPD and EXA) as part of induced 
sputum  procedures if subject is participat ing in the sputum sub study, after post -BD 
spi[INVESTIGATOR_038] (refer to Section
 [IP_ADDRESS] ). It is conducted solely to ensure patient safet y in 
inducing sputum and results will neit her be captured for the eCRF, nor for study  endpo ints. 
More details will be provided in the sputum sub- study  manual  to cl arify assess ment 
applicabilit y and purpose.  
Secti on 8.1.3 FeNO: Removed ‘including ICS/LABA’ and added reference to Section 
6.5.[ADDRESS_298249] -rando mizat ion. Sites will be blinded to 
FeNO values for the whole study  durati on.
Secti on
 8.2.1 Clinical Safety Laboratory Assessments, Table 7Laborat ory Safety  Variables: 
Added a footnote with clarification on the urinalysis dipst ick and added instruction on how 
site shoul d manage reporting of clinically  significant resul ts as, ‘ Urinalysis (Dipst ick) 
central  laboratory  report will contain results from variables as listed in the laboratory  
manual, however only  for variables U -Hb/Ery throcytes/Bl ood, U -Protein/Albumin and U -
Glucose is requi red confirmation in the laboratory  eCRF m odule if the result i s clinically  
significant. If there are any  clinically si gnificant results from other variables, it will be the 
investigator decisio n to document them in the eCRF as an AE.’
Secti on 8.2.7 Supplemental Oxygen (O2): Added e CRF reporting instruction, ‘Use of 
oxygen shoul d be recorded as a concomitant medication in the eCRF.’ 
Secti on
 8.2.9 : Updated section, ‘Chest X- ray, CT Scan or MRI’ to include MRI as an 
acceptable historical scan.
Secti on 8.3.2 Time Period and Frequency  for Collecting AE and SAE Informat ion: Updated 
to clarify  that Adverse Even ts (AEs) are to be collected only  for randomized patients and 
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 216of 217Serious Adverse Events (SAEs) should be recorded and reported from the time of signing of 
ICF throughout the duration o f the study  for all patients.
Secti on 8.8.[ADDRESS_298250] ion: Added ‘In a s ubset of subjects only  parti cipat ing in the sub -study . If 
sputum  and nasal collect ions occur at the same visit, nasal sampling should occur before 
spontaneous/sputum induct ion’ to clarify that the assessment is only applicable for patients 
participat ing inthe sub -study  and the nasal sampling should be done prior to sputum 
sampling. Also added ‘If subject is not able to produce sputum (spontaneous or induced) at 
Visit [ADDRESS_298251] shoul d be wi thdrawn from  the sub -study  and nasal samples should be 
discarde d.’ Nasal samples will not be analyzed if the subject cannot produce sputum sample 
at Vi sit 3.
Secti on 8.8.6 Nasal Lining Fluid: Added ‘In a subset of subjects only participating in the 
sub-study . If sputum  and nasal collect ions occur at the same visit, nasal sampling should 
occur before spontaneous/sputum induction’ to clarify that assessment is only applicable for 
patients parti cipat ing in sub -study  and the nasal sampling should be done prior to sputum 
sampling.
Secti on
 9.2Sample Size Determinat ion: Added ‘In the absence of the interim analysis for 
futilit y, thi s design woul d provi de 81.2% power, and only 136 subjects per treatment arm 
woul d be requi red for 80% power. This power statement accounts for the power loss 
associ ated wi th the f utilit y interim analysis that will occur when [ADDRESS_298252] been 
rando mized.  In simul ated resul ts, 1.2% of simulated trials were stopped early  for futilit y 
but would have been successful at the final analysis of the primary endpoint had they been 
allowed to continue.  Therefore, the overall power for this trial account ing for the interim 
analysis is 80%.’ This sect ion was added to explain how the sample size was adjusted to 
account for the fut ility analysis, so that the sample size calculat ions coul d be fully 
reconstructed.
Secti on [IP_ADDRESS] Exacerbat ion rate: Added ‘The number of days that the subject experiences 
an exacerbat ion during the fo llow
-up time, including the subsequent 7 days (when a further 
exacerbation would not be considered a separate ev ent (and if wit hin the fo llow-up time) 
will be subtracted from the fo llow
-up time to gi ve the time at risk o f exacerbation’ and 
updated the formula to calculate the annual exacerbat ion rate to be, ‘ Annual exacerbat ion 
rate=Number of exacerbat ions*365.25 / (Time at Risk of Exacerbat ion).’ Using time at risk 
rather than total fo llow-up tim e (i.e. taking into account the duration of exacerbat ion & 
recovery ) when est imating annual exacerbat ion rates, can avo id an under -estimation of the 
treatm ent effect.
Clinical Study Protocol -7.0 [COMPANY_008]
Tezepelumab -D5241C00001
CONFIDENTIAL AND PROPRIETARY Page 217of 217Secti on [IP_ADDRESS] Primary Analysis Methods and Section [IP_ADDRESS] Exacerbat ion rate: Am ended 
from ‘corresponding fo llow up time’ to ‘corresponding time at risk of exacerbation’.
Appendix A1, Regulatory  and Ethical Considerat ions: Added Regulatory  Reporting 
Requi rements for SAEs in accordance with the European Direct ive 2001/20/EC.
Appendix F Maintenance Therapy Equivalence Table: Appendix F removed as data 
included in the appendix were from GINA Asthma guidance [ADDRESS_298253] that was signed
electronically and this page is the manifestation of the electronic signature
[CONTACT_24558]: d5241c00001-csp-v7
Document Title: D5241C00001 Clinical Study Protocol version 7
Document ID: Doc ID-003939289
Version Label: 10.[ADDRESS_298254] APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by [CONTACT_24557]
04-Nov-2022 09:40 UTC Content Approval
03-Nov-2022 21:29 UTC Content Approval
04-Nov-2022 05:33 UTC Content Approval
Notes: (1) Document details as stored in ANGEL, an [COMPANY_008] document management system.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]